US20200254177A1 - Methods and systems for promoting glucose management - Google Patents
Methods and systems for promoting glucose management Download PDFInfo
- Publication number
- US20200254177A1 US20200254177A1 US16/862,429 US202016862429A US2020254177A1 US 20200254177 A1 US20200254177 A1 US 20200254177A1 US 202016862429 A US202016862429 A US 202016862429A US 2020254177 A1 US2020254177 A1 US 2020254177A1
- Authority
- US
- United States
- Prior art keywords
- data
- sensor data
- reward
- receiver
- user
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 152
- 239000008103 glucose Substances 0.000 title claims abstract description 152
- 238000000034 method Methods 0.000 title claims abstract description 96
- 230000001737 promoting effect Effects 0.000 title 1
- 230000003993 interaction Effects 0.000 claims abstract description 101
- 238000012544 monitoring process Methods 0.000 claims abstract description 25
- 230000004044 response Effects 0.000 claims description 58
- 206010012601 diabetes mellitus Diseases 0.000 claims description 26
- 238000012545 processing Methods 0.000 claims description 16
- 230000008859 change Effects 0.000 claims description 15
- 230000006872 improvement Effects 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 7
- 230000002641 glycemic effect Effects 0.000 claims description 7
- 238000003825 pressing Methods 0.000 claims description 7
- 230000001960 triggered effect Effects 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 3
- 235000019577 caloric intake Nutrition 0.000 claims description 2
- 238000005259 measurement Methods 0.000 abstract description 22
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 239000012491 analyte Substances 0.000 description 91
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 70
- 230000009471 action Effects 0.000 description 46
- 102000004877 Insulin Human genes 0.000 description 35
- 108090001061 Insulin Proteins 0.000 description 35
- 229940125396 insulin Drugs 0.000 description 35
- 230000008569 process Effects 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 238000004891 communication Methods 0.000 description 11
- 230000002218 hypoglycaemic effect Effects 0.000 description 10
- 235000012054 meals Nutrition 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 238000004422 calculation algorithm Methods 0.000 description 9
- 238000007726 management method Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 208000013016 Hypoglycemia Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000003345 hyperglycaemic effect Effects 0.000 description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 4
- 229940127560 insulin pen Drugs 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 241000258920 Chilopoda Species 0.000 description 3
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- -1 PreState Chemical compound 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 238000009499 grossing Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 3
- HZCBWYNLGPIQRK-LBPRGKRZSA-N 3,3',5'-triiodo-L-thyronine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC=C1OC1=CC(I)=C(O)C(I)=C1 HZCBWYNLGPIQRK-LBPRGKRZSA-N 0.000 description 2
- DIVQKHQLANKJQO-UHFFFAOYSA-N 3-methoxytyramine Chemical compound COC1=CC(CCN)=CC=C1O DIVQKHQLANKJQO-UHFFFAOYSA-N 0.000 description 2
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 2
- 102000004452 Arginase Human genes 0.000 description 2
- 108700024123 Arginases Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940107161 cholesterol Drugs 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000006855 networking Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
- 229950010883 phencyclidine Drugs 0.000 description 2
- PAHGJZDQXIOYTH-UHFFFAOYSA-N pristanic acid Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C(O)=O PAHGJZDQXIOYTH-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940034208 thyroxine Drugs 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- CIKNYWFPGZCHDL-ZHFUJENKSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N CIKNYWFPGZCHDL-ZHFUJENKSA-N 0.000 description 1
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- UUEZOEBHFHYMGR-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;3-(4-chlorophenyl)-n,n-dimethyl-3-pyridin-2-ylpropan-1-amine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC UUEZOEBHFHYMGR-RNWHKREASA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- QNJJECIHYZJXRL-UHFFFAOYSA-N 1-(2-chlorophenyl)-2-methylpropan-2-amine;hydrochloride Chemical compound Cl.CC(C)(N)CC1=CC=CC=C1Cl QNJJECIHYZJXRL-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QNLDTXPVZPRSAM-UHFFFAOYSA-N 17146-95-1 Chemical compound CC(O)C(O)=O.C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 QNLDTXPVZPRSAM-UHFFFAOYSA-N 0.000 description 1
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 description 1
- UYVVLXVBEQAATF-WAIVXGPNSA-N 1b-Hydroxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)C[C@@H](O)[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 UYVVLXVBEQAATF-WAIVXGPNSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- LCZBQMKVFQNSJR-UJPCIWJBSA-N 21-deoxycortisol Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)C[C@@H]2O LCZBQMKVFQNSJR-UJPCIWJBSA-N 0.000 description 1
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 description 1
- WYEPBHZLDUPIOD-UHFFFAOYSA-N 4,6-dioxoheptanoic acid Chemical compound CC(=O)CC(=O)CCC(O)=O WYEPBHZLDUPIOD-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 description 1
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- KZFBHCCLJSAHBQ-UHFFFAOYSA-N Benzoylecgonine Natural products CN1C2CCC1C(C(C2)OC(=C)c3ccccc3)C(=O)O KZFBHCCLJSAHBQ-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108010039206 Biotinidase Proteins 0.000 description 1
- 102100026044 Biotinidase Human genes 0.000 description 1
- JQJPBYFTQAANLE-UHFFFAOYSA-N Butyl nitrite Chemical compound CCCCON=O JQJPBYFTQAANLE-UHFFFAOYSA-N 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- 108010033547 Carbonic Anhydrase I Proteins 0.000 description 1
- 102100025518 Carbonic anhydrase 1 Human genes 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000003808 Cystic echinococcosis Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108010071840 Cytosol nonspecific dipeptidase Proteins 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical class OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- LHQIJBMDNUYRAM-AWFVSMACSA-N D-erythro-biopterin Chemical compound N1=C(N)NC(=O)C2=NC([C@H](O)[C@H](O)C)=CN=C21 LHQIJBMDNUYRAM-AWFVSMACSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 108010028196 Dihydropteridine Reductase Proteins 0.000 description 1
- 102100022317 Dihydropteridine reductase Human genes 0.000 description 1
- 241001319090 Dracunculus medinensis Species 0.000 description 1
- 241000244170 Echinococcus granulosus Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102100029115 Fumarylacetoacetase Human genes 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 description 1
- 239000004866 Hashish Substances 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 108010085682 Hemoglobin A Proteins 0.000 description 1
- 102000007513 Hemoglobin A Human genes 0.000 description 1
- 108010085686 Hemoglobin C Proteins 0.000 description 1
- 108010068323 Hemoglobin E Proteins 0.000 description 1
- 108091005880 Hemoglobin F Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 102000016871 Hexosaminidase A Human genes 0.000 description 1
- 108010053317 Hexosaminidase A Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- ZAGRKAFMISFKIO-UHFFFAOYSA-N Isolysergic acid Natural products C1=CC(C2=CC(CN(C2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-UHFFFAOYSA-N 0.000 description 1
- LHQIJBMDNUYRAM-UHFFFAOYSA-N L-erythro-Biopterin Natural products N1=C(N)NC(=O)C2=NC(C(O)C(O)C)=CN=C21 LHQIJBMDNUYRAM-UHFFFAOYSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000883511 Lophophora williamsii Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 1
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 description 1
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010016797 Sickle Hemoglobin Proteins 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040860 Skin haemorrhages Diseases 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000002248 Thyroxine-Binding Globulin Human genes 0.000 description 1
- 108010000259 Thyroxine-Binding Globulin Proteins 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 241000223097 Trypanosoma rangeli Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100021436 UDP-glucose 4-epimerase Human genes 0.000 description 1
- 108010075202 UDP-glucose 4-epimerase Proteins 0.000 description 1
- 108010058532 UTP-hexose-1-phosphate uridylyltransferase Proteins 0.000 description 1
- 102000006321 UTP-hexose-1-phosphate uridylyltransferase Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000244005 Wuchereria bancrofti Species 0.000 description 1
- 102100039662 Xaa-Pro dipeptidase Human genes 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 108010063628 acarboxyprothrombin Proteins 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960003116 amyl nitrite Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ANFSNXAXVLRZCG-RSAXXLAASA-N benzphetamine hydrochloride Chemical compound [Cl-].C([C@H](C)[NH+](C)CC=1C=CC=CC=1)C1=CC=CC=C1 ANFSNXAXVLRZCG-RSAXXLAASA-N 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000747 designer drug Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- QMQBBUPJKANITL-MYXGOWFTSA-N dextropropoxyphene hydrochloride Chemical compound [H+].[Cl-].C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 QMQBBUPJKANITL-MYXGOWFTSA-N 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229940120144 didrex Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- QCHSEDTUUKDTIG-UHFFFAOYSA-L dipotassium clorazepate Chemical compound [OH-].[K+].[K+].C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 QCHSEDTUUKDTIG-UHFFFAOYSA-L 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- GVGYEFKIHJTNQZ-RFQIPJPRSA-N ecgonine benzoate Chemical compound O([C@@H]1[C@@H]([C@H]2CC[C@@H](C1)N2C)C(O)=O)C(=O)C1=CC=CC=C1 GVGYEFKIHJTNQZ-RFQIPJPRSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 108010022687 fumarylacetoacetase Proteins 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 229960003242 halofantrine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 108010047389 hemoglobin D Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940087973 lomotil Drugs 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960002803 methaqualone Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- FYHCHSNOXWVJJT-UHFFFAOYSA-N n-debutylhalofantrine Chemical compound FC(F)(F)C1=CC=C2C(C(O)CCNCCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FYHCHSNOXWVJJT-UHFFFAOYSA-N 0.000 description 1
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229940011043 percocet Drugs 0.000 description 1
- 238000011338 personalized therapy Methods 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- OOBHFESNSZDWIU-UHFFFAOYSA-N phenmetrazine Chemical compound CC1NCCOC1C1=CC=CC=C1 OOBHFESNSZDWIU-UHFFFAOYSA-N 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 229950009829 prasterone sulfate Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 108010066823 proline dipeptidase Proteins 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 229940099204 ritalin Drugs 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 108010093322 s-formylglutathione hydrolase Proteins 0.000 description 1
- 102000028528 s-formylglutathione hydrolase Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 206010039766 scrub typhus Diseases 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000005236 sound signal Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960004673 sulfadoxine Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940066690 talwin Drugs 0.000 description 1
- 229960005367 tetanus antitoxin Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940063648 tranxene Drugs 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 238000013024 troubleshooting Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940071950 tussionex Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- HUHWZXWWOFSFKF-UHFFFAOYSA-N uroporphyrinogen-III Chemical compound C1C(=C(C=2CCC(O)=O)CC(O)=O)NC=2CC(=C(C=2CCC(O)=O)CC(O)=O)NC=2CC(N2)=C(CC(O)=O)C(CCC(=O)O)=C2CC2=C(CCC(O)=O)C(CC(O)=O)=C1N2 HUHWZXWWOFSFKF-UHFFFAOYSA-N 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- FUTVBRXUIKZACV-UHFFFAOYSA-J zinc;3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoate Chemical compound [Zn+2].[N-]1C2=C(C)C(CCC([O-])=O)=C1C=C([N-]1)C(CCC([O-])=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 FUTVBRXUIKZACV-UHFFFAOYSA-J 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0004—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by the type of physiological signal transmitted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1495—Calibrating or testing of in-vivo probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4833—Assessment of subject's compliance to treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
- A61B5/725—Details of waveform analysis using specific filters therefor, e.g. Kalman or adaptive filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/742—Details of notification to user or communication with user or patient ; user input means using visual displays
- A61B5/743—Displaying an image simultaneously with additional graphical information, e.g. symbols, charts, function plots
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/742—Details of notification to user or communication with user or patient ; user input means using visual displays
- A61B5/744—Displaying an avatar, e.g. an animated cartoon character
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/7475—User input or interface means, e.g. keyboard, pointing device, joystick
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3303—Using a biosensor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/502—User interfaces, e.g. screens or keyboards
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/582—Means for facilitating use, e.g. by people with impaired vision by tactile feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/04—Heartbeat characteristics, e.g. ECG, blood pressure modulation
- A61M2230/06—Heartbeat rate only
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/201—Glucose concentration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/63—Motion, e.g. physical activity
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Definitions
- Diabetes mellitus is a disorder in which the pancreas cannot create sufficient insulin (Type I or insulin dependent) and/or in which insulin is not effective (Type 2 or non-insulin dependent).
- Type I or insulin dependent in which the pancreas cannot create sufficient insulin
- Type 2 or non-insulin dependent in which insulin is not effective
- a hypoglycemic reaction low blood sugar may be induced by an inadvertent overdose of insulin, or after a normal dose of insulin or glucose-lowering agent accompanied by extraordinary exercise or insufficient food intake.
- SMBG self-monitoring blood glucose
- the invention comprises a method of encouraging interactions with a receiver configured to receive sensor data from a glucose sensor.
- the method comprises sensing an interaction from a user with a receiver, wherein the receiver is configured to receive sensor data from the glucose sensor and to selectively display information associated with the sensor data and/or the sensor data in response to interactions from the user.
- a reward counter is incremented, and in response to determining that the reward counter has reached a predetermined reward threshold, a reward indication on the receiver is displayed, and/or a reward indication is transmitted.
- a method of encouraging interactions with a continuous glucose monitoring system comprises sensing a user interaction with a portion of the continuous glucose monitoring system and incrementing a reward counter in response to the sensed interaction independent of the creation or value of any sensor data.
- a portable sensor system comprising a glucose sensor configured to provide real-time continuous glucose sensor data, a device comprising a user interface configured to receive user input and display the real time glucose sensor data responsive to user-interaction with the portable device, and a processor module configured to tabulate a score based at least in part on user interactions with the user interface.
- FIG. 1 is a block diagram that illustrates a configuration of a medical device in one embodiment, including a continuous analyte sensor, a receiver, and an external device.
- FIG. 2 is a flowchart that illustrates a process of displaying sensor data as a game.
- FIGS. 3A-3H are drawings illustrating various embodiments of displayed sensor data.
- FIGS. 4A-4G are drawings illustrating an embodiment of displayed sensor data.
- FIG. 5 is a drawing illustrating an animation graphically comparing two sets of sensor data.
- FIG. 6 is a flowchart that illustrates a process of displaying sensor data as a game where rewards are given.
- FIG. 7A is a flowchart that illustrates a process of generating rewards based on user interaction.
- FIG. 7B is a flowchart that illustrates another process of generating rewards based on user interaction.
- FIG. 8A is a flowchart that illustrates a process of displaying tutorial data for a user.
- FIG. 8B illustrates exemplary frames of a tutorial.
- FIGS. 9A and 9B are drawings illustrating embodiments of displayed tutorial data.
- FIG. 10 is a drawing illustrating an embodiment of displaying data with a graphical character.
- analyte is a broad term and is used in its ordinary sense, including, without limitation, to refer to a substance or chemical constituent in a biological fluid (for example, blood, interstitial fluid, cerebral spinal fluid, lymph fluid or urine) that can be analyzed. Analytes can include naturally occurring substances, artificial substances, metabolites, and/or reaction products.
- a biological fluid for example, blood, interstitial fluid, cerebral spinal fluid, lymph fluid or urine
- Analytes can include naturally occurring substances, artificial substances, metabolites, and/or reaction products.
- analytes are contemplated as well, including but not limited to acarboxyprothrombin; acylcarnitine; adenine phosphoribosyl transferase; adenosine deaminase; albumin; alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, tryptophan); andrenostenedione; antipyrine; arabinitol enantiomers; arginase; benzoylecgonine (cocaine); biotinidase; biopterin; c-reactive protein; carnitine; carnosinase; CD4; ceruloplasmin; chenodeoxycholic acid; chloroquine; cholesterol; cholinesterase; conjugated 1- ⁇ hydroxy-cholic acid; cortisol; creatine kinase; creatine kinase
- Salts, sugar, protein, fat, vitamins and hormones naturally occurring in blood or interstitial fluids can also constitute analytes in certain embodiments.
- the analyte can be naturally present in the biological fluid, for example, a metabolic product, a hormone, an antigen, an antibody, and the like.
- the analyte can be introduced into the body, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbituates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyote, p
- Analytes such as neurochemicals and other chemicals generated within the body can also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (3MT), 3,4-Dihydroxyphenylacetic acid (DOPAC), Homovanillic acid (HVA), 5-Hydroxytryptamine (5HT), and 5-Hydroxyindoleacetic acid (FHIAA).
- continuous analyte sensor is a broad term and is used in its ordinary sense, including, but not limited to, a device that continuously or continually measures a concentration of an analyte, for example, at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes, or longer.
- the continuous analyte sensor is a glucose sensor such as described in U.S. Pat. No. 6,001,067, which is incorporated herein by reference in its entirety.
- continuous analyte sensing is a broad term and is used in its ordinary sense, including, but not limited to, monitoring of an analyte continuously, for example, at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes, or longer.
- host as used herein is a broad term and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and furthermore refers without limitation to mammal, such as a human implanted with a device.
- sensor data is a broad term and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and furthermore refers without limitation to any data associated with a sensor, such as a continuous analyte sensor.
- Sensor data includes a raw data stream, or simply data stream, of analog or digital signal directly related to a measured analyte from an analyte sensor (or other signal received from another sensor), as well as calibrated and/or filtered raw data.
- the sensor data comprises digital data in “counts” converted by an A/D converter from an analog signal (e.g., voltage or amps) and includes one or more data points representative of a glucose concentration.
- sensor data point and “data point” refer generally to a digital representation of sensor data at a particular time.
- the term broadly encompasses a plurality of time spaced data points from a sensor, such as a from a substantially continuous glucose sensor, which comprises individual measurements taken at time intervals ranging from fractions of a second up to, e.g., 1, 2, or 5 minutes or longer.
- the sensor data includes an integrated digital value representative of one or more data points averaged over a time period.
- Sensor data may include calibrated data, smoothed data, filtered data, transformed data, and/or any other data associated with a sensor.
- transformed sensor data is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and furthermore refers without limitation to any data that is derived, either fully or in part, from raw sensor data from one or more sensors. For example, raw sensor data over a time period (e.g., 5 minutes) may be processed in order to generated transformed sensor data including one or more trend indicators (e.g., a 5 minute trend).
- a time period e.g., 5 minutes
- trend indicators e.g., a 5 minute trend
- transformed data examples include filtered sensor data (e.g., one or more filtered analyte concentration values), calibrated sensor data (e.g., one or more calibrated analyte concentration values), rate of change information, trend information, rate of acceleration information, sensor diagnostic information, location information, alarm/alert information, calibration information, and/or the like.
- calibration is a broad term and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and furthermore refers without limitation to a process of determining a relationship between sensor data and corresponding reference data, which can be used to convert sensor data into calibrated data (defined below).
- calibration can be updated or recalibrated over time as changes in the relationship between the sensor data and reference data occur, for example, due to changes in sensitivity, baseline, transport, metabolism, and the like.
- calibrated data and “calibrated data stream” as used herein are broad terms and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and furthermore refer without limitation to data that has been transformed from its raw state to another state using a function, for example a conversion function, to provide a meaningful value to a user.
- a function for example a conversion function
- smoothed data and “filtered data” as used herein are broad terms and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and furthermore refer without limitation to data that has been modified to make it smoother and more continuous and/or to remove or diminish outlying points, for example, by performing a moving average of the raw data stream.
- data filters include FIR (finite impulse response), IIR (infinite impulse response), moving average filters, and the like.
- smoothing and “filtering” as used herein are broad terms and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and furthermore refer without limitation to a mathematical computation that attenuates or normalizes components of a signal, such as reducing noise errors in a raw data stream.
- smoothing refers to modification of a data stream to make it smoother and more continuous or to remove or diminish outlying data points, for example, by performing a moving average of the raw data stream.
- time period is a broad term and is used in its ordinary sense, including, but not limited to, an amount of time including a single point in time and a path (for example, range of time) that extends from a first point in time to a second point in time.
- measured analyte values is a broad term and is used in its ordinary sense, including, but not limited to, an analyte value or set of analyte values for a time period for which analyte data has been measured by an analyte sensor.
- the term is broad enough to include data from the analyte sensor before or after data processing in the sensor and/or receiver (for example, data smoothing, calibration, or the like).
- estimated analyte values is a broad term and is used in its ordinary sense, including, but not limited to, an analyte value or set of analyte values, which have been algorithmically extrapolated from measured analyte values.
- estimated analyte values are estimated for a time period during which no data exists.
- estimated analyte values can also be estimated during a time period for which measured data exists, but is to be replaced by algorithmically extrapolated data due to a time lag in the measured data, for example.
- alarm is a broad term and is used in its ordinary sense, including, but not limited to, audible, visual, or tactile signals that are triggered in response to detection of clinical risk to a patient.
- hyperglycemic and hypoglycemic alarms are triggered when present or future clinical danger is assessed based on continuous analyte data.
- target analyte values and “analyte value goal,” as used herein, are broad terms and are used in their ordinary sense, including, but not limited to, an analyte value or set of analyte values that are clinically acceptable.
- a target analyte value is visually or audibly presented to a patient in order to aid in guiding the patient in understanding how they should avoid a clinically risky analyte concentration.
- therapy and “therapy recommendations,” as used herein, are broad terms and are used in their ordinary sense, including, but not limited to, the treatment of disease or disorder by any method.
- a patient is prompted with therapy recommendations such as “inject insulin” or “consume carbohydrates” in order to avoid a clinically risky glucose concentration.
- modem is a broad term and is used in its ordinary sense, including, but not limited to, an electronic device for converting between serial data from a computer and an audio signal suitable for transmission over a telecommunications connection to another modem.
- insulin pen is a broad term and is used in its ordinary sense, including, but not limited to, an insulin injection device generally the size of a pen that includes a needle and holds a vial of insulin. It can be used instead of syringes for giving insulin injections.
- insulin pump is a broad term and is used in its ordinary sense, including, but not limited to, a device that delivers a continuous supply of insulin into the body.
- the insulin flows from the pump through a plastic tube (called a catheter) that is connected to a needle inserted into the skin and taped in place, for example.
- Certain embodiments provide a continuous analyte sensor that measures a concentration of analyte within a host and provides a data stream representative of the concentration of the analyte in the host, and a receiver that processes the data stream received from the analyte sensor for output as part of a user interface that is displayed on a display of the receiver, for example.
- the analyte sensor is integral with the receiver, while in other embodiments, the analyte sensor is operatively linked to the receiver, for example, via a wired link or a wireless link.
- Sensor data associated with a host may be displayed in a variety of manners that are interesting to the user, and are configured to motivate the user to interact with the receiver, for example, pediatric users.
- the data may be depicted with graphical indicia so as to form a scene unrelated to glucose measurement.
- the scene may form a real-life picture or an animation of an event.
- the data may be depicted with an interactive animation, video game or cartoon.
- the data may be depicted as a series of frames associated with a game or a cartoon that changes in accordance with changes in sensor data.
- the graphics displayed on the frames may include rewards based on actions taken by the user or based on sensor data.
- the data displayed may be used as a tutorial for educational interaction between the sensor system and the host.
- data may be displayed with an avatar, an icon, or other character that is recognizable to the host.
- therapy recommendations can be provided that are useful in guiding the host away from clinical risk.
- interesting and/or intuitive display methods can help users to be more involved and aware of their glucose levels. This increased awareness provides the user with better recognition of current glucose trends and therefore better ability to react to and to control glucose excursions.
- the receiver casts diabetes management as a game in which users can earn and lose points according to their glycemic control over a length of time.
- the game may be played with instructions, such as “avoid glucose excursions outside target range for high score.” Points may be earned for each sensor data point indicating a glucose level that falls within the target range. In some embodiments, points may be lost for each sensor data point indicating a glucose level above or below the target range. Scores may be tallied for a fixed period of time, such as 24 hours, 1 week, 1 month, 3 months or more, and compared from period to period. In some embodiments, the number of excursions that occur after a game begins may limit the duration of the game.
- game scores may be related to clinical measures of glycemic control, such as HbA1c, and provide users and their caregivers continuous assessment of their diabetes management.
- a receiver generates user interfaces that are based on and/or include real-time sensor data, such as measured analyte values, transformed sensor data, estimated analyte values, possible variations of estimated analyte values, targets or goals for analyte values, single-point values and/or the like.
- user interfaces and/or data that is useable to generate user interfaces can be sent to a device external from the receiver, for example, a mobile computing device of a caretaker of the host, a computer, an electronic medical records system, a modem, or medical device.
- input from the user or from another device such as insulin injections (time and amount), meal times, exercise, personalized therapy recommendations, or the like, can be input into the receiver and processed to provide more customized data analysis and/or data output.
- the systems and methods described herein display sensor data in such a way as to entice interaction between the user and the sensor system. This may increase the likelihood that the host will recognize that they are in a state, e.g., hypoglycemia or hyperglycemia, for which some action should be taken for their benefit.
- a glucose sensor comprises an analyte sensor that measures a concentration of analyte of interest or a substance indicative of the concentration or presence of the analyte.
- a glucose sensor may use any known method, including invasive, minimally invasive, and non-invasive sensing techniques, to provide an output signal indicative of the concentration of the analyte of interest.
- a glucose sensor comprises a continuous analyte sensor, for example a subcutaneous, transdermal, or intravascular device.
- a glucose sensor can take a plurality of intermittent measurements.
- An analyte sensor can use any method of analyte-measurement, including enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, radiometric, or the like.
- an analyte sensor can be any sensor capable of determining the level of any analyte in the body, for example glucose, oxygen, lactase, hormones, cholesterol, medicaments, viruses, or the like. It should be understood that the devices and methods described herein can be applied to any device capable of continually or continuously detecting a concentration of analyte and providing an output signal that represents the concentration of that analyte.
- an analyte sensor is an implantable glucose sensor, such as described with reference to U.S. Pat. No. 6,001,067 and co-pending U.S. Patent Publication 2005/0027463 which are incorporated herein by reference in their entirety.
- an analyte sensor is a transcutaneous glucose sensor, such as described with reference to U.S. Provisional Patent Application 60/587,787 and 60/614,683.
- the continuous glucose sensor comprises a transcutaneous sensor such as described in U.S. Pat. No. 6,565,509 to Say et al., for example.
- a continuous glucose sensor comprises a subcutaneous sensor such as described with reference to U.S. Pat. No.
- the continuous glucose sensor comprises a refillable subcutaneous sensor such as described with reference to U.S. Pat. No. 6,512,939 to Colvin et al., for example.
- a continuous glucose sensor comprises an intravascular sensor such as described with reference to U.S. Pat. No. 6,477,395 to Schulman et al., for example.
- the continuous glucose sensor comprises an intravascular sensor such as described with reference to U.S. Pat. No. 6,424,847 to Mastrototaro et al.
- FIG. 1 is a block diagram that illustrates a receiver 12 in communication with a sensor 10 and an external device 34 .
- the continuous analyte sensor 10 is any sensor configuration that provides an output signal indicative of a concentration of an analyte.
- the output signal e.g., sensor data, such as a raw data stream, filtered data, smoothed data, and/or otherwise transformed sensor data
- the output signal may include a raw data stream that is used to provide a useful value of the measured analyte concentration to a patient or doctor, for example.
- the sensor data from the sensor 10 can be continuously or periodically algorithmically smoothed, calibrated, or otherwise modified to diminish outlying points that do not accurately represent the analyte concentration, for example due to signal noise or other signal artifacts, such as described in co-pending U.S. Pat. No. 6,931,327, which is incorporated herein by reference in its entirety.
- the receiver 12 which is operatively linked to the sensor 10 , receives a data stream from the sensor 10 via the input module 14 .
- the input module 14 includes a quartz crystal operably connected to an RF transceiver (not shown) that together function to receive and synchronize data streams from the sensor 10 .
- the input module 14 can be configured in any manner that is capable of receiving data from the sensor. Once received, the input module 14 sends the data stream to a processor 16 that processes the data stream, such as described in more detail below.
- the processor 16 is the central control unit that performs the processing, such as storing data, analyzing data streams, calibrating analyte sensor data, estimating analyte values, comparing estimated analyte values with time corresponding measured analyte values, analyzing a variation of estimated analyte values, downloading data, and controlling the user interface by providing analyte values, prompts, messages, warnings, alarms, or the like.
- the processor includes hardware that performs the processing described herein, for example read-only memory (ROM) provides permanent or semi-permanent storage of data, storing data such as sensor ID, receiver ID, and programming to process data streams (for example, programming for performing estimation and other algorithms described elsewhere herein) and random access memory (RAM) stores the system's cache memory and is helpful in data processing.
- ROM read-only memory
- RAM random access memory
- An output module 18 which may be integral with and/or operatively connected with the processor 16 , includes programming for generating output based on the sensor data received from the sensor 10 and its processing incurred in the processor 16 . In some embodiments, output is generated via one or more input/output devices 20 .
- the input/output devices 20 of this embodiment comprise a keyboard 22 , speaker 24 , vibrator 26 , backlight 28 , display device 30 , and one or more buttons 32 .
- the components that comprise the input/output devices 20 include controls to allow interaction of the user with the receiver.
- the keyboard 22 can allow, for example, input of user information about himself/herself, such as mealtime, insulin and carbohydrate ratios, exercise, insulin administration, customized therapy recommendations, and reference analyte values.
- the speaker 24 can produce, for example, audible signals or alerts for conditions such as present and/or estimated hyper- and hypoglycemic conditions in a person with diabetes.
- the vibrator 26 can provide, for example, tactile signals or alerts for reasons such as described with reference to the speaker, above.
- the display device 30 is a touch-sensitive screen.
- the buttons 32 can provide for toggle, menu selection, option selection, mode selection, and reset, for example.
- a microphone can be provided to allow for voice-activated control.
- analyte values are displayed on the display device 30 .
- prompts or messages can be displayed on the display device 30 to convey information to the user, such as reference outlier values, requests for reference analyte values, therapy recommendations, deviation of the measured analyte values from the estimated analyte values, or the like. Additionally, prompts can be displayed to guide the user through calibration or trouble-shooting of the calibration.
- data output from the output module 18 can provide wired or wireless, one- or two-way communication between the receiver 12 and an external device 34 .
- the external device 34 can be any device that interfaces or communicates with the receiver 12 .
- the external device 34 is a computer, and the receiver 12 is able to download historical data for retrospective analysis by the physician, for example.
- the external device 34 is a modem, and the receiver 12 is able to send alerts, warnings, emergency messages, or the like, via telecommunication lines to another party, such as a doctor or family member.
- the external device 34 is an insulin pen, and the receiver 12 is able to communicate therapy recommendations, such as insulin amount and time to the insulin pen.
- the external device 34 is an insulin pump, and the receiver 12 is able to communicate therapy recommendations, such as insulin amount and time to the insulin pump.
- the external device 34 can include other technology or medical devices, for example pacemakers, implanted analyte sensor patches, other infusion devices, telemetry devices, or the like.
- the receiver 12 may communicate with the external device 34 , and/or any number of additional external devices, via any suitable communication protocol, including radio frequency, Bluetooth, universal serial bus, any of the wireless local area network (WLAN) communication standards, including the IEEE 802.11, 802.15, 802.20, 802.22 and other 802 communication protocols, ZigBee, wireless (e.g., cellular) telecommunication, paging network communication, magnetic induction, satellite data communication, GPRS, ANT, and/or a proprietary communication protocol.
- WLAN wireless local area network
- the input/output devices 20 including keyboard 22 , buttons 32 , a microphone (not shown), as well as the external device 34 , can be configured to allow input of data.
- Data input can be helpful in obtaining information about the patient (for example, meal time, exercise, or the like), receiving instructions from a physician (for example, customized therapy recommendations, targets, or the like), and downloading software updates, for example.
- Keyboard, buttons, touch-screen, and microphone are all examples of mechanisms by which a user can input data directly into the receiver.
- a server, personal computer, personal digital assistant, insulin pump, and insulin pen are examples of external devices that can provide useful information to the receiver.
- Other devices internal or external to the sensor that measure other aspects of a patient's body can be used to provide input helpful in data processing.
- the user interface can prompt the patient to select an activity most closely related to their present activity, which can be helpful in linking to an individual's physiological patterns, or other data processing.
- a temperature sensor and/or heart rate monitor can provide information helpful in linking activity, metabolism, and glucose excursions of an individual.
- input/output devices can be used to generate data for tracking physical exercise performed by the host.
- a global positioning device (GPS) and/or accelerometer can be incorporated internally with or communicatively coupled externally to receiving unit 12 to provide positional and/or movement data of a host.
- Other sensors such as a heart monitor, can also be used either alone or in combination with the GPS and accelerometer, to provide exercise-related data for tracking exercise performed by the host. In doing so, types of rewards and reward values can be tracked and awarded based partly or wholly on exercise performed by the host, as discussed in more detail later in this disclosure.
- a data stream received from a continuous analyte sensor can provide an analyte value and/or other sensor data, and display the same to the host, which can be used to warn the host (or other interested party, such as a caretaker of the host or doctor) of existing clinical risk.
- a data stream received from an analyte sensor can provide historical trend analyte values, which can be used to educate a patient, caretaker, and/or doctor of individual historical trends of the patient's analyte concentration.
- Sensor data may be displayed in such a way as to be more interesting to the user than a line graph, for example.
- sensor data may be depicted as a series of frames of a game, an animation, or a cartoon.
- the display may include rewards based on actions taken by the user or based on measurement data.
- the data displayed may be used as a tutorial for educational interaction between the sensor system and the user.
- data may be displayed and/or otherwise conveyed (e.g., spoken instruction may be emitted from the speaker 24 of the receiver 12 ) by an avatar, an icon or a character depicted on the display device 30 .
- receivers such as receiver 12 of FIG. 1 have multiple games which can be selected by the user.
- the game is selected randomly or pseudorandomly.
- Each game may have graphics which are used by the receiver 12 to display the frames of the game, where each frame comprises a depiction of graphical and/or textual data on a display device.
- the graphics associated with each game may be game-specific or may be applied to multiple games.
- the graphics may be used to represent one or more aspects of sensor data received from a sensor, such as sensor 10 of FIG. 1 , and to represent game context information for the sensor data.
- FIG. 2 is a flowchart illustrating one embodiment of a method 54 of displaying sensor data as a game or a cartoon.
- the process is used by, for example, a receiver, such as receiver 12 of FIG. 1 to display a user interface that incorporates and/or is based on sensor data received.
- the process 54 includes receiving current sensor data from the sensor, which is the data point or data set most recently received, adding the received current sensor data to previously received data, determining a next frame to display based on the current sensor data and/or the previously received sensor data, and displaying the frame.
- the receiver 12 generates graphical data indicative of a sequence of historical sensor data, as well as current sensor data, in a currently displayed frame.
- the method of FIG. 3 may include fewer or additional blocks and the blocks may be performed in a different order than is illustrated.
- current sensor data is received from the sensor 10 .
- the current sensor data is added to a memory containing sensor data received previously.
- the current sensor data and the previously received sensor data collectively form stored sensor data, which is used at block 60 to determine a next frame of the game.
- the sensor data may, for example, represent a glucose level, or a range of levels.
- the sensor data is displayed with a resolution corresponding to the uncertainty of the measurement.
- Each frame may be determined based on one or more selected sets of sensor data of the stored sensor data.
- the selection of a data set for determining a next frame may be based on a certain time frame. For example, the most recent sensor data may be selected. For example, the sensor data taken in the most recent 1 hour, 3 hours, 6 hours, day, week, month, or year may be selected. Sensor data in other most recent times may also be used.
- sensor data received since a reference time may be selected. The reference time may include such times as when waking up, going to sleep, eating a meal, exercising, or taking insulin. Other reference times may be used.
- sensor data received during specified time periods may be selected. For example, sensor data received between 1 pm and 5 pm on one or more days may be selected. Other time periods may be used.
- a host's glucose response associated with a consistent event, such as lunch is analyzed such that a carbohydrate (referred to also as a “carb”) estimate and insulin amount given, for example, are analyzed to determine a “typical” lunch size.
- a carbohydrate referred to also as a “carb”
- insulin amount given for example
- the insulin delivery information may be more accurate, with the time to action being the key variable such that reasonable estimates for that might estimate not only the typical, approximate meal size, but also the diversity of the meal (all carbs, high fat, etc.) based on the response, thereby allowing more customization for bolus calculation in the future based on “typical” meals.
- hosts estimate a meal size (small, medium or large, for example) and/or meal makeup (high fat, high carb, low carb, balanced carb/fat/protein, etc.), and the sensor electronics may determine insulin delivery based on “learned” knowledge of the particular patients behavior and “typical” meal size and response.
- the selection of sensor data for a data set is based on the content of the sensor data, such as characteristics of transformed sensor data. For example, in some embodiments, sensor data taken over a specified time having glucose levels within a specified measurement range are selected and/or sensor data between upper and lower thresholds are selected. In some embodiments, sensor data greater than or less than a certain threshold are selected.
- the thresholds may, for example, correspond to blood glucose target range boundaries.
- the selected sensor data for a data set is selected based on processed data. For example, in some embodiments, raw sensor data is processed to determine rates of change in blood glucose levels for each time point for which sensor data is acquired, and data for the data set are selected for times when the rate of change in the sensor data meets certain criteria. For example, sensor data taken when the rate of change in the blood glucose levels is greater than a certain limit, less than a certain limit, or within a certain range may be selected. As another example, average glucose values for days of the past month during which the rate of change in data does not exceed a threshold may be selected for a data set. In some embodiments, the average values for days of the past month during which the rate of change in data does exceed a threshold may be also be selected as a second data set.
- the selected one or more data sets are used in conjunction with graphics associated with the current game to determine the next frame of the game.
- a selected data set may be represented with a series of frames, where each frame of the series depicts one or more data points, e.g. blood glucose levels, of the selected data set.
- the most recent data point is represented with a first graphic and the historical data is represented as multiple second graphics.
- game context graphics may also be determined based on the current game and the previous frames of the game.
- the game context graphics include graphics which represent target range boundaries.
- the range boundaries may be defined through an interface to a database storing the boundary data.
- the range boundaries may be defined by a caretaker of a child with diabetes via a computing device in communication with the child's receiver, for example.
- operation of the games may be customized according to the particular characteristics of the host.
- the game context graphics include graphics which represent a qualitative or quantitative assessment of performance. For example, a score can be shown, or an estimated HbA1c value.
- Other assessment graphics include a character having a smiling face or a frowning face, and/or a variation in a color of a graphic.
- game context graphics include a target, which indicates a desired analyte level or analyte performance characteristic.
- graphics illustrative of at least portions of the selected one or more data sets are displayed in the next frame.
- a sequence of frames is shown to generate an animation or a cartoon.
- a series of frames, each depicting a subset of the selected data set may be shown sequentially, such that each successive frame shows more of the selected data.
- the series may be displayed in response to an input from the user.
- FIG. 3A is a drawing illustrating an embodiment of a frame 64 representing sensor data.
- the frame 64 includes a graphic 66 representing an upper limit of a target range for the host's glucose level, a graphic 68 representing a lower limit of the target range for the host's glucose level, a series 70 of graphics representing historical glucose level measurements, a graphic 72 representing the most recent measurement, and a graphic 74 representing an assessment of performance.
- the graphics 70 and 72 cooperatively represent a centipede, where the centipede comprises body segment graphics 70 associated with historical sensor data, and a head graphic 72 associated with the latest sensor data.
- the head graphic 72 has a face which is frowning because the latest glucose level is outside of a desired target range.
- graphic 74 represents an assessment of performance as a numerical score.
- FIG. 3B is a drawing illustrating an embodiment of a frame 76 representing sensor data.
- Frame 76 includes a target graphic 78 , which indicates a desired glucose level or range of glucose levels
- the target graphic 78 can change positions from frame to frame in order to entice better analyte control from the user.
- FIG. 3C is a drawing illustrating an embodiment of a frame 80 representing sensor data.
- the frame 80 includes a graphic 82 representing a higher than target range for the host's glucose level, a graphic 84 representing a lower than target range for the host's glucose level, a series 86 of graphics representing historical glucose levels, a graphic 88 representing the latest glucose level, and a graphic 90 representing a target glucose level.
- the frames of a game e.g., FIGS.
- the graphic 90 is at the high end of the target range so as to entice the user to generate higher glucose levels.
- FIG. 3D is a drawing representing another exemplary frame illustrating graphics representative of historical and current sensor data.
- a vehicle graphic 91 represents the latest sensor data and a plurality of a track graphics 93 represent historical sensor data.
- the graphics 95 and 97 represent the boundaries of the desired target range, such as the sides of a road or racetrack, and may be generally vertical. In other embodiments, the boundaries, e.g., sides of the road, may be generally horizontal.
- graphics 95 and 97 are non-linear. The non-linear boundaries can be used to further entice the user to achieve preferred glucose levels.
- the boundaries (e.g., similar to graphics 95 and 97 ), which illustrates the sides of a road or racetrack, for example, may be non-linear, but parallel, or the boundaries may be linear.
- the boundaries may be user-settable and may be representative of a target glucose levels or ranges and/or may be representative of an alarm level (e.g. alert setting for hypo- or hyper-glycemia actual, predicted, or near).
- FIGS. 3E-3H are drawings representing other exemplary frames illustrating graphics representative of historical and current sensor data.
- the graphics 92 associated with historical sensor data trace paths of respective objects 94 moving toward respective targets 96 .
- an animation is displayed. For example, in the embodiment of FIG. 3E , an animation showing a bowling ball knocking down the pins may be displayed.
- the hitter may be shown hitting a home run.
- the dog may be shown eating the treat.
- the frog may be shown eating the fly.
- the games may be configured so that the targets 96 are reached at predetermined times of the day, such as just before lunch, dinner, and/or bedtime.
- various embodiments can be configured to give different types of awards depending upon whether the historical and current data stay within one or more predefined ranges (e.g., 1, 2, 3, 4 or more different ranges).
- Each award can correspond to a different award value or range of values, so that a higher award can be given if a host achieves a higher award value and a lower award can be given if the host achieves a lower award value. For example, if the historical and current data stay within a first, narrow range for a predetermined amount of time, then a higher award is given than if the historical and current data exceeds the first, narrow range during one or more time periods, but never exceeds a second, broader range during the predetermined amount of time.
- this process can be used in an environment of a virtual baseball game provided on receiver 12 .
- the highest award such as a home run
- the second highest award such as a triple base hit
- the third highest award such as a double base hit
- the historical and current data exceed the first, second and third ranges, but does not exceed a fourth range for the predetermined amount of time, then a fourth highest reward, such as a single base hit, is awarded
- the historical and current data exceed the first, second, third and fourth ranges at one or more points in time during the predetermined amount of time, then the lowest reward, such as a strike, out, end
- a type of reward given can be based wholly or partly on other criteria.
- the type of reward given can depend on a duration and/or amplitude of the historical and current data exceeding one or more ranges before the historical and current data fall back within the range during the predetermined amount of time.
- a homerun can be awarded if the historical and current data never fall outside of a range during the predetermined time period
- a triple base hit can be awarded if the historical and current data fall outside of the range for less than a threshold duration and/or the amplitude of the sensor data exceeds the range by less than a threshold amplitude.
- Second and single base hits can similarly be awarded based on other thresholds not being exceeded.
- An “out” or “end of game” can be given if one or more (including all) thresholds are exceeded.
- various weighting measures can be applied to the amplitude and duration threshold exceeded for determining the type of reward given.
- FIGS. 4A-4G are a series of drawings representing other exemplary frames illustrating an animation representative of historical and current sensor data.
- a number of flames 98 are shown, where each of the first three frames ( FIGS. 4A-4C ) illustrate a successively greater number of flames 98 .
- Each flame 98 represents a good glucose level, for example, a day in the past 30 days when the glucose level stayed within a target range, or an amount of time of the current day when the rate of change in the glucose level was less than a threshold. If a sufficient number of flames 98 are generated, an animation follows, which shows a fuse being lit, and fireworks exploding (e.g., FIGS. 4D-4G ).
- FIG. 5 shows another exemplary frame illustrating graphics representative of historical and current sensor data.
- the graphics are associated with at least two types of sensor data, such as data sets associated with a percentage of time within a target glucose range and percentage of time outside of the target glucose range.
- two cars 100 and 102 are on a race track. Each car represents one of the data sets. Some aspect of each cars performance corresponds to the data of the associated data set. For example, the speed or the distance traveled for car 100 may represent a first data set—the percentage of time in target range, and the speed or distance traveled for car 102 may represent a second data set—percentage of time out of target range.
- the animation of FIG. 5 illustrates a graphical comparison of the two data sets.
- the two data sets may be corresponding data (e.g., data from the same host) taken during two different time periods (e.g., the first data set may represent sensor data from a current week and the second data set may represent sensor data from a previous weeks).
- the animation may illustrate a graphical comparison of, for example, glucose control performance this week compared to last week.
- FIG. 6 is a flowchart illustrating an embodiment of a method of displaying sensor data as a game where rewards are given.
- the process is used by, for example, a receiver, such as receiver 12 of FIG. 1 .
- the process includes retrieving sensor data 104 , determining whether the retrieved data meets a reward criteria 106 , and displaying (or otherwise providing) a reward indication 108 .
- the process illustrated in FIG. 6 is initiated by a command generated in response to a request by a user.
- the process is initiated by any interaction with the receiver which contributes toward meeting the reward criteria.
- any interaction with the receiver contributes toward meeting the reward criteria.
- the sensor data retrieved at block 104 includes at least one of current data and historical data.
- the retrieved data may include the sensor data for the past 24 hours, or may include the sensor data for measurements taken between 12 pm and 6 pm.
- the retrieved data may include transformed sensor data, such as calibrated and/or filtered blood glucose levels and/or one or more trend or rate of change indicators, for example.
- the reward criteria to which the retrieved data is compared at block 106 may be dependent on the type of data retrieved. For example, if the retrieved data comprises sensor data for the past 24 hours, the reward criteria may be based on a minimum percentage of time for which the sensor data is within a target range. For example, the reward criteria may be set to 75%, and the retrieved data may indicate that the sensor data was within the target range 85% of the past 24 hours. In some embodiments, the reward criteria may be based on improvements in the sensor data. Accordingly, a comparison of the criteria with the retrieved data determines that the criteria for a reward has been met. If the reward criteria is not met, in some embodiments, the receiver displays an indication that the criteria is not met.
- points are awarded in response to certain actions by the host, such as receiving sensor data including a glucose level that is within an acceptable range.
- the host may receive more points every 5 minutes.
- the points may be incremented until they reach a reward threshold and then the receiver may initiate communication of a reward to the host and/or caretaker, for example.
- the reward threshold may be an incremental point level, e.g., every 5,000 points, and/or may be associated with reaching a high score (e.g., higher than previously reached by the host, possibly within a certain time period).
- the receiver displays an indication of a reward.
- the indication may include a series of frames forming an animation.
- the indication includes a single frame.
- the display depicts the retrieved data, the criteria, and the reward indication simultaneously.
- Other rewards include having the opportunity to select a new “skin” for the receiver (e.g., colors, icon designs, etc.), unlocking levels of a game, unlocking an avatar, receiving credits towards purchase of a product.
- the reward indicator is transmitted to a caretaker indicating that the user has met the reward criteria.
- the reward indication may be transmitted, for example, to a mobile device of the caretaker via email or sms.
- the reward indication is randomly or pseudorandomly selected from a plurality of stored reward indications.
- analysis information for the retrieved data such as the target range
- the reward criteria such as the 75% time within range
- access to the entry of the analysis information and the reward criteria is limited by a security device, such as a password.
- a security device such as a password
- a parent may enter a password to gain access to a data entry mode by which the parent enters reward criteria, e.g., 75% within a target range over a 24 hour period.
- FIGS. 7A and 7B illustrate embodiments including systems and methods for providing rewards to a user to encourage interactions associated with a continuous glucose monitoring system.
- Encouraging a variety of different interactions with the system will indirectly promote familiarity with the system operation, familiarity with typical user glucose levels, and familiarity with the effects user behavior has on their glucose levels. All these things will help the user control glucose levels better.
- the frequency of hypoglycemic and/or hyperglycemic events may in turn be decreased.
- the continuous glucose monitoring system includes a glucose sensor configured to provide real-time continuous glucose sensor data, a portable device comprising a user interface configured to receive user input and display the real time glucose sensor data responsive to user-interaction with the portable device and a processor module configured to tabulate a score based at least in part on user interactions with the user interface.
- the exemplary embodiment may include a configuration wherein the processor module may be located within the portable display device, it should be understood that some or all of the processing and electronic circuitry associated therewith can be located local to the sensor, for example, within a transmitter body wired to the sensor. Additionally, some or all of the processing and electronic circuitry associated therewith can be located within hardware or software operably connected with the monitoring system, for example, through a download cable or through a wireless connection to a personal computer, mainframe computer, server, or the like.
- the processor module is configured to retrieve the sensor data, either directly or indirectly through a wired or wireless connection with the sensor.
- the data can be transformed using a variety of algorithms to provide useful data to a user.
- useful data include not only real-time analyte values, but can also include trend information in the form of graphs or directional indicators, statistical data associated with a period of time, improvement in diabetes management or other metabolic control associated with an improvement with analyzed data from one time period to another time period, amount of time within a target range, and/or the like.
- a user interaction with the continuous glucose monitoring system is sensed or detected.
- the device is configured to receive sensor data from the glucose sensor
- the device is configured to selectively display information associated with the sensor data and/or the sensor data in response to interactions from the user, which can be sensed by the device.
- other user interactions with the continuous glucose monitoring system can be sensed; for example, interactions associated with a remotely located device, such as a software program or internet site running on a computer system associated with the continuous glucose monitoring system, and these interactions can be provided to the portable display device, or any processing circuitry associated with the continuous glucose monitoring system that tabulates a score or increments a reward, as described in more detail elsewhere herein.
- the sensed interaction includes at least one of pressing a button, touching a screen of the receiver, activating another input device, selecting sensor data for viewing on the receiver, downloading data, inputting events, setting parameters, confirming sensor data, and the like.
- the score may be based at least in part on receiving sensor data during a predetermined time period.
- the system may sense an interaction with the system that comprises the attachment or continuous wearing of at least a portion of the glucose monitoring system for a predetermined amount of time.
- the attachment or placement of the receiver on the user may, for example, be detected by continuous or periodic reception of sensor data from an implanted sensor without significant interruption or periods of failed data reception.
- score or reward counters may be incremented based at least in part on a completion of a sensor session (e.g., 3-, 5-, 7- or 10-day sensor session), a plurality of sensor sessions (e.g., 1, 2, 3, 4, 5, 6, 7, or more sensor sessions), predetermined number of substantially consecutive sensor sessions, a predetermined time period (e.g., 1-, 3-, 5-, 7-, 10, 14-, 21-, 30-day, or more), or the like.
- the sensed interaction is any action that causes current sensor data to be displayed. For example, pressing a button, touching a screen, adjusting an alarm for increased sensitivity (e.g., more sensitive alarm thresholds).
- the sensed interaction causes historical sensor data to be displayed, for example display of the 1, 3, 6, 9, 12, 24 hour trend screen(s) or the like.
- the sensed interaction initiates or changes a display on the receiver. For example, pressing a button or touchscreen may awaken the device from a sleep mode and cause the device to display current sensor data. A button push may change the display from current data to historical data, or may change the display to one that contains a projected future glucose concentration.
- the score increase or reward may be given in response to many different interactions regardless of the user's diligence in measuring glucose levels or success at maintaining them. Providing rewards based at least in part on such interactions, however, may lead to better success at glucose control in the future.
- the processor module is configured to tabulate a score, also referred to as incrementing a reward counter, associated with one or more user interactions, such as the user interactions described herein.
- the processor module is configured to detect substantially all sensed interactions, where substantially all sensed interactions are input into the score tabulation or reward counter.
- the processor module is configured to detect one or a plurality of predefined interactions, whereby the score or reward counter can be incremented.
- the sensed interactions used to increment the score or reward counter are independent of the creation or value of any sensor data; for example, a user can be simply rewarded for interacting with the device regardless of any performance associated with their disease management.
- the processor module is configured for sensing time periods between interactions, and incrementing the reward counter in response to a second interaction when the second interaction is sensed within a predetermined time period from a first interaction.
- the score may be incremented only if interactions with the device are performed with a certain pre-defined frequency or frequency range. Excessive delay between interactions may result in reduced or no score increment.
- a limit on the amount of reward or score may be set for a given time period, for example, a user may achieve up to a predetermined number of points for up to a predetermined number of interactions in a predetermined time period.
- a limit on the amount of reward or score may be set for a given time period, for example, a user may achieve up to a predetermined number of points for up to a predetermined number of interactions in a predetermined time period.
- the score may also be based at least in part on one or more sensor data values falling within a predetermined range. For example, when a predetermined number or average of a predetermined number of glucose values are within a target glycemic range over a period of time.
- the score is based at least in part on sensor data associated with a predetermined time period meeting one or more criteria.
- criteria can include target range of analyte values, average and/or statistical measures of analyte information over a time period.
- Average and/or statistical measures can include area under the curve, MARD, ARD, A1c, and the like.
- Some additional examples include measures of, sustained outcomes of increased normoglycemia, decreased area under curve, decreased hypoglycemic episodes, decreased variability, and the like.
- the score is based at least in part on a change in one or more sensor data values within a predetermined time period immediately after an alarm is triggered. For example, when a hypoglycemic alarm is triggered, a score can be tabulated based on the amount of time before the user achieves normoglycemia (e.g., glucose within a predefined target range). For example, the increment or value of the score can be based on whether the user achieves normoglycemia within 10, 20, 30, 40, 50, 60, 90, 120 or more minutes.
- normoglycemia e.g., glucose within a predefined target range
- the score is based at least in part on sensor data associated with a first time period indicative of an improvement in glycemic control or diabetes management as compared to sensor data associated with a historical time period, including averages or statistical measures evaluated over a predetermined time period. For example, if a user decreases the amount of time spent in a hyperglycemic range during a week time period as compare to a previous week time period, a particular score or reward amount can be calculated or tabulated. It should be appreciated that numerous other statistical and/or analytical measures of analyte data can be used to compare between any definable time periods and provided with any number or scoring options associated therewith, as can be understood by one of ordinary skill in the art.
- the score is based at least in part on user interactions involving setting of or changing of receiver operation parameters.
- Some receiver operation parameters include alarm settings (e.g., analyte thresholds, rate of change thresholds, predictive alarm settings, type of output, display features, and the like). It should be noted that operational parameters can be also be set, displayed and/or applied in a portable device type receiver and/or any other device that receives and/or displays the sensor data, including, downloadable software, web-hosted databases, servers, and the like.
- the score is based at least in part on user interactions that cause downloading of data by a user from the receiver to another processing system, for example downloadable software, web-hosted databases, servers, and the like. In some embodiments, the score is based at least in part on whether or how the user sets or confirms alarm settings on the receiver; for example, when an alarm criteria is met, the receiver triggers an alarm, and the user acknowledges the alarm by pressing a button, touching the screen, or the like.
- the score is based at least in part on an evaluation of the sensor data to determine whether the user is maintaining good control, for example by tracking a running average of average glucose over time.
- Maintaining good control can include a variety of statistical and clinical evaluations of the data, wherein the determination of good control or improvement in a particular patient's diabetes can be user settable, physician settable, adaptable by an algorithm on the system, relative to a previous sensor session or time period, or the like.
- the score is based at least in part on user events, for example, when a user enters an event into the receiver and/or other systems associated with the system.
- events include caloric intake, level of activity, health, and the like.
- the processor module is configured to display a reward indication (or score) on the receiver and/or transmit a reward indication (or score).
- a score can be a numerical value associated with a calculation with a variety of user interactions, however, other methods of scoring are possible.
- a reward indication which can include a score and/or be based at least in part on a score, can provide a physical and/or conceptual reward, including but not limited to a numerical value, credit from the manufacturer, an “opt-in” to a social networking group or site, changing of a display on the receiver when the score reaches a predetermined reward threshold (e.g., transformation of character or display animation as a reward such as described above with reference to FIGS. 3-5 ), achieving new sounds (e.g., tones, downloading of tones, animation, etc), and the like.
- a predetermined reward threshold e.g., transformation of character or display animation as a reward such as described above with reference to FIGS. 3-5
- new sounds e.g., tones, downloading
- the reward indication can be displayed on and/or transmitted to any component associated with the continuous glucose monitoring system, including, a user interface of a portable receiver, a text or email to a care giver's device linked to the user's system, downloadable software, internet site, and the like). Additionally, the score or reward indication can be configured to be displayed or transmitted continuously, at predetermined levels of achievement, at a predetermined reward threshold or value, at predetermined time periods or events, and the like.
- displaying and/or transmitting the reward includes transmitting a score and/or reward to an internet site, whereby users can connect with other users and/or their physician to share or compete. It is believed that by interacting through social networking or data sharing, additional motivation can be achieved. Additionally, rewards can be used by a manufacturer to provide credits, new features, upgrades, accessories, and the like.
- FIG. 7B is a flowchart that illustrates another exemplary process of generating rewards based on interactions of the host with the receiver.
- the method of FIG. 7B may be performed by a receiver, such as receiver 12 of FIG. 1 .
- the method of FIG. 7B may include fewer or additional blocks and/or the blocks may be performed in an order than is different than illustrated.
- interactions with the receiver contribute towards meeting one or more reward criteria.
- the method of FIG. 7B includes determining that an interaction with the receiver has occurred 110, incrementing a reward counter 112 , determining whether a reward threshold has been reached 114 , and providing a reward indication 116 .
- an interaction with the receiver is sensed.
- the interaction may include pressing a button, touching the screen, or activating another input device on the receiver.
- Interactions may also include other actions taken by the user, such as viewing sensor data on an external device.
- interaction includes downloading data, inputting events, setting parameters, confirming sensor data, and the like, as described in more detail elsewhere herein.
- interaction is based on an amount of time the sensor is used, for example, over a predetermined time period.
- a reward counter is incremented in response to sensing of an interaction at block 110 .
- all interactions generate a same increment value.
- some interactions have higher increment values than other interactions.
- interacting with the receiver in order to view glucose level trend information may be associated with a higher increment value than interacting with the receiver in order to view a current glucose level.
- increment values for the same or similar interaction may be limited during a predetermined time period. For example, a child may be limited to receiving reward points only for a first 5 times that a particular button on the receiver is pressed within any 5 minute period.
- increment values for various interactions are programmable.
- a higher increment value award can be given if a first interaction is followed by a particular second interaction.
- the first interaction can be different from or the same as the second interaction.
- a higher increment value can be given if a user follows interacting with the receiver 12 in order to view glucose level trend (a first interaction) with exercise (a second interaction).
- the receiver 12 receives or generates exercise data for determining whether the host has exercised from one or more external or internal devices, such as a GPS device, accelerometer and a heart rate sensor.
- a higher increment value can be awarded based on the level of exercise performed as determined from the exercise data.
- the value of the reward counter is compared to a reward threshold. If the comparison indicates that a reward has not been achieved, the method returns to block 110 . However, if the comparison indicates that a reward has been achieved, the method moves to block 116 , where a reward indication is provided to the host, a caretaker, a doctor, and/or other interested party.
- the reward indication may be similar to the reward indication of block 108 of FIG. 6 .
- FIG. 8A is a flowchart illustrating one embodiment of a method of interacting with a host via a tutorial.
- the method of FIG. 8A displaying tutorial data to the host, such as a series of glucose levels of an exemplary host, receiving input from the host of an action that should be taken in response to the provided exemplary glucose levels, and generating next glucose levels in response to the received input from the host.
- the tutorial may be used to educate the host as to how certain actions affect (or don't affect) the blood glucose levels.
- the tutorial data may be used to educate the user about expected consequences to various actions in various circumstances.
- the method may be performed by, for example, a receiver, such as receiver 12 of FIG. 1 .
- the method of FIG. 8 may include fewer or additional blocks and/or the blocks may be performed in an order than is different than illustrated.
- a tutorial may display graphics representing glucose measurements that are increasing. The user may select exercise as a response. The tutorial then calculates simulated glucose values based at least in part on the response. In this example, the tutorial helps the user become more familiar with expected results of performing the various actions.
- FIG. 8B illustrates three series 810 A, 810 B, 810 C, of frames that may be displayed on a receiver as part of an interactive tutorial.
- Each of the frame series 810 has three frames, including a first frame 121 that corresponds with block 120 of FIG. 8A wherein tutorial data is displayed to the host, a second frame 123 that correspond with block 122 of FIG. 8A wherein input of a simulated action is received from the host, and a third frame 127 that correspond with block 126 of FIG. 8A including graphics indicating simulated glucose measurements that are responsive to the simulated action received from the host.
- the receiver determines tutorial data.
- the tutorial data may be based at least in part on actual measurements from a glucose monitor and/or other sensor, such as episodic SMBG.
- the measurements were taken while monitoring the current host and stored in a memory.
- the memory has data from one or more other users.
- the memory data may additionally contain synthesized data, which is not the result of measurements, but is generated by a method or using a synthesis algorithm.
- the memory may contain data representing various glucose excursion scenarios, such as blood glucose levels increasing towards hyperglycemia and decreasing towards hypoglycemia.
- patterns in the tutorial data are identified and a list of potential causes, allowing user, doctor/HCP, algorithm or remote analysis to determine most likely causes, are generated and displayed as a list of potential solutions or responses.
- the potential solutions/responses the user, doctor/HCP, algorithm or remote analysis can then determine the most likely actions or responses to recommend.
- the response impact may be estimated by the sensor electronics and/or documented, e.g. whether the user/caretaker followed the advice, and if not what actions were taken.
- similar methods may be used in data management software or any remote analysis done whether by algorithm or remote HCP or clinical personnel or other trained to interpret data.
- the tutorial data is displayed.
- the tutorial data may be displayed as a series of frames displaying a game, an animation, or a cartoon.
- a series of blood glucose levels may be displayed as graphics similar to those of any of FIGS. 3A-3H .
- the tutorial data may be displayed in the form of textual data or as one or more graphs.
- frames 121 of FIG. 8B illustrates exemplary displayed tutorial data.
- the receiver receives an indication of an input from the host.
- the input indicates an action to be taken in response to the currently displayed tutorial data.
- the action can be any of eating food, eating a glucose tablet, exercising, injecting insulin, responding to stress or injury, contacting someone for help, such as a teacher, a parent, or a medical professional, and/or taking no action.
- frames 123 of FIG. 8B illustrate selected actions 125 displayed alongside the glucose data so as to indicate the relative timing of the actions 125 and the glucose data.
- the receiver simulates a response to the action indicated by the user. For example, based on the glucose levels, trends in the glucose levels, and/or the action indicated by the user, a processor in the receiver may generate a simulated response to the action based on a simulation algorithm.
- a trend in the tutorial data may not change immediately after the host indicates that an action should be taken. For example, if the host indicates an action of eating food, the tutorial data may not indicate any changes in the current trend of the blood glucose levels for 30 minutes (or some other time period) representative of a time period that is required to digest the food and increase the blood sugar levels of the exemplary host.
- the simulated responses may be compared to sensor data that was actually measured/seen, and the different in the simulated responses and the actual responses may be utilized in by the algorithm for additional user customization and response knowledge.
- the simulated response to the action is displayed.
- frames 127 of FIG. 8B illustrate simulated responses displayed along with the tutorial data and the actions 125 .
- the simulated response is displayed along with the data representing measurements prior to the action.
- the action take is represented with an icon in the display.
- an animation is generated indicating the simulated response.
- a reward indication is displayed if reward criteria are met.
- simulated responses for one or more alternate actions may be generated and displayed, for example, in response to an input indicating a request for such a display.
- a simulated response of an alternate action is generated and displayed if the action indicated by the user is not optimal.
- the method repeats blocks 120 - 126 as more simulated actions are received from the host and more simulated blood glucose levels responsive to the actions are generated by the receiver.
- the host is able to simulate an extended time period of activities (e.g., from morning until night) in a very short time frame (e.g., in 1-15 minutes, for example) while learning how certain actions affect blood glucose levels.
- the graphics used for the tutorial are similar/same as used for the actual sensor data of the host, e.g., one or more of the games illustrated in FIGS. 3A-3H or the like.
- FIGS. 9A and 9B are drawings illustrating embodiments of displayed tutorial data.
- FIG. 9A shows tutorial data 128 representing a selected glucose scenario.
- Icons 130 represent eating food, eating a glucose tablet, exercising, injecting insulin, or contacting someone for help, respectively.
- FIG. 9B shows tutorial data with actions and results of the actions.
- the actions are real actions taken by a user from whom measurements were taken and are included in the tutorial data.
- at least some of the actions are actions selected within a tutorial, and the measurements shown after the actions are simulated responses to the selected actions.
- icons such as icons 130 are used outside of a tutorial to graphically indicate actions taken by the user.
- Systems and methods can also be configured to provide a diabetes management game based on simulated or sample data. These games can be run and played on a computer system such as a PC, a PDA, a mobile phone, or the receiver 12 described above, for example.
- One mode can be configured to cause a user to compete against the computer system, wherein the computer system makes decisions (e.g., insulin dosing decisions) based on standard bolus wizards that take into account single point glucose sensor data (e.g., from a meter or significantly time spaced sensor data by at least about 4 hours) in one embodiment or continuous glucose sensor data (e.g., from an implantable sensor) in another embodiment.
- the goal of this game is for the user to achieve a good score or beat the computer system.
- the largest contributor to the score is based on exposure to glucose; in one embodiment, it could be an A1c score derived from the area under the curve over time. Deductions from the score can occur if a player has a severe hypoglycemia episode. Low variability of glucose concentration can amplify the score.
- the game can be designed to be repeatedly played by the user. In this exemplary embodiment, the game does not provide help or assistance or any advice about actions to take, but the game requires the user to read only the glucose information provided by an actual continuous glucose sensor session (e.g., glucose value, trend arrow, and/or graphical time display) and make insulin dosing decisions.
- an actual continuous glucose sensor session e.g., glucose value, trend arrow, and/or graphical time display
- the game begins with simulated and/or sample data consistent with an “out of control” patient level (e.g., high glucose variability and/or high A1c) and sequentially move toward simulated and/or sample data consistent with a “well controlled” patient level (e.g., low glucose variability and/or low A1c) as the user successfully achieves tighter glucose control (e.g., reduced exposure to glucose).
- an “out of control” patient level e.g., high glucose variability and/or high A1c
- a “well controlled” patient level e.g., low glucose variability and/or low A1c
- tighter glucose control e.g., reduced exposure to glucose
- a defined series of levels with increasing difficulty can be provided. All players may start with an A1c of 11 or higher.
- Corresponding high and low settings can be 120 and 300, for example.
- the user successfully completing this level can mean that the user has achieved an improved A1c of, for example, 10 or 10.5, and the game gets progressively more difficult as the A
- the screen moves along at about 1 hour every few seconds and at periodic times it freezes and states a scenario (e.g., “you are about to stop at fast food restaurant for a specified meal deal. How much insulin should you take?”)
- the user enters their estimation for insulin dosing, while the computer enters its estimation for insulin dosing based on the bolus wizard value.
- the player either loses or wins against the computer.
- the user is motivated to play again and again until they beat the computer and improved the glycemic control of the simulated or sample data is revealed.
- the bolus wizard is based on single point glucose sensor data
- the bolus wizard is based on continuous glucose sensor data
- the simplicity and ease of use of graphical and/or trend information associated with continuous glucose sensor data can be illustrated.
- the system can be configured to cause the user to play against a physician.
- the system is configured to display a retrospective data set from a sensor session (e.g., 3, 5 or 7 days of sample data) to the patient.
- the user is not given physician information, but instead makes insulin dosing decisions at specified events and/or time points in the data set.
- the computer system is programmed with physicians' instructions (from a real or sample physician). The goal of this game is to beat the physician.
- this mode raises awareness of the difficulty of analyzing data sets retrospectively, and points to the power of real time continuous glucose sensor data.
- the system can be configured to allow two or more users to compete.
- the same simulated and sample data (real-time or retrospective) is provided to multiple users (e.g., user vs. doctor, users online, etc).
- FIG. 10 is a drawing illustrating an embodiment of presenting information, such as sensor data or help information, in conjunction with an avatar or other graphical character.
- a graphical character 132 such as a character that may be selected by a pediatric host (e.g., as a reward for maintaining their blood glucose level within a predetermined range over a certain time period) is displayed with sensor data 134 , however, in some embodiments a graphical character is displayed without sensor data.
- the graphical character 132 is displayed with a message 136 , however, in some embodiments a graphical character is displayed without a message.
- the graphical character 132 may be, for example, any of a person, a child, an imaginary creature, an avatar, an animal, or the like. In some embodiments, the graphical character 132 is a character used with other media, such as in television or movies. In some embodiments, the graphical character 132 is displayed as having human abilities. The graphical character 132 may include one or more characters. In some embodiments, two or more characters are displayed as interacting with one another. In some embodiments, the graphical character 132 is selected through an input to the receiver. The graphical character 132 may include a portion or all of an uploaded pictures, such as pictures of family members, children, bucket list, etc. In some embodiments, the graphical character 132 is selected randomly or pseudorandomly from a group of selectable characters.
- the graphical character 132 provides a message 136 .
- the message 136 contains a therapeutic suggestion and/or motivational message in response to the sensor data 134 .
- Other messages in response to the sensor data 134 may be used.
- messages may include any of encouragement, congratulations, and warnings in response to the sensor data 134 .
- the message is not in response to sensor data.
- the message may ask for input, such as requesting the user to indicate if the user has eaten lunch.
- the message may give a reminder to perform an action, such as to request the receiver to display sensor data from the past week.
- the message may not be related to glucose monitoring.
- the message may be a joke, or display the current time of day.
- Messages may be displayed on a display device of the receiver, may be pictoral or graphical, and/or spoken (e.g., in the voice of the character) using a speaker of the receiver.
- a character is displayed in response to an input by the user, such as the push of a button.
- the character is displayed in response to another event, such as the sensor data having a specified characteristic, such as being above or below a threshold.
- the character may also be displayed in response to a time. The time may be programmed, or may be a random or pseudorandom time.
- the character is used to display the sensor data, such as the centipede 134 of FIG. 10 .
- a receiver (such as receiver 12 ) is configured to interface with a network to upload and/or download data.
- the user may upload game scores, sensor data, and/or tutorial scenarios.
- the user can download data representing games, graphics (such as graphics 70 and 72 of FIGS. 3A and 3B and graphic 82 of FIG. 3C ), target graphics (such as target graphic 78 of FIG. 3B ), animations (such as that shown in FIGS. 4A-4H and 5 ), rewards, backgrounds, sensor data, tutorial data, icons (such as icons 130 of FIGS. 9A and 9B ), graphical characters (such as graphical character 132 of FIG.
- the downloaded data may, for example, be accessible only as a reward.
- a reward may be achieved for glycemic control, where the reward allows the user or caregiver, for example, to access a network database and download a new avatar.
- parents, doctors, and/or other caretakers of patients with diabetes may make recommendations that are provided to a particular host (or a group of hosts) in response to particular alerts.
- the doctor of a particular pediatric patient may customize textual, graphical, audible, and/or other information that may be provided to the particular patient in view of the doctors knowledge of the patient needs, tolerances, etc.
- any of the above methods of data input and output can be combined, modified, selectively viewed, selectively applied, or otherwise altered without departing from the scope of the present invention.
- the various tasks performed in connection with processes (i.e. methods) described herein may be implemented by software, hardware, firmware, a computer-readable medium storing computer executable instructions for performing the process, or any combination thereof. It should be appreciated that the processes described herein may include any number of additional or alternative tasks. The tasks described and illustrated in the figures need not be performed in the described and illustrated order, and the processes may be incorporated into a more comprehensive procedure or process having additional functionality not described in detail herein. Moreover, the descriptions of the processes may refer to elements mentioned above in connection with FIG. 1 , but it is understood that other devices and systems may be used to implement aspects of the processes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Physiology (AREA)
- General Business, Economics & Management (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Business, Economics & Management (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Psychiatry (AREA)
- Signal Processing (AREA)
- Computer Networks & Wireless Communication (AREA)
- Diabetes (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Description
- Any and all priority claims identified in the Application Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 CFR 1.57. This application is a continuation of U.S. application Ser. No. 14/960,127, filed Dec. 4, 2015, which is a continuation of U.S. application Ser. No. 14/144,489, filed on Dec. 30, 2013, now U.S. Pat. No. 10,610,642, which is a continuation of U.S. application Ser. No. 12/748,069, filed on Mar. 26, 2010, now U.S. Pat. No. 9,446,194, which claims priority to U.S. Provisional Application 61/164,326, filed on Mar. 27, 2009. Each of the aforementioned applications is incorporated by reference herein in its entirety, and each is hereby expressly made a part of this specification.
- Diabetes mellitus is a disorder in which the pancreas cannot create sufficient insulin (Type I or insulin dependent) and/or in which insulin is not effective (Type 2 or non-insulin dependent). In the diabetic state, the victim suffers from high blood sugar, which may cause an array of physiological derangements (for example, kidney failure, skin ulcers, or bleeding into the vitreous of the eye) associated with the deterioration of small blood vessels. A hypoglycemic reaction (low blood sugar) may be induced by an inadvertent overdose of insulin, or after a normal dose of insulin or glucose-lowering agent accompanied by extraordinary exercise or insufficient food intake.
- Conventionally, a person with diabetes carries a self-monitoring blood glucose (SMBG) monitor, which typically requires uncomfortable finger pricking methods. Due to the lack of comfort and convenience, a person with diabetes will normally only measure his or her glucose levels two to four times per day. Unfortunately, these time intervals are so far apart that the person with diabetes will likely find out too late about hyper- or hypo-glycemic conditions. In fact, it is not only unlikely that a person with diabetes will take a timely SMBG value, it is likely that the person with diabetes will not know if their blood glucose value is going up (higher) or down (lower) based on conventional methods. Thus, their ability to make educated insulin therapy decisions is inhibited.
- Some attempts have been made to continuously measure the glucose concentration in a person with diabetes. More frequent measurements can allow the person with diabetes to know of essentially current blood sugar conditions and to make appropriate decisions in response to the current conditions. However, these continuous glucose sensors typically use methods of displaying measurement data which is uninteresting to the person with diabetes. This is especially the case when the person with diabetes is young. Pediatric persons with diabetes often do not understand, forget about, or intentionally ignore the data displayed from their continuously measured glucose monitor. Accordingly, people with diabetes experience blood sugar excursions which may have been avoided had they been more diligently interacting with their sensor system.
- Accordingly, there exists a need for improvements in displaying data from continuous glucose sensors in order to better entice the person with diabetes, such as pediatric patients, to use and interact with their monitor system.
- In one embodiment, the invention comprises a method of encouraging interactions with a receiver configured to receive sensor data from a glucose sensor. The method comprises sensing an interaction from a user with a receiver, wherein the receiver is configured to receive sensor data from the glucose sensor and to selectively display information associated with the sensor data and/or the sensor data in response to interactions from the user. In response to a plurality of different sensed interactions, a reward counter is incremented, and in response to determining that the reward counter has reached a predetermined reward threshold, a reward indication on the receiver is displayed, and/or a reward indication is transmitted.
- In another embodiment, a method of encouraging interactions with a continuous glucose monitoring system comprises sensing a user interaction with a portion of the continuous glucose monitoring system and incrementing a reward counter in response to the sensed interaction independent of the creation or value of any sensor data.
- In another embodiment, a portable sensor system is provided. The sensor system comprises a glucose sensor configured to provide real-time continuous glucose sensor data, a device comprising a user interface configured to receive user input and display the real time glucose sensor data responsive to user-interaction with the portable device, and a processor module configured to tabulate a score based at least in part on user interactions with the user interface.
-
FIG. 1 is a block diagram that illustrates a configuration of a medical device in one embodiment, including a continuous analyte sensor, a receiver, and an external device. -
FIG. 2 is a flowchart that illustrates a process of displaying sensor data as a game. -
FIGS. 3A-3H are drawings illustrating various embodiments of displayed sensor data. -
FIGS. 4A-4G are drawings illustrating an embodiment of displayed sensor data. -
FIG. 5 is a drawing illustrating an animation graphically comparing two sets of sensor data. -
FIG. 6 is a flowchart that illustrates a process of displaying sensor data as a game where rewards are given. -
FIG. 7A is a flowchart that illustrates a process of generating rewards based on user interaction. -
FIG. 7B is a flowchart that illustrates another process of generating rewards based on user interaction. -
FIG. 8A is a flowchart that illustrates a process of displaying tutorial data for a user. -
FIG. 8B illustrates exemplary frames of a tutorial. -
FIGS. 9A and 9B are drawings illustrating embodiments of displayed tutorial data. -
FIG. 10 is a drawing illustrating an embodiment of displaying data with a graphical character. - The following description and examples illustrate some exemplary embodiments of the disclosed invention in detail. Those of skill in the art will recognize that there are numerous variations and modifications of this invention that are encompassed by its scope. Accordingly, the description of a certain exemplary embodiment should not be deemed to limit the scope of the present invention.
- In order to facilitate an understanding of the disclosed invention, a number of terms are defined below.
- The term “analyte,” as used herein, is a broad term and is used in its ordinary sense, including, without limitation, to refer to a substance or chemical constituent in a biological fluid (for example, blood, interstitial fluid, cerebral spinal fluid, lymph fluid or urine) that can be analyzed. Analytes can include naturally occurring substances, artificial substances, metabolites, and/or reaction products. However, other analytes are contemplated as well, including but not limited to acarboxyprothrombin; acylcarnitine; adenine phosphoribosyl transferase; adenosine deaminase; albumin; alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, tryptophan); andrenostenedione; antipyrine; arabinitol enantiomers; arginase; benzoylecgonine (cocaine); biotinidase; biopterin; c-reactive protein; carnitine; carnosinase; CD4; ceruloplasmin; chenodeoxycholic acid; chloroquine; cholesterol; cholinesterase; conjugated 1-β hydroxy-cholic acid; cortisol; creatine kinase; creatine kinase MM isoenzyme; cyclosporin A; d-penicillamine; de-ethylchloroquine; dehydroepiandrosterone sulfate; DNA (acetylator polymorphism, alcohol dehydrogenase, alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, analyte-6-phosphate dehydrogenase, hemoglobin A, hemoglobin S, hemoglobin C, hemoglobin D, hemoglobin E, hemoglobin F, D-Punjab, beta-thalassemia, hepatitis B virus, HCMV, HIV-1, HTLV-1, Leber hereditary optic neuropathy, MCAD, RNA, PKU, Plasmodium vivax, sexual differentiation, 21-deoxycortisol); desbutylhalofantrine; dihydropteridine reductase; diptheria/tetanus antitoxin; erythrocyte arginase; erythrocyte protoporphyrin; esterase D; fatty acids/acylglycines; free β-human chorionic gonadotropin; free erythrocyte porphyrin; free thyroxine (FT4); free tri-iodothyronine (FT3); fumarylacetoacetase; galactose/gal-1-phosphate; galactose-1-phosphate uridyltransferase; gentamicin; analyte-6-phosphate dehydrogenase; glutathione; glutathione perioxidase; glycocholic acid; glycosylated hemoglobin; halofantrine; hemoglobin variants; hexosaminidase A; human erythrocyte carbonic anhydrase I; 17-alpha-hydroxyprogesterone; hypoxanthine phosphoribosyl transferase; immunoreactive trypsin; lactate; lead; lipoproteins ((a), B/A-1, β); lysozyme; mefloquine; netilmicin; phenobarbitone; phenytoin; phytanic/pristanic acid; progesterone; prolactin; prolidase; purine nucleoside phosphorylase; quinine; reverse tri-iodothyronine (rT3); selenium; serum pancreatic lipase; sissomicin; somatomedin C; specific antibodies (adenovirus, anti-nuclear antibody, anti-zeta antibody, arbovirus, Aujeszky's disease virus, dengue virus, Dracunculus medinensis, Echinococcus granulosus, Entamoeba histolytica, enterovirus, Giardia duodenalisa, Helicobacter pylori, hepatitis B virus, herpes virus, HIV-1, IgE (atopic disease), influenza virus, Leishmania donovani, leptospira, measles/mumps/rubella, Mycobacterium leprae, Mycoplasma pneumoniae, Myoglobin, Onchocerca volvulus, parainfluenza virus, Plasmodium falciparum, poliovirus, Pseudomonas aeruginosa, respiratory syncytial virus, Rickettsia (scrub typhus), Schistosoma mansoni, Toxoplasma gondii, Trepenoma pallidium, Trypanosoma cruzi/rangeli, vesicular stomatis virus, Wuchereria bancrofti, yellow fever virus); specific antigens (hepatitis B virus, HIV-1); succinylacetone; sulfadoxine; theophylline; thyrotropin (TSH); thyroxine (T4); thyroxine-binding globulin; trace elements; transferrin; UDP-galactose-4-epimerase; urea; uroporphyrinogen 1 synthase; vitamin A; white blood cells; and zinc protoporphyrin. Salts, sugar, protein, fat, vitamins and hormones naturally occurring in blood or interstitial fluids can also constitute analytes in certain embodiments. The analyte can be naturally present in the biological fluid, for example, a metabolic product, a hormone, an antigen, an antibody, and the like. Alternatively, the analyte can be introduced into the body, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbituates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyote, psilocybin); narcotics (heroin, codeine, morphine, opium, meperidine, Percocet, Percodan, Tussionex, Fentanyl, Darvon, Talwin, Lomotil); designer drugs (analogs of fentanyl, meperidine, amphetamines, methamphetamines, and phencyclidine, for example, Ecstasy); anabolic steroids; and nicotine. The metabolic products of drugs and pharmaceutical compositions are also contemplated analytes. Analytes such as neurochemicals and other chemicals generated within the body can also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (3MT), 3,4-Dihydroxyphenylacetic acid (DOPAC), Homovanillic acid (HVA), 5-Hydroxytryptamine (5HT), and 5-Hydroxyindoleacetic acid (FHIAA).
- The term “continuous analyte sensor,” as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, a device that continuously or continually measures a concentration of an analyte, for example, at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes, or longer. In one exemplary embodiment, the continuous analyte sensor is a glucose sensor such as described in U.S. Pat. No. 6,001,067, which is incorporated herein by reference in its entirety.
- The term “continuous analyte sensing,” as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, monitoring of an analyte continuously, for example, at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes, or longer.
- The term “host” as used herein is a broad term and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and furthermore refers without limitation to mammal, such as a human implanted with a device.
- The term “sensor data”, as used herein is a broad term and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and furthermore refers without limitation to any data associated with a sensor, such as a continuous analyte sensor. Sensor data includes a raw data stream, or simply data stream, of analog or digital signal directly related to a measured analyte from an analyte sensor (or other signal received from another sensor), as well as calibrated and/or filtered raw data. In one example, the sensor data comprises digital data in “counts” converted by an A/D converter from an analog signal (e.g., voltage or amps) and includes one or more data points representative of a glucose concentration. Thus, the terms “sensor data point” and “data point” refer generally to a digital representation of sensor data at a particular time. The term broadly encompasses a plurality of time spaced data points from a sensor, such as a from a substantially continuous glucose sensor, which comprises individual measurements taken at time intervals ranging from fractions of a second up to, e.g., 1, 2, or 5 minutes or longer. In another example, the sensor data includes an integrated digital value representative of one or more data points averaged over a time period. Sensor data may include calibrated data, smoothed data, filtered data, transformed data, and/or any other data associated with a sensor.
- The term “transformed sensor data” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and furthermore refers without limitation to any data that is derived, either fully or in part, from raw sensor data from one or more sensors. For example, raw sensor data over a time period (e.g., 5 minutes) may be processed in order to generated transformed sensor data including one or more trend indicators (e.g., a 5 minute trend). Other examples of transformed data include filtered sensor data (e.g., one or more filtered analyte concentration values), calibrated sensor data (e.g., one or more calibrated analyte concentration values), rate of change information, trend information, rate of acceleration information, sensor diagnostic information, location information, alarm/alert information, calibration information, and/or the like.
- The term “calibration” as used herein is a broad term and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and furthermore refers without limitation to a process of determining a relationship between sensor data and corresponding reference data, which can be used to convert sensor data into calibrated data (defined below). In some embodiments, such as continuous analyte sensors, for example, calibration can be updated or recalibrated over time as changes in the relationship between the sensor data and reference data occur, for example, due to changes in sensitivity, baseline, transport, metabolism, and the like.
- The terms “calibrated data” and “calibrated data stream” as used herein are broad terms and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and furthermore refer without limitation to data that has been transformed from its raw state to another state using a function, for example a conversion function, to provide a meaningful value to a user.
- The terms “smoothed data” and “filtered data” as used herein are broad terms and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and furthermore refer without limitation to data that has been modified to make it smoother and more continuous and/or to remove or diminish outlying points, for example, by performing a moving average of the raw data stream. Examples of data filters include FIR (finite impulse response), IIR (infinite impulse response), moving average filters, and the like.
- The terms “smoothing” and “filtering” as used herein are broad terms and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and furthermore refer without limitation to a mathematical computation that attenuates or normalizes components of a signal, such as reducing noise errors in a raw data stream. In some embodiments, smoothing refers to modification of a data stream to make it smoother and more continuous or to remove or diminish outlying data points, for example, by performing a moving average of the raw data stream.
- The term “time period,” as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, an amount of time including a single point in time and a path (for example, range of time) that extends from a first point in time to a second point in time.
- The term “measured analyte values,” as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, an analyte value or set of analyte values for a time period for which analyte data has been measured by an analyte sensor. The term is broad enough to include data from the analyte sensor before or after data processing in the sensor and/or receiver (for example, data smoothing, calibration, or the like).
- The term “estimated analyte values,” as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, an analyte value or set of analyte values, which have been algorithmically extrapolated from measured analyte values. Typically, estimated analyte values are estimated for a time period during which no data exists. However, estimated analyte values can also be estimated during a time period for which measured data exists, but is to be replaced by algorithmically extrapolated data due to a time lag in the measured data, for example.
- The term “alarm,” as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, audible, visual, or tactile signals that are triggered in response to detection of clinical risk to a patient. In one embodiment, hyperglycemic and hypoglycemic alarms are triggered when present or future clinical danger is assessed based on continuous analyte data.
- The terms “target analyte values” and “analyte value goal,” as used herein, are broad terms and are used in their ordinary sense, including, but not limited to, an analyte value or set of analyte values that are clinically acceptable. In one example, a target analyte value is visually or audibly presented to a patient in order to aid in guiding the patient in understanding how they should avoid a clinically risky analyte concentration.
- The terms “therapy” and “therapy recommendations,” as used herein, are broad terms and are used in their ordinary sense, including, but not limited to, the treatment of disease or disorder by any method. In one exemplary embodiment, a patient is prompted with therapy recommendations such as “inject insulin” or “consume carbohydrates” in order to avoid a clinically risky glucose concentration.
- The term “computer,” as used herein, is broad term and is used in its ordinary sense, including, but not limited to, machine that can be programmed to manipulate data.
- The term “modem,” as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, an electronic device for converting between serial data from a computer and an audio signal suitable for transmission over a telecommunications connection to another modem.
- The term “insulin pen,” as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, an insulin injection device generally the size of a pen that includes a needle and holds a vial of insulin. It can be used instead of syringes for giving insulin injections.
- The term “insulin pump,” as used herein, is a broad term and is used in its ordinary sense, including, but not limited to, a device that delivers a continuous supply of insulin into the body. The insulin flows from the pump through a plastic tube (called a catheter) that is connected to a needle inserted into the skin and taped in place, for example.
- Overview
- Certain embodiments provide a continuous analyte sensor that measures a concentration of analyte within a host and provides a data stream representative of the concentration of the analyte in the host, and a receiver that processes the data stream received from the analyte sensor for output as part of a user interface that is displayed on a display of the receiver, for example. In some embodiments, the analyte sensor is integral with the receiver, while in other embodiments, the analyte sensor is operatively linked to the receiver, for example, via a wired link or a wireless link.
- Sensor data associated with a host may be displayed in a variety of manners that are interesting to the user, and are configured to motivate the user to interact with the receiver, for example, pediatric users. For example, the data may be depicted with graphical indicia so as to form a scene unrelated to glucose measurement. In some embodiments, the scene may form a real-life picture or an animation of an event. In some embodiments, the data may be depicted with an interactive animation, video game or cartoon. For example, the data may be depicted as a series of frames associated with a game or a cartoon that changes in accordance with changes in sensor data. The graphics displayed on the frames may include rewards based on actions taken by the user or based on sensor data. The data displayed may be used as a tutorial for educational interaction between the sensor system and the host. In some embodiments, data may be displayed with an avatar, an icon, or other character that is recognizable to the host. In some embodiments, therapy recommendations can be provided that are useful in guiding the host away from clinical risk. Interesting and/or intuitive display methods can help users to be more involved and aware of their glucose levels. This increased awareness provides the user with better recognition of current glucose trends and therefore better ability to react to and to control glucose excursions.
- In some embodiments, the receiver casts diabetes management as a game in which users can earn and lose points according to their glycemic control over a length of time. The game may be played with instructions, such as “avoid glucose excursions outside target range for high score.” Points may be earned for each sensor data point indicating a glucose level that falls within the target range. In some embodiments, points may be lost for each sensor data point indicating a glucose level above or below the target range. Scores may be tallied for a fixed period of time, such as 24 hours, 1 week, 1 month, 3 months or more, and compared from period to period. In some embodiments, the number of excursions that occur after a game begins may limit the duration of the game. For example, the user may be allowed 3 excursions before the game is over, at which time the final score is tallied. With improved scores, the target ranges may be tightened to encouraged further improvement. In some embodiments, game scores may be related to clinical measures of glycemic control, such as HbA1c, and provide users and their caregivers continuous assessment of their diabetes management.
- In some embodiments, a receiver generates user interfaces that are based on and/or include real-time sensor data, such as measured analyte values, transformed sensor data, estimated analyte values, possible variations of estimated analyte values, targets or goals for analyte values, single-point values and/or the like. Additionally or alternatively, user interfaces and/or data that is useable to generate user interfaces, can be sent to a device external from the receiver, for example, a mobile computing device of a caretaker of the host, a computer, an electronic medical records system, a modem, or medical device. In some embodiments, input from the user or from another device, such as insulin injections (time and amount), meal times, exercise, personalized therapy recommendations, or the like, can be input into the receiver and processed to provide more customized data analysis and/or data output.
- Accordingly, the systems and methods described herein display sensor data in such a way as to entice interaction between the user and the sensor system. This may increase the likelihood that the host will recognize that they are in a state, e.g., hypoglycemia or hyperglycemia, for which some action should be taken for their benefit.
- Continuous Sensor
- In some embodiments, a glucose sensor comprises an analyte sensor that measures a concentration of analyte of interest or a substance indicative of the concentration or presence of the analyte. A glucose sensor may use any known method, including invasive, minimally invasive, and non-invasive sensing techniques, to provide an output signal indicative of the concentration of the analyte of interest. In some embodiments, a glucose sensor comprises a continuous analyte sensor, for example a subcutaneous, transdermal, or intravascular device. In some embodiments, a glucose sensor can take a plurality of intermittent measurements. An analyte sensor can use any method of analyte-measurement, including enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, radiometric, or the like. Generally, an analyte sensor can be any sensor capable of determining the level of any analyte in the body, for example glucose, oxygen, lactase, hormones, cholesterol, medicaments, viruses, or the like. It should be understood that the devices and methods described herein can be applied to any device capable of continually or continuously detecting a concentration of analyte and providing an output signal that represents the concentration of that analyte.
- In one embodiment, an analyte sensor is an implantable glucose sensor, such as described with reference to U.S. Pat. No. 6,001,067 and co-pending U.S. Patent Publication 2005/0027463 which are incorporated herein by reference in their entirety. In another embodiment, an analyte sensor is a transcutaneous glucose sensor, such as described with reference to U.S.
Provisional Patent Application 60/587,787 and 60/614,683. In one alternative embodiment, the continuous glucose sensor comprises a transcutaneous sensor such as described in U.S. Pat. No. 6,565,509 to Say et al., for example. In another alternative embodiment, a continuous glucose sensor comprises a subcutaneous sensor such as described with reference to U.S. Pat. No. 6,579,690 to Bonnecaze et al. or U.S. Pat. No. 6,484,046 to Say et al., for example. In another alternative embodiment, the continuous glucose sensor comprises a refillable subcutaneous sensor such as described with reference to U.S. Pat. No. 6,512,939 to Colvin et al., for example. In another alternative embodiment, a continuous glucose sensor comprises an intravascular sensor such as described with reference to U.S. Pat. No. 6,477,395 to Schulman et al., for example. In another alternative embodiment, the continuous glucose sensor comprises an intravascular sensor such as described with reference to U.S. Pat. No. 6,424,847 to Mastrototaro et al. All of the above patents are incorporated by reference herein in their entirety. Other signal processing techniques and glucose monitoring system embodiments suitable for use with the inventions described herein are also described in U.S. Patent Publications 2005/0203360 and 2009/0192745, both of which are incorporated herein by reference in their entireties. -
FIG. 1 is a block diagram that illustrates areceiver 12 in communication with asensor 10 and anexternal device 34. In general, thecontinuous analyte sensor 10 is any sensor configuration that provides an output signal indicative of a concentration of an analyte. The output signal (e.g., sensor data, such as a raw data stream, filtered data, smoothed data, and/or otherwise transformed sensor data) is sent to thereceiver 12 and received by aninput module 14, which is described in more detail below. The output signal may include a raw data stream that is used to provide a useful value of the measured analyte concentration to a patient or doctor, for example. In some embodiments, the sensor data from thesensor 10 can be continuously or periodically algorithmically smoothed, calibrated, or otherwise modified to diminish outlying points that do not accurately represent the analyte concentration, for example due to signal noise or other signal artifacts, such as described in co-pending U.S. Pat. No. 6,931,327, which is incorporated herein by reference in its entirety. - Receiver
- Referring again to
FIG. 1 , thereceiver 12, which is operatively linked to thesensor 10, receives a data stream from thesensor 10 via theinput module 14. In one embodiment, theinput module 14 includes a quartz crystal operably connected to an RF transceiver (not shown) that together function to receive and synchronize data streams from thesensor 10. However, theinput module 14 can be configured in any manner that is capable of receiving data from the sensor. Once received, theinput module 14 sends the data stream to aprocessor 16 that processes the data stream, such as described in more detail below. - The
processor 16 is the central control unit that performs the processing, such as storing data, analyzing data streams, calibrating analyte sensor data, estimating analyte values, comparing estimated analyte values with time corresponding measured analyte values, analyzing a variation of estimated analyte values, downloading data, and controlling the user interface by providing analyte values, prompts, messages, warnings, alarms, or the like. The processor includes hardware that performs the processing described herein, for example read-only memory (ROM) provides permanent or semi-permanent storage of data, storing data such as sensor ID, receiver ID, and programming to process data streams (for example, programming for performing estimation and other algorithms described elsewhere herein) and random access memory (RAM) stores the system's cache memory and is helpful in data processing. - An
output module 18, which may be integral with and/or operatively connected with theprocessor 16, includes programming for generating output based on the sensor data received from thesensor 10 and its processing incurred in theprocessor 16. In some embodiments, output is generated via one or more input/output devices 20. - The input/
output devices 20 of this embodiment comprise akeyboard 22,speaker 24,vibrator 26, backlight 28,display device 30, and one ormore buttons 32. The components that comprise the input/output devices 20 include controls to allow interaction of the user with the receiver. Thekeyboard 22 can allow, for example, input of user information about himself/herself, such as mealtime, insulin and carbohydrate ratios, exercise, insulin administration, customized therapy recommendations, and reference analyte values. Thespeaker 24 can produce, for example, audible signals or alerts for conditions such as present and/or estimated hyper- and hypoglycemic conditions in a person with diabetes. Thevibrator 26 can provide, for example, tactile signals or alerts for reasons such as described with reference to the speaker, above. In some embodiments, thedisplay device 30 is a touch-sensitive screen. Thebuttons 32 can provide for toggle, menu selection, option selection, mode selection, and reset, for example. In some alternative embodiments, a microphone can be provided to allow for voice-activated control. - In some embodiments, analyte values are displayed on the
display device 30. In some embodiments, prompts or messages can be displayed on thedisplay device 30 to convey information to the user, such as reference outlier values, requests for reference analyte values, therapy recommendations, deviation of the measured analyte values from the estimated analyte values, or the like. Additionally, prompts can be displayed to guide the user through calibration or trouble-shooting of the calibration. - Additionally, data output from the
output module 18 can provide wired or wireless, one- or two-way communication between thereceiver 12 and anexternal device 34. Theexternal device 34 can be any device that interfaces or communicates with thereceiver 12. In some embodiments, theexternal device 34 is a computer, and thereceiver 12 is able to download historical data for retrospective analysis by the physician, for example. In some embodiments, theexternal device 34 is a modem, and thereceiver 12 is able to send alerts, warnings, emergency messages, or the like, via telecommunication lines to another party, such as a doctor or family member. In some embodiments, theexternal device 34 is an insulin pen, and thereceiver 12 is able to communicate therapy recommendations, such as insulin amount and time to the insulin pen. In some embodiments, theexternal device 34 is an insulin pump, and thereceiver 12 is able to communicate therapy recommendations, such as insulin amount and time to the insulin pump. Theexternal device 34 can include other technology or medical devices, for example pacemakers, implanted analyte sensor patches, other infusion devices, telemetry devices, or the like. Thereceiver 12 may communicate with theexternal device 34, and/or any number of additional external devices, via any suitable communication protocol, including radio frequency, Bluetooth, universal serial bus, any of the wireless local area network (WLAN) communication standards, including the IEEE 802.11, 802.15, 802.20, 802.22 and other 802 communication protocols, ZigBee, wireless (e.g., cellular) telecommunication, paging network communication, magnetic induction, satellite data communication, GPRS, ANT, and/or a proprietary communication protocol. - The input/
output devices 20 includingkeyboard 22,buttons 32, a microphone (not shown), as well as theexternal device 34, can be configured to allow input of data. Data input can be helpful in obtaining information about the patient (for example, meal time, exercise, or the like), receiving instructions from a physician (for example, customized therapy recommendations, targets, or the like), and downloading software updates, for example. Keyboard, buttons, touch-screen, and microphone are all examples of mechanisms by which a user can input data directly into the receiver. A server, personal computer, personal digital assistant, insulin pump, and insulin pen are examples of external devices that can provide useful information to the receiver. Other devices internal or external to the sensor that measure other aspects of a patient's body (for example, temperature sensor, accelerometer, heart rate monitor, oxygen monitor, or the like) can be used to provide input helpful in data processing. In one embodiment, the user interface can prompt the patient to select an activity most closely related to their present activity, which can be helpful in linking to an individual's physiological patterns, or other data processing. In another embodiment, a temperature sensor and/or heart rate monitor can provide information helpful in linking activity, metabolism, and glucose excursions of an individual. - In a further embodiment, input/output devices can be used to generate data for tracking physical exercise performed by the host. In this regard, a global positioning device (GPS) and/or accelerometer can be incorporated internally with or communicatively coupled externally to receiving
unit 12 to provide positional and/or movement data of a host. Other sensors, such as a heart monitor, can also be used either alone or in combination with the GPS and accelerometer, to provide exercise-related data for tracking exercise performed by the host. In doing so, types of rewards and reward values can be tracked and awarded based partly or wholly on exercise performed by the host, as discussed in more detail later in this disclosure. - While a few examples of data input have been provided here, a variety of information can be input, which can be helpful in data processing as will be understood by one skilled in the art.
- Customized User Interfaces Depicting Sensor Data
- A data stream received from a continuous analyte sensor can provide an analyte value and/or other sensor data, and display the same to the host, which can be used to warn the host (or other interested party, such as a caretaker of the host or doctor) of existing clinical risk. A data stream received from an analyte sensor can provide historical trend analyte values, which can be used to educate a patient, caretaker, and/or doctor of individual historical trends of the patient's analyte concentration.
- Sensor data may be displayed in such a way as to be more interesting to the user than a line graph, for example. In one embodiment, for example, sensor data may be depicted as a series of frames of a game, an animation, or a cartoon. The display may include rewards based on actions taken by the user or based on measurement data. The data displayed may be used as a tutorial for educational interaction between the sensor system and the user. In some embodiments, data may be displayed and/or otherwise conveyed (e.g., spoken instruction may be emitted from the
speaker 24 of the receiver 12) by an avatar, an icon or a character depicted on thedisplay device 30. - In some embodiments, receivers, such as
receiver 12 ofFIG. 1 have multiple games which can be selected by the user. In some embodiments, the game is selected randomly or pseudorandomly. Each game may have graphics which are used by thereceiver 12 to display the frames of the game, where each frame comprises a depiction of graphical and/or textual data on a display device. The graphics associated with each game may be game-specific or may be applied to multiple games. The graphics may be used to represent one or more aspects of sensor data received from a sensor, such assensor 10 ofFIG. 1 , and to represent game context information for the sensor data. -
FIG. 2 is a flowchart illustrating one embodiment of amethod 54 of displaying sensor data as a game or a cartoon. The process is used by, for example, a receiver, such asreceiver 12 ofFIG. 1 to display a user interface that incorporates and/or is based on sensor data received. Theprocess 54 includes receiving current sensor data from the sensor, which is the data point or data set most recently received, adding the received current sensor data to previously received data, determining a next frame to display based on the current sensor data and/or the previously received sensor data, and displaying the frame. In some embodiments, thereceiver 12 generates graphical data indicative of a sequence of historical sensor data, as well as current sensor data, in a currently displayed frame. Depending on the embodiment, the method ofFIG. 3 may include fewer or additional blocks and the blocks may be performed in a different order than is illustrated. - At
block 56, current sensor data is received from thesensor 10. Atblock 58, the current sensor data is added to a memory containing sensor data received previously. - The current sensor data and the previously received sensor data collectively form stored sensor data, which is used at
block 60 to determine a next frame of the game. The sensor data may, for example, represent a glucose level, or a range of levels. In some embodiments, the sensor data is displayed with a resolution corresponding to the uncertainty of the measurement. - Each frame may be determined based on one or more selected sets of sensor data of the stored sensor data. The selection of a data set for determining a next frame may be based on a certain time frame. For example, the most recent sensor data may be selected. For example, the sensor data taken in the most recent 1 hour, 3 hours, 6 hours, day, week, month, or year may be selected. Sensor data in other most recent times may also be used. In some embodiments, sensor data received since a reference time may be selected. The reference time may include such times as when waking up, going to sleep, eating a meal, exercising, or taking insulin. Other reference times may be used. In some embodiments, sensor data received during specified time periods may be selected. For example, sensor data received between 1 pm and 5 pm on one or more days may be selected. Other time periods may be used.
- In one embodiment, a host's glucose response associated with a consistent event, such as lunch, is analyzed such that a carbohydrate (referred to also as a “carb”) estimate and insulin amount given, for example, are analyzed to determine a “typical” lunch size. For example, the insulin delivery information may be more accurate, with the time to action being the key variable such that reasonable estimates for that might estimate not only the typical, approximate meal size, but also the diversity of the meal (all carbs, high fat, etc.) based on the response, thereby allowing more customization for bolus calculation in the future based on “typical” meals. In one embodiment, hosts estimate a meal size (small, medium or large, for example) and/or meal makeup (high fat, high carb, low carb, balanced carb/fat/protein, etc.), and the sensor electronics may determine insulin delivery based on “learned” knowledge of the particular patients behavior and “typical” meal size and response.
- In some embodiments, the selection of sensor data for a data set is based on the content of the sensor data, such as characteristics of transformed sensor data. For example, in some embodiments, sensor data taken over a specified time having glucose levels within a specified measurement range are selected and/or sensor data between upper and lower thresholds are selected. In some embodiments, sensor data greater than or less than a certain threshold are selected. The thresholds may, for example, correspond to blood glucose target range boundaries.
- In some embodiments, the selected sensor data for a data set is selected based on processed data. For example, in some embodiments, raw sensor data is processed to determine rates of change in blood glucose levels for each time point for which sensor data is acquired, and data for the data set are selected for times when the rate of change in the sensor data meets certain criteria. For example, sensor data taken when the rate of change in the blood glucose levels is greater than a certain limit, less than a certain limit, or within a certain range may be selected. As another example, average glucose values for days of the past month during which the rate of change in data does not exceed a threshold may be selected for a data set. In some embodiments, the average values for days of the past month during which the rate of change in data does exceed a threshold may be also be selected as a second data set.
- The selected one or more data sets are used in conjunction with graphics associated with the current game to determine the next frame of the game. For example, a selected data set may be represented with a series of frames, where each frame of the series depicts one or more data points, e.g. blood glucose levels, of the selected data set. In some embodiments, the most recent data point is represented with a first graphic and the historical data is represented as multiple second graphics. In addition, game context graphics may also be determined based on the current game and the previous frames of the game. In some embodiments, the game context graphics include graphics which represent target range boundaries. The range boundaries may be defined through an interface to a database storing the boundary data. The range boundaries may be defined by a caretaker of a child with diabetes via a computing device in communication with the child's receiver, for example. Thus, operation of the games may be customized according to the particular characteristics of the host.
- In some embodiments, the game context graphics include graphics which represent a qualitative or quantitative assessment of performance. For example, a score can be shown, or an estimated HbA1c value. Other assessment graphics include a character having a smiling face or a frowning face, and/or a variation in a color of a graphic. In some embodiments, game context graphics include a target, which indicates a desired analyte level or analyte performance characteristic.
- At
block 62, graphics illustrative of at least portions of the selected one or more data sets are displayed in the next frame. In some embodiments, a sequence of frames is shown to generate an animation or a cartoon. For example, a series of frames, each depicting a subset of the selected data set may be shown sequentially, such that each successive frame shows more of the selected data. The series may be displayed in response to an input from the user. -
FIG. 3A is a drawing illustrating an embodiment of aframe 64 representing sensor data. Theframe 64 includes a graphic 66 representing an upper limit of a target range for the host's glucose level, a graphic 68 representing a lower limit of the target range for the host's glucose level, aseries 70 of graphics representing historical glucose level measurements, a graphic 72 representing the most recent measurement, and a graphic 74 representing an assessment of performance. In this embodiment, thegraphics body segment graphics 70 associated with historical sensor data, and a head graphic 72 associated with the latest sensor data. In this embodiment, the head graphic 72 has a face which is frowning because the latest glucose level is outside of a desired target range. In this embodiment, graphic 74 represents an assessment of performance as a numerical score. -
FIG. 3B is a drawing illustrating an embodiment of aframe 76 representing sensor data.Frame 76 includes a target graphic 78, which indicates a desired glucose level or range of glucose levels In some embodiments, the target graphic 78 can change positions from frame to frame in order to entice better analyte control from the user. -
FIG. 3C is a drawing illustrating an embodiment of aframe 80 representing sensor data. Theframe 80 includes a graphic 82 representing a higher than target range for the host's glucose level, a graphic 84 representing a lower than target range for the host's glucose level, aseries 86 of graphics representing historical glucose levels, a graphic 88 representing the latest glucose level, and a graphic 90 representing a target glucose level. Depending on the embodiment, the frames of a game (e.g.,FIGS. 2 and 3 ) may be updated in response to each newly received sensor data point or set, after a predetermined quantity of sensor data points or sets are received (e.g., a new frame is provided after five sensor data points or sets are received by the receiver), and/or in response to receiving sensor data matching a predefined criteria (e.g., a glucose level that is approaching a hypoglycemic level). In the embodiment ofFIG. 3C , the graphic 90 is at the high end of the target range so as to entice the user to generate higher glucose levels. -
FIG. 3D is a drawing representing another exemplary frame illustrating graphics representative of historical and current sensor data. In this embodiment a vehicle graphic 91 represents the latest sensor data and a plurality of atrack graphics 93 represent historical sensor data. Thegraphics graphics graphics 95 and 97), which illustrates the sides of a road or racetrack, for example, may be non-linear, but parallel, or the boundaries may be linear. Depending of the embodiment, the boundaries may be user-settable and may be representative of a target glucose levels or ranges and/or may be representative of an alarm level (e.g. alert setting for hypo- or hyper-glycemia actual, predicted, or near). -
FIGS. 3E-3H are drawings representing other exemplary frames illustrating graphics representative of historical and current sensor data. In these embodiments thegraphics 92 associated with historical sensor data trace paths ofrespective objects 94 moving towardrespective targets 96. In some embodiments, once the object hits the target, such as by having the latest sensor data within a desired range, an animation is displayed. For example, in the embodiment ofFIG. 3E , an animation showing a bowling ball knocking down the pins may be displayed. In the embodiment ofFIG. 3F the hitter may be shown hitting a home run. In the embodiment ofFIG. 3G , the dog may be shown eating the treat. In the embodiment ofFIG. 3H , the frog may be shown eating the fly. Depending on the embodiment, the games may be configured so that thetargets 96 are reached at predetermined times of the day, such as just before lunch, dinner, and/or bedtime. - In addition, various embodiments can be configured to give different types of awards depending upon whether the historical and current data stay within one or more predefined ranges (e.g., 1, 2, 3, 4 or more different ranges). Each award can correspond to a different award value or range of values, so that a higher award can be given if a host achieves a higher award value and a lower award can be given if the host achieves a lower award value. For example, if the historical and current data stay within a first, narrow range for a predetermined amount of time, then a higher award is given than if the historical and current data exceeds the first, narrow range during one or more time periods, but never exceeds a second, broader range during the predetermined amount of time. To illustrate, this process can be used in an environment of a virtual baseball game provided on
receiver 12. In this regard, should the historical and current data stay within a first range for a predetermined amount of time, then the highest award, such as a home run, is awarded; if the historical and current data exceed the first range, but does not exceed a second range for the predetermined amount of time, then the second highest award, such as a triple base hit, is awarded; if the historical and current data exceed the first and second ranges, but does not exceed a third range for the predetermined amount of time, then the third highest award, such as a double base hit, is awarded; if the historical and current data exceed the first, second and third ranges, but does not exceed a fourth range for the predetermined amount of time, then a fourth highest reward, such as a single base hit, is awarded; and if the historical and current data exceed the first, second, third and fourth ranges at one or more points in time during the predetermined amount of time, then the lowest reward, such as a strike, out, end of game or the like, will be given. The process can then repeat with a new predetermined amount of time and a score of the baseball game can be tallied based on the results. In this manner, a virtual baseball game can be played based on a host's glucose sensor data. - Moreover, in place of or in addition to the various ranges discussed above, a type of reward given (e.g., homerun, base hit or out) can be based wholly or partly on other criteria. For example, the type of reward given can depend on a duration and/or amplitude of the historical and current data exceeding one or more ranges before the historical and current data fall back within the range during the predetermined amount of time. To illustrate, a homerun can be awarded if the historical and current data never fall outside of a range during the predetermined time period, and a triple base hit can be awarded if the historical and current data fall outside of the range for less than a threshold duration and/or the amplitude of the sensor data exceeds the range by less than a threshold amplitude. Second and single base hits can similarly be awarded based on other thresholds not being exceeded. An “out” or “end of game” can be given if one or more (including all) thresholds are exceeded. In the event both the amplitude and duration thresholds are taken into account for awarding a type of award, various weighting measures can be applied to the amplitude and duration threshold exceeded for determining the type of reward given.
-
FIGS. 4A-4G are a series of drawings representing other exemplary frames illustrating an animation representative of historical and current sensor data. In the series of Figures, a number offlames 98 are shown, where each of the first three frames (FIGS. 4A-4C ) illustrate a successively greater number offlames 98. Eachflame 98 represents a good glucose level, for example, a day in the past 30 days when the glucose level stayed within a target range, or an amount of time of the current day when the rate of change in the glucose level was less than a threshold. If a sufficient number offlames 98 are generated, an animation follows, which shows a fuse being lit, and fireworks exploding (e.g.,FIGS. 4D-4G ). -
FIG. 5 shows another exemplary frame illustrating graphics representative of historical and current sensor data. In this embodiment, the graphics are associated with at least two types of sensor data, such as data sets associated with a percentage of time within a target glucose range and percentage of time outside of the target glucose range. In this embodiment, twocars car 100 may represent a first data set—the percentage of time in target range, and the speed or distance traveled forcar 102 may represent a second data set—percentage of time out of target range. Thus, the animation ofFIG. 5 illustrates a graphical comparison of the two data sets. In some embodiments, the two data sets may be corresponding data (e.g., data from the same host) taken during two different time periods (e.g., the first data set may represent sensor data from a current week and the second data set may represent sensor data from a previous weeks). Accordingly, the animation may illustrate a graphical comparison of, for example, glucose control performance this week compared to last week. -
FIG. 6 is a flowchart illustrating an embodiment of a method of displaying sensor data as a game where rewards are given. The process is used by, for example, a receiver, such asreceiver 12 ofFIG. 1 . The process includes retrievingsensor data 104, determining whether the retrieved data meets areward criteria 106, and displaying (or otherwise providing) areward indication 108. In some embodiments, the process illustrated inFIG. 6 is initiated by a command generated in response to a request by a user. In some embodiments, the process is initiated by any interaction with the receiver which contributes toward meeting the reward criteria. In some embodiments, any interaction with the receiver contributes toward meeting the reward criteria. - The sensor data retrieved at
block 104 includes at least one of current data and historical data. For example, the retrieved data may include the sensor data for the past 24 hours, or may include the sensor data for measurements taken between 12 pm and 6 pm. In some embodiments, the retrieved data may include transformed sensor data, such as calibrated and/or filtered blood glucose levels and/or one or more trend or rate of change indicators, for example. - The reward criteria to which the retrieved data is compared at
block 106 may be dependent on the type of data retrieved. For example, if the retrieved data comprises sensor data for the past 24 hours, the reward criteria may be based on a minimum percentage of time for which the sensor data is within a target range. For example, the reward criteria may be set to 75%, and the retrieved data may indicate that the sensor data was within the target range 85% of the past 24 hours. In some embodiments, the reward criteria may be based on improvements in the sensor data. Accordingly, a comparison of the criteria with the retrieved data determines that the criteria for a reward has been met. If the reward criteria is not met, in some embodiments, the receiver displays an indication that the criteria is not met. - In one embodiment, points are awarded in response to certain actions by the host, such as receiving sensor data including a glucose level that is within an acceptable range. Thus, if sensor data is received every 5 minutes, for example, the host may receive more points every 5 minutes. The points may be incremented until they reach a reward threshold and then the receiver may initiate communication of a reward to the host and/or caretaker, for example. The reward threshold may be an incremental point level, e.g., every 5,000 points, and/or may be associated with reaching a high score (e.g., higher than previously reached by the host, possibly within a certain time period).
- If the reward criteria is met, at
block 108 the receiver displays an indication of a reward. The indication may include a series of frames forming an animation. In some embodiments, the indication includes a single frame. In some embodiments, the display depicts the retrieved data, the criteria, and the reward indication simultaneously. Other rewards include having the opportunity to select a new “skin” for the receiver (e.g., colors, icon designs, etc.), unlocking levels of a game, unlocking an avatar, receiving credits towards purchase of a product. In some embodiments, the reward indicator is transmitted to a caretaker indicating that the user has met the reward criteria. The reward indication may be transmitted, for example, to a mobile device of the caretaker via email or sms. In some embodiments, the reward indication is randomly or pseudorandomly selected from a plurality of stored reward indications. - In some embodiments, analysis information for the retrieved data, such as the target range, and the reward criteria, such as the 75% time within range, are entered by the user. In some embodiments, access to the entry of the analysis information and the reward criteria is limited by a security device, such as a password. For example, a parent may enter a password to gain access to a data entry mode by which the parent enters reward criteria, e.g., 75% within a target range over a 24 hour period.
-
FIGS. 7A and 7B illustrate embodiments including systems and methods for providing rewards to a user to encourage interactions associated with a continuous glucose monitoring system. Some studies of pediatric diabetes have shown that as the child increases interactions with their receiver, hypoglycemic and hyperglycemic events are decreased. Much of this difference in glucose control may be due to the fact that users that are interested in being diligent in controlling glucose levels will interact with the receiver more according to this interest. However, this improvement in control can also be attained with less naturally diligent users by encouraging interactions of all kinds with the glucose monitoring system, even when those interactions are independent of the creation of or value of any sensor data. Encouraging a variety of different interactions with the system (in some embodiments all or substantially all interactions) will indirectly promote familiarity with the system operation, familiarity with typical user glucose levels, and familiarity with the effects user behavior has on their glucose levels. All these things will help the user control glucose levels better. Thus, by providing rewards to a child or other user with diabetes in response to many different types of interactions with their receiver or other portions of the monitoring system (e.g. pressing various buttons, changing display outputs, setting alarms, etc.), the frequency of hypoglycemic and/or hyperglycemic events may in turn be decreased. - In one such exemplary embodiment, the continuous glucose monitoring system includes a glucose sensor configured to provide real-time continuous glucose sensor data, a portable device comprising a user interface configured to receive user input and display the real time glucose sensor data responsive to user-interaction with the portable device and a processor module configured to tabulate a score based at least in part on user interactions with the user interface. While the exemplary embodiment may include a configuration wherein the processor module may be located within the portable display device, it should be understood that some or all of the processing and electronic circuitry associated therewith can be located local to the sensor, for example, within a transmitter body wired to the sensor. Additionally, some or all of the processing and electronic circuitry associated therewith can be located within hardware or software operably connected with the monitoring system, for example, through a download cable or through a wireless connection to a personal computer, mainframe computer, server, or the like.
- Referring now to
FIG. 7A , atblock 111, the processor module is configured to retrieve the sensor data, either directly or indirectly through a wired or wireless connection with the sensor. As described in more detail elsewhere herein, the data can be transformed using a variety of algorithms to provide useful data to a user. Examples of useful data include not only real-time analyte values, but can also include trend information in the form of graphs or directional indicators, statistical data associated with a period of time, improvement in diabetes management or other metabolic control associated with an improvement with analyzed data from one time period to another time period, amount of time within a target range, and/or the like. - At
block 113, a user interaction with the continuous glucose monitoring system is sensed or detected. In the exemplary embodiment of a portable display device, wherein the device is configured to receive sensor data from the glucose sensor, the device is configured to selectively display information associated with the sensor data and/or the sensor data in response to interactions from the user, which can be sensed by the device. However, other user interactions with the continuous glucose monitoring system can be sensed; for example, interactions associated with a remotely located device, such as a software program or internet site running on a computer system associated with the continuous glucose monitoring system, and these interactions can be provided to the portable display device, or any processing circuitry associated with the continuous glucose monitoring system that tabulates a score or increments a reward, as described in more detail elsewhere herein. - In some embodiments, the sensed interaction includes at least one of pressing a button, touching a screen of the receiver, activating another input device, selecting sensor data for viewing on the receiver, downloading data, inputting events, setting parameters, confirming sensor data, and the like. In some embodiments, the score may be based at least in part on receiving sensor data during a predetermined time period. In some of these embodiments, the system may sense an interaction with the system that comprises the attachment or continuous wearing of at least a portion of the glucose monitoring system for a predetermined amount of time. The attachment or placement of the receiver on the user may, for example, be detected by continuous or periodic reception of sensor data from an implanted sensor without significant interruption or periods of failed data reception. For example, wherein the monitoring system is configured for a particular sensor session time period (e.g., 3, 5, 7, 10 days, or the like), score or reward counters may be incremented based at least in part on a completion of a sensor session (e.g., 3-, 5-, 7- or 10-day sensor session), a plurality of sensor sessions (e.g., 1, 2, 3, 4, 5, 6, 7, or more sensor sessions), predetermined number of substantially consecutive sensor sessions, a predetermined time period (e.g., 1-, 3-, 5-, 7-, 10, 14-, 21-, 30-day, or more), or the like.
- In some embodiments, the sensed interaction is any action that causes current sensor data to be displayed. For example, pressing a button, touching a screen, adjusting an alarm for increased sensitivity (e.g., more sensitive alarm thresholds). In some embodiments, the sensed interaction causes historical sensor data to be displayed, for example display of the 1, 3, 6, 9, 12, 24 hour trend screen(s) or the like. In some embodiments, the sensed interaction initiates or changes a display on the receiver. For example, pressing a button or touchscreen may awaken the device from a sleep mode and cause the device to display current sensor data. A button push may change the display from current data to historical data, or may change the display to one that contains a projected future glucose concentration. It may be noted here that the score increase or reward may be given in response to many different interactions regardless of the user's diligence in measuring glucose levels or success at maintaining them. Providing rewards based at least in part on such interactions, however, may lead to better success at glucose control in the future.
- At
block 115, the processor module is configured to tabulate a score, also referred to as incrementing a reward counter, associated with one or more user interactions, such as the user interactions described herein. In some embodiments, the processor module is configured to detect substantially all sensed interactions, where substantially all sensed interactions are input into the score tabulation or reward counter. In some embodiments, the processor module is configured to detect one or a plurality of predefined interactions, whereby the score or reward counter can be incremented. In some embodiments, the sensed interactions used to increment the score or reward counter are independent of the creation or value of any sensor data; for example, a user can be simply rewarded for interacting with the device regardless of any performance associated with their disease management. - In some cases, it is advantageous to include time based limitations on which interactions can cause the score or reward counter to be incremented. Thus, in some embodiments, the processor module is configured for sensing time periods between interactions, and incrementing the reward counter in response to a second interaction when the second interaction is sensed within a predetermined time period from a first interaction. For example, the score may be incremented only if interactions with the device are performed with a certain pre-defined frequency or frequency range. Excessive delay between interactions may result in reduced or no score increment. At the other end of the spectrum, to avoid having a user just mindlessly press buttons to achieve high scores, a limit on the amount of reward or score may be set for a given time period, for example, a user may achieve up to a predetermined number of points for up to a predetermined number of interactions in a predetermined time period. One of ordinary skill in the art can appreciate a variety of numerical and time-based limits that may be applied to encourage a reasonable or optimal interaction frequency.
- As noted above, it is believed to be advantageous to increment scores/reward counters based on interactions that are not dependent on glucose measurements themselves. However, this does not mean that providing rewards for direct success in glucose management is not also worthwhile as part of a reward system. Thus, in some embodiments, the score may also be based at least in part on one or more sensor data values falling within a predetermined range. For example, when a predetermined number or average of a predetermined number of glucose values are within a target glycemic range over a period of time.
- In some embodiments, the score is based at least in part on sensor data associated with a predetermined time period meeting one or more criteria. For example, criteria can include target range of analyte values, average and/or statistical measures of analyte information over a time period. Average and/or statistical measures can include area under the curve, MARD, ARD, A1c, and the like. Some additional examples include measures of, sustained outcomes of increased normoglycemia, decreased area under curve, decreased hypoglycemic episodes, decreased variability, and the like.
- In some embodiments, the score is based at least in part on a change in one or more sensor data values within a predetermined time period immediately after an alarm is triggered. For example, when a hypoglycemic alarm is triggered, a score can be tabulated based on the amount of time before the user achieves normoglycemia (e.g., glucose within a predefined target range). For example, the increment or value of the score can be based on whether the user achieves normoglycemia within 10, 20, 30, 40, 50, 60, 90, 120 or more minutes.
- In some embodiments, the score is based at least in part on sensor data associated with a first time period indicative of an improvement in glycemic control or diabetes management as compared to sensor data associated with a historical time period, including averages or statistical measures evaluated over a predetermined time period. For example, if a user decreases the amount of time spent in a hyperglycemic range during a week time period as compare to a previous week time period, a particular score or reward amount can be calculated or tabulated. It should be appreciated that numerous other statistical and/or analytical measures of analyte data can be used to compare between any definable time periods and provided with any number or scoring options associated therewith, as can be understood by one of ordinary skill in the art.
- In some embodiments, the score is based at least in part on user interactions involving setting of or changing of receiver operation parameters. Some receiver operation parameters include alarm settings (e.g., analyte thresholds, rate of change thresholds, predictive alarm settings, type of output, display features, and the like). It should be noted that operational parameters can be also be set, displayed and/or applied in a portable device type receiver and/or any other device that receives and/or displays the sensor data, including, downloadable software, web-hosted databases, servers, and the like.
- In some embodiments, the score is based at least in part on user interactions that cause downloading of data by a user from the receiver to another processing system, for example downloadable software, web-hosted databases, servers, and the like. In some embodiments, the score is based at least in part on whether or how the user sets or confirms alarm settings on the receiver; for example, when an alarm criteria is met, the receiver triggers an alarm, and the user acknowledges the alarm by pressing a button, touching the screen, or the like.
- In some embodiments, the score is based at least in part on an evaluation of the sensor data to determine whether the user is maintaining good control, for example by tracking a running average of average glucose over time. Maintaining good control can include a variety of statistical and clinical evaluations of the data, wherein the determination of good control or improvement in a particular patient's diabetes can be user settable, physician settable, adaptable by an algorithm on the system, relative to a previous sensor session or time period, or the like.
- In some embodiments, the score is based at least in part on user events, for example, when a user enters an event into the receiver and/or other systems associated with the system. Some examples of events include caloric intake, level of activity, health, and the like.
- Whether tabulating a score, incrementing a reward counter, or the like, it should be appreciated by one of ordinary skill in the art that different criteria can be given different weighting and/or points. For example, wherein the goal of a physician is to simply encourage regular wear of the continuous glucose monitoring system, the system can be set with a heavy weight (e.g., highest scoring) for continuous sensor wear and/or user interaction as compared to achieving targets with regard to sensor data. Numerous scoring or incrementing methods can be implemented by the manufacturer, user settable (e.g., by a user or care giver), via downloadable software, via communication with an internet site and/or the like.
- At
block 117, the processor module is configured to display a reward indication (or score) on the receiver and/or transmit a reward indication (or score). A score can be a numerical value associated with a calculation with a variety of user interactions, however, other methods of scoring are possible. A reward indication, which can include a score and/or be based at least in part on a score, can provide a physical and/or conceptual reward, including but not limited to a numerical value, credit from the manufacturer, an “opt-in” to a social networking group or site, changing of a display on the receiver when the score reaches a predetermined reward threshold (e.g., transformation of character or display animation as a reward such as described above with reference toFIGS. 3-5 ), achieving new sounds (e.g., tones, downloading of tones, animation, etc), and the like. - The reward indication can be displayed on and/or transmitted to any component associated with the continuous glucose monitoring system, including, a user interface of a portable receiver, a text or email to a care giver's device linked to the user's system, downloadable software, internet site, and the like). Additionally, the score or reward indication can be configured to be displayed or transmitted continuously, at predetermined levels of achievement, at a predetermined reward threshold or value, at predetermined time periods or events, and the like.
- In some embodiments, displaying and/or transmitting the reward includes transmitting a score and/or reward to an internet site, whereby users can connect with other users and/or their physician to share or compete. It is believed that by interacting through social networking or data sharing, additional motivation can be achieved. Additionally, rewards can be used by a manufacturer to provide credits, new features, upgrades, accessories, and the like.
-
FIG. 7B is a flowchart that illustrates another exemplary process of generating rewards based on interactions of the host with the receiver. The method ofFIG. 7B may be performed by a receiver, such asreceiver 12 ofFIG. 1 . Depending on the embodiment, the method ofFIG. 7B may include fewer or additional blocks and/or the blocks may be performed in an order than is different than illustrated. - In the embodiment of
FIG. 7B , interactions with the receiver contribute towards meeting one or more reward criteria. The method ofFIG. 7B includes determining that an interaction with the receiver has occurred 110, incrementing areward counter 112, determining whether a reward threshold has been reached 114, and providing areward indication 116. - At
block 110 an interaction with the receiver is sensed. Depending on the embodiment, and as described above as well, the interaction may include pressing a button, touching the screen, or activating another input device on the receiver. Interactions may also include other actions taken by the user, such as viewing sensor data on an external device. In some embodiments, interaction includes downloading data, inputting events, setting parameters, confirming sensor data, and the like, as described in more detail elsewhere herein. In some embodiments, interaction is based on an amount of time the sensor is used, for example, over a predetermined time period. - At block 112 a reward counter is incremented in response to sensing of an interaction at
block 110. In some embodiments, all interactions generate a same increment value. In some embodiments, some interactions have higher increment values than other interactions. For example, interacting with the receiver in order to view glucose level trend information may be associated with a higher increment value than interacting with the receiver in order to view a current glucose level. In one embodiment, increment values for the same or similar interaction may be limited during a predetermined time period. For example, a child may be limited to receiving reward points only for a first 5 times that a particular button on the receiver is pressed within any 5 minute period. In some embodiments, increment values for various interactions are programmable. - In addition, a higher increment value award can be given if a first interaction is followed by a particular second interaction. The first interaction can be different from or the same as the second interaction. As an example, a higher increment value can be given if a user follows interacting with the
receiver 12 in order to view glucose level trend (a first interaction) with exercise (a second interaction). In various embodiments, thereceiver 12 receives or generates exercise data for determining whether the host has exercised from one or more external or internal devices, such as a GPS device, accelerometer and a heart rate sensor. Furthermore, a higher increment value can be awarded based on the level of exercise performed as determined from the exercise data. - At
block 114 the value of the reward counter is compared to a reward threshold. If the comparison indicates that a reward has not been achieved, the method returns to block 110. However, if the comparison indicates that a reward has been achieved, the method moves to block 116, where a reward indication is provided to the host, a caretaker, a doctor, and/or other interested party. The reward indication may be similar to the reward indication ofblock 108 ofFIG. 6 . -
FIG. 8A is a flowchart illustrating one embodiment of a method of interacting with a host via a tutorial. The method ofFIG. 8A displaying tutorial data to the host, such as a series of glucose levels of an exemplary host, receiving input from the host of an action that should be taken in response to the provided exemplary glucose levels, and generating next glucose levels in response to the received input from the host. In this way, the tutorial may be used to educate the host as to how certain actions affect (or don't affect) the blood glucose levels. The tutorial data may be used to educate the user about expected consequences to various actions in various circumstances. The method may be performed by, for example, a receiver, such asreceiver 12 ofFIG. 1 . Depending on the embodiment, the method ofFIG. 8 may include fewer or additional blocks and/or the blocks may be performed in an order than is different than illustrated. - For example, a tutorial may display graphics representing glucose measurements that are increasing. The user may select exercise as a response. The tutorial then calculates simulated glucose values based at least in part on the response. In this example, the tutorial helps the user become more familiar with expected results of performing the various actions.
-
FIG. 8B illustrates three series 810A, 810B, 810C, of frames that may be displayed on a receiver as part of an interactive tutorial. Each of the frame series 810 has three frames, including afirst frame 121 that corresponds withblock 120 ofFIG. 8A wherein tutorial data is displayed to the host, asecond frame 123 that correspond withblock 122 ofFIG. 8A wherein input of a simulated action is received from the host, and athird frame 127 that correspond withblock 126 ofFIG. 8A including graphics indicating simulated glucose measurements that are responsive to the simulated action received from the host. - Beginning in
block 118, the receiver determines tutorial data. The tutorial data may be based at least in part on actual measurements from a glucose monitor and/or other sensor, such as episodic SMBG. In some embodiments, the measurements were taken while monitoring the current host and stored in a memory. In some embodiments, the memory has data from one or more other users. The memory data may additionally contain synthesized data, which is not the result of measurements, but is generated by a method or using a synthesis algorithm. The memory may contain data representing various glucose excursion scenarios, such as blood glucose levels increasing towards hyperglycemia and decreasing towards hypoglycemia. - In one embodiment, patterns in the tutorial data are identified and a list of potential causes, allowing user, doctor/HCP, algorithm or remote analysis to determine most likely causes, are generated and displayed as a list of potential solutions or responses. With the potential solutions/responses, the user, doctor/HCP, algorithm or remote analysis can then determine the most likely actions or responses to recommend. In one embodiment, the response impact may be estimated by the sensor electronics and/or documented, e.g. whether the user/caretaker followed the advice, and if not what actions were taken. In one embodiment, similar methods may be used in data management software or any remote analysis done whether by algorithm or remote HCP or clinical personnel or other trained to interpret data.
- At
block 120, the tutorial data is displayed. The tutorial data may be displayed as a series of frames displaying a game, an animation, or a cartoon. For example, a series of blood glucose levels may be displayed as graphics similar to those of any ofFIGS. 3A-3H . In other embodiments, the tutorial data may be displayed in the form of textual data or as one or more graphs. As noted above, frames 121 ofFIG. 8B illustrates exemplary displayed tutorial data. - Next, in
block 122, the receiver receives an indication of an input from the host. The input indicates an action to be taken in response to the currently displayed tutorial data. For example, the action can be any of eating food, eating a glucose tablet, exercising, injecting insulin, responding to stress or injury, contacting someone for help, such as a teacher, a parent, or a medical professional, and/or taking no action. As noted above, frames 123 ofFIG. 8B illustrate selectedactions 125 displayed alongside the glucose data so as to indicate the relative timing of theactions 125 and the glucose data. - At
block 124, the receiver simulates a response to the action indicated by the user. For example, based on the glucose levels, trends in the glucose levels, and/or the action indicated by the user, a processor in the receiver may generate a simulated response to the action based on a simulation algorithm. In one embodiment, a trend in the tutorial data may not change immediately after the host indicates that an action should be taken. For example, if the host indicates an action of eating food, the tutorial data may not indicate any changes in the current trend of the blood glucose levels for 30 minutes (or some other time period) representative of a time period that is required to digest the food and increase the blood sugar levels of the exemplary host. In one embodiment, the simulated responses may be compared to sensor data that was actually measured/seen, and the different in the simulated responses and the actual responses may be utilized in by the algorithm for additional user customization and response knowledge. - At
block 126, the simulated response to the action is displayed. As noted above, frames 127 ofFIG. 8B illustrate simulated responses displayed along with the tutorial data and theactions 125. In some embodiments, the simulated response is displayed along with the data representing measurements prior to the action. In some embodiments, the action take is represented with an icon in the display. In some embodiments, an animation is generated indicating the simulated response. In some embodiments, a reward indication is displayed if reward criteria are met. In some embodiments, simulated responses for one or more alternate actions may be generated and displayed, for example, in response to an input indicating a request for such a display. In some embodiments, a simulated response of an alternate action is generated and displayed if the action indicated by the user is not optimal. - In one embodiment, the method repeats blocks 120-126 as more simulated actions are received from the host and more simulated blood glucose levels responsive to the actions are generated by the receiver. In this way, the host is able to simulate an extended time period of activities (e.g., from morning until night) in a very short time frame (e.g., in 1-15 minutes, for example) while learning how certain actions affect blood glucose levels. In one embodiment, the graphics used for the tutorial are similar/same as used for the actual sensor data of the host, e.g., one or more of the games illustrated in
FIGS. 3A-3H or the like. -
FIGS. 9A and 9B are drawings illustrating embodiments of displayed tutorial data.FIG. 9A showstutorial data 128 representing a selected glucose scenario.Icons 130 represent eating food, eating a glucose tablet, exercising, injecting insulin, or contacting someone for help, respectively.FIG. 9B shows tutorial data with actions and results of the actions. In some embodiments, the actions are real actions taken by a user from whom measurements were taken and are included in the tutorial data. In some embodiments, at least some of the actions are actions selected within a tutorial, and the measurements shown after the actions are simulated responses to the selected actions. In some embodiments, icons such asicons 130 are used outside of a tutorial to graphically indicate actions taken by the user. - Systems and methods can also be configured to provide a diabetes management game based on simulated or sample data. These games can be run and played on a computer system such as a PC, a PDA, a mobile phone, or the
receiver 12 described above, for example. One mode can be configured to cause a user to compete against the computer system, wherein the computer system makes decisions (e.g., insulin dosing decisions) based on standard bolus wizards that take into account single point glucose sensor data (e.g., from a meter or significantly time spaced sensor data by at least about 4 hours) in one embodiment or continuous glucose sensor data (e.g., from an implantable sensor) in another embodiment. Preferably, the goal of this game is for the user to achieve a good score or beat the computer system. In one embodiment, the largest contributor to the score is based on exposure to glucose; in one embodiment, it could be an A1c score derived from the area under the curve over time. Deductions from the score can occur if a player has a severe hypoglycemia episode. Low variability of glucose concentration can amplify the score. The game can be designed to be repeatedly played by the user. In this exemplary embodiment, the game does not provide help or assistance or any advice about actions to take, but the game requires the user to read only the glucose information provided by an actual continuous glucose sensor session (e.g., glucose value, trend arrow, and/or graphical time display) and make insulin dosing decisions. - In one example, the game begins with simulated and/or sample data consistent with an “out of control” patient level (e.g., high glucose variability and/or high A1c) and sequentially move toward simulated and/or sample data consistent with a “well controlled” patient level (e.g., low glucose variability and/or low A1c) as the user successfully achieves tighter glucose control (e.g., reduced exposure to glucose). For example, a defined series of levels with increasing difficulty can be provided. All players may start with an A1c of 11 or higher. Corresponding high and low settings can be 120 and 300, for example. The user successfully completing this level can mean that the user has achieved an improved A1c of, for example, 10 or 10.5, and the game gets progressively more difficult as the A1c gets lower, and the high and low limits narrow.
- For example, the screen moves along at about 1 hour every few seconds and at periodic times it freezes and states a scenario (e.g., “you are about to stop at fast food restaurant for a specified meal deal. How much insulin should you take?”) The user enters their estimation for insulin dosing, while the computer enters its estimation for insulin dosing based on the bolus wizard value. At the end of a prescribed period of time, the player either loses or wins against the computer. Advantageously, the user is motivated to play again and again until they beat the computer and improved the glycemic control of the simulated or sample data is revealed. In embodiments wherein the bolus wizard is based on single point glucose sensor data, it is believed that the usefulness of continuous glucose sensor data can easily be exemplified. In embodiments wherein the bolus wizard is based on continuous glucose sensor data, the simplicity and ease of use of graphical and/or trend information associated with continuous glucose sensor data can be illustrated.
- In another mode, the system can be configured to cause the user to play against a physician. In this mode, the system is configured to display a retrospective data set from a sensor session (e.g., 3, 5 or 7 days of sample data) to the patient. The user is not given physician information, but instead makes insulin dosing decisions at specified events and/or time points in the data set. The computer system is programmed with physicians' instructions (from a real or sample physician). The goal of this game is to beat the physician. Advantageously, this mode raises awareness of the difficulty of analyzing data sets retrospectively, and points to the power of real time continuous glucose sensor data.
- In yet another mode, the system can be configured to allow two or more users to compete. In this mode, the same simulated and sample data (real-time or retrospective) is provided to multiple users (e.g., user vs. doctor, users online, etc).
-
FIG. 10 is a drawing illustrating an embodiment of presenting information, such as sensor data or help information, in conjunction with an avatar or other graphical character. In this embodiment, agraphical character 132, such as a character that may be selected by a pediatric host (e.g., as a reward for maintaining their blood glucose level within a predetermined range over a certain time period) is displayed withsensor data 134, however, in some embodiments a graphical character is displayed without sensor data. In this embodiment, thegraphical character 132 is displayed with amessage 136, however, in some embodiments a graphical character is displayed without a message. - The
graphical character 132 may be, for example, any of a person, a child, an imaginary creature, an avatar, an animal, or the like. In some embodiments, thegraphical character 132 is a character used with other media, such as in television or movies. In some embodiments, thegraphical character 132 is displayed as having supernatural abilities. Thegraphical character 132 may include one or more characters. In some embodiments, two or more characters are displayed as interacting with one another. In some embodiments, thegraphical character 132 is selected through an input to the receiver. Thegraphical character 132 may include a portion or all of an uploaded pictures, such as pictures of family members, children, bucket list, etc. In some embodiments, thegraphical character 132 is selected randomly or pseudorandomly from a group of selectable characters. - In the embodiment of
FIG. 10 , thegraphical character 132 provides amessage 136. Themessage 136 contains a therapeutic suggestion and/or motivational message in response to thesensor data 134. Other messages in response to thesensor data 134 may be used. For example, messages may include any of encouragement, congratulations, and warnings in response to thesensor data 134. In some embodiments, the message is not in response to sensor data. For example, the message may ask for input, such as requesting the user to indicate if the user has eaten lunch. The message may give a reminder to perform an action, such as to request the receiver to display sensor data from the past week. In some embodiments, the message may not be related to glucose monitoring. For example, the message may be a joke, or display the current time of day. Messages may be displayed on a display device of the receiver, may be pictoral or graphical, and/or spoken (e.g., in the voice of the character) using a speaker of the receiver. - In some embodiments, a character is displayed in response to an input by the user, such as the push of a button. In some embodiments, the character is displayed in response to another event, such as the sensor data having a specified characteristic, such as being above or below a threshold. The character may also be displayed in response to a time. The time may be programmed, or may be a random or pseudorandom time. In some embodiments, the character is used to display the sensor data, such as the
centipede 134 ofFIG. 10 . - In some embodiments, a receiver (such as receiver 12) is configured to interface with a network to upload and/or download data. For example, using the
receiver 12, the user may upload game scores, sensor data, and/or tutorial scenarios. In some embodiments, using thereceiver 12, the user can download data representing games, graphics (such asgraphics FIGS. 3A and 3B and graphic 82 ofFIG. 3C ), target graphics (such as target graphic 78 ofFIG. 3B ), animations (such as that shown inFIGS. 4A-4H and 5 ), rewards, backgrounds, sensor data, tutorial data, icons (such asicons 130 ofFIGS. 9A and 9B ), graphical characters (such asgraphical character 132 ofFIG. 10 ), and messages (such asmessage 136 ofFIG. 10 ). The downloaded data, may, for example, be accessible only as a reward. For example, a reward may be achieved for glycemic control, where the reward allows the user or caregiver, for example, to access a network database and download a new avatar. In some embodiments, parents, doctors, and/or other caretakers of patients with diabetes may make recommendations that are provided to a particular host (or a group of hosts) in response to particular alerts. For example, the doctor of a particular pediatric patient may customize textual, graphical, audible, and/or other information that may be provided to the particular patient in view of the doctors knowledge of the patient needs, tolerances, etc. - In general, any of the above methods of data input and output can be combined, modified, selectively viewed, selectively applied, or otherwise altered without departing from the scope of the present invention. The various tasks performed in connection with processes (i.e. methods) described herein may be implemented by software, hardware, firmware, a computer-readable medium storing computer executable instructions for performing the process, or any combination thereof. It should be appreciated that the processes described herein may include any number of additional or alternative tasks. The tasks described and illustrated in the figures need not be performed in the described and illustrated order, and the processes may be incorporated into a more comprehensive procedure or process having additional functionality not described in detail herein. Moreover, the descriptions of the processes may refer to elements mentioned above in connection with
FIG. 1 , but it is understood that other devices and systems may be used to implement aspects of the processes. - For example, methods and devices that can be suitable for use in conjunction with aspects of the embodiments described herein are disclosed in U.S. applications including U.S. application Ser. No. 11/007,920 filed Dec. 8, 2004 and entitled, “SIGNAL PROCESSING FOR CONTINUOUS ANALYTE SENSOR”; U.S. application Ser. No. 10/695,636 filed Oct. 28, 2003 and entitled, “SILICONE COMPOSITION FOR BIOCOMPATIBLE MEMBRANE”; U.S. application Ser. No. 10/633,367 filed Aug. 1, 2003 entitled, “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA”; U.S. application Ser. No. 09/916,711 filed Jul. 27, 2001 and entitled “SENSOR HEAD FOR USE WITH IMPLANTABLE DEVICE”; U.S. application Ser. No. 09/447,227 filed Nov. 22, 1999 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. application Ser. No. 10/153,356 filed May 22, 2002 and entitled “TECHNIQUES TO IMPROVE POLYURETHANE MEMBRANES FOR IMPLANTABLE GLUCOSE SENSORS”; as well as issued patents including U.S. Pat. No. 6,001,067 issued Dec. 14, 1999 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. Pat. No. 4,994,167 issued Feb. 19, 1991 and entitled “BIOLOGICAL FLUID MEASURING DEVICE”; and U.S. Pat. No. 4,757,022 filed Jul. 12, 1988 and entitled “BIOLOGICAL FLUID MEASURING DEVICE;” U.S. Pat. No. 6,931,327 issued Aug. 16, 2005 and entitled, “SYSTEMS AND METHODS FOR REPLACING SIGNAL ARTIFACTS IN A GLUCOSE SENSOR DATA STREAM”; U.S. Pat. No. 7,134,999 issued Nov. 14, 2006 and entitled, “OPTIMIZED SENSOR GEOMETRY FOR AN IMPLANTABLE GLUCOSE SENSOR”; U.S. Pat. No. 7,192,450 issued Mar. 20, 2007 and entitled, “POROUS MEMBRANES FOR USE WITH IMPLANTABLE DEVICES”; U.S. Pat. No. 6,702,857 issued Mar. 9, 2004 and entitled “MEMBRANE FOR USE WITH IMPLANTABLE DEVICES”; U.S. Pat. No. 6,741,877 issued May 25, 2004 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. Pat. No. 6,558,321 issued May 6, 2003 and entitled “SYSTEMS AND METHODS FOR REMOTE MONITORING AND MODULATION OF MEDICAL DEVICES”; and U.S. Pat. No. 6,862,465 issued Mar. 1, 2005 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS.” All of the above patents and patent applications are incorporated in their entirety herein by reference.
- The above description provides several methods and materials of the invention. This invention is susceptible to modifications in the methods and materials, as well as alterations in the fabrication methods and equipment. Such modifications will become apparent to those skilled in the art from a consideration of this application or practice of the invention provided herein. Consequently, it is not intended that this invention be limited to the specific embodiments provided herein, but that it cover all modifications and alternatives coming within the true scope and spirit of the invention as embodied in the attached claims. All patents, applications, and other references cited herein are hereby incorporated by reference in their entirety.
- All numbers expressing quantities are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/862,429 US20200254177A1 (en) | 2009-03-27 | 2020-04-29 | Methods and systems for promoting glucose management |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16432609P | 2009-03-27 | 2009-03-27 | |
US12/748,069 US9446194B2 (en) | 2009-03-27 | 2010-03-26 | Methods and systems for promoting glucose management |
US14/144,489 US10610642B2 (en) | 2009-03-27 | 2013-12-30 | Methods and systems for promoting glucose management |
US14/960,127 US10675405B2 (en) | 2009-03-27 | 2015-12-04 | Methods and systems for simulating glucose response to simulated actions |
US16/862,429 US20200254177A1 (en) | 2009-03-27 | 2020-04-29 | Methods and systems for promoting glucose management |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/960,127 Continuation US10675405B2 (en) | 2009-03-27 | 2015-12-04 | Methods and systems for simulating glucose response to simulated actions |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200254177A1 true US20200254177A1 (en) | 2020-08-13 |
Family
ID=42781565
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/748,069 Active 2034-10-07 US9446194B2 (en) | 2009-03-27 | 2010-03-26 | Methods and systems for promoting glucose management |
US14/144,489 Active 2032-11-29 US10610642B2 (en) | 2009-03-27 | 2013-12-30 | Methods and systems for promoting glucose management |
US14/960,127 Active 2030-09-26 US10675405B2 (en) | 2009-03-27 | 2015-12-04 | Methods and systems for simulating glucose response to simulated actions |
US14/971,886 Active 2030-12-24 US10537678B2 (en) | 2009-03-27 | 2015-12-16 | Methods and systems for promoting glucose management |
US16/706,425 Pending US20200114078A1 (en) | 2009-03-27 | 2019-12-06 | Methods and systems for promoting glucose management |
US16/862,429 Pending US20200254177A1 (en) | 2009-03-27 | 2020-04-29 | Methods and systems for promoting glucose management |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/748,069 Active 2034-10-07 US9446194B2 (en) | 2009-03-27 | 2010-03-26 | Methods and systems for promoting glucose management |
US14/144,489 Active 2032-11-29 US10610642B2 (en) | 2009-03-27 | 2013-12-30 | Methods and systems for promoting glucose management |
US14/960,127 Active 2030-09-26 US10675405B2 (en) | 2009-03-27 | 2015-12-04 | Methods and systems for simulating glucose response to simulated actions |
US14/971,886 Active 2030-12-24 US10537678B2 (en) | 2009-03-27 | 2015-12-16 | Methods and systems for promoting glucose management |
US16/706,425 Pending US20200114078A1 (en) | 2009-03-27 | 2019-12-06 | Methods and systems for promoting glucose management |
Country Status (3)
Country | Link |
---|---|
US (6) | US9446194B2 (en) |
EP (1) | EP2410910A4 (en) |
WO (1) | WO2010111660A1 (en) |
Families Citing this family (218)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
US7381184B2 (en) | 2002-11-05 | 2008-06-03 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
USD914881S1 (en) | 2003-11-05 | 2021-03-30 | Abbott Diabetes Care Inc. | Analyte sensor electronic mount |
US7731657B2 (en) | 2005-08-30 | 2010-06-08 | Abbott Diabetes Care Inc. | Analyte sensor introducer and methods of use |
US9572534B2 (en) | 2010-06-29 | 2017-02-21 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US8333714B2 (en) | 2006-09-10 | 2012-12-18 | Abbott Diabetes Care Inc. | Method and system for providing an integrated analyte sensor insertion device and data processing unit |
US9351669B2 (en) | 2009-09-30 | 2016-05-31 | Abbott Diabetes Care Inc. | Interconnect for on-body analyte monitoring device |
US9788771B2 (en) | 2006-10-23 | 2017-10-17 | Abbott Diabetes Care Inc. | Variable speed sensor insertion devices and methods of use |
US7883464B2 (en) | 2005-09-30 | 2011-02-08 | Abbott Diabetes Care Inc. | Integrated transmitter unit and sensor introducer mechanism and methods of use |
US9398882B2 (en) | 2005-09-30 | 2016-07-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor and data processing device |
US9259175B2 (en) | 2006-10-23 | 2016-02-16 | Abbott Diabetes Care, Inc. | Flexible patch for fluid delivery and monitoring body analytes |
US9743862B2 (en) | 2011-03-31 | 2017-08-29 | Abbott Diabetes Care Inc. | Systems and methods for transcutaneously implanting medical devices |
US8545403B2 (en) | 2005-12-28 | 2013-10-01 | Abbott Diabetes Care Inc. | Medical device insertion |
US8029441B2 (en) | 2006-02-28 | 2011-10-04 | Abbott Diabetes Care Inc. | Analyte sensor transmitter unit configuration for a data monitoring and management system |
US8512243B2 (en) | 2005-09-30 | 2013-08-20 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
US10226207B2 (en) | 2004-12-29 | 2019-03-12 | Abbott Diabetes Care Inc. | Sensor inserter having introducer |
US20090105569A1 (en) | 2006-04-28 | 2009-04-23 | Abbott Diabetes Care, Inc. | Introducer Assembly and Methods of Use |
US7697967B2 (en) | 2005-12-28 | 2010-04-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US8613703B2 (en) | 2007-05-31 | 2013-12-24 | Abbott Diabetes Care Inc. | Insertion devices and methods |
US9521968B2 (en) | 2005-09-30 | 2016-12-20 | Abbott Diabetes Care Inc. | Analyte sensor retention mechanism and methods of use |
US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US7630748B2 (en) | 2006-10-25 | 2009-12-08 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
US8140312B2 (en) | 2007-05-14 | 2012-03-20 | Abbott Diabetes Care Inc. | Method and system for determining analyte levels |
US7653425B2 (en) | 2006-08-09 | 2010-01-26 | Abbott Diabetes Care Inc. | Method and system for providing calibration of an analyte sensor in an analyte monitoring system |
US8224415B2 (en) | 2009-01-29 | 2012-07-17 | Abbott Diabetes Care Inc. | Method and device for providing offset model based calibration for analyte sensor |
US8219173B2 (en) | 2008-09-30 | 2012-07-10 | Abbott Diabetes Care Inc. | Optimizing analyte sensor calibration |
US9675290B2 (en) | 2012-10-30 | 2017-06-13 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
US8346335B2 (en) | 2008-03-28 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte sensor calibration management |
US7618369B2 (en) | 2006-10-02 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for dynamically updating calibration parameters for an analyte sensor |
US20130324823A1 (en) * | 2006-11-20 | 2013-12-05 | Modz Oy | Measurement device, system and method |
US20080199894A1 (en) | 2007-02-15 | 2008-08-21 | Abbott Diabetes Care, Inc. | Device and method for automatic data acquisition and/or detection |
US20080228056A1 (en) | 2007-03-13 | 2008-09-18 | Michael Blomquist | Basal rate testing using frequent blood glucose input |
CA2683962C (en) | 2007-04-14 | 2017-06-06 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US8260558B2 (en) | 2007-05-14 | 2012-09-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8103471B2 (en) | 2007-05-14 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8600681B2 (en) | 2007-05-14 | 2013-12-03 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8560038B2 (en) | 2007-05-14 | 2013-10-15 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US9125548B2 (en) | 2007-05-14 | 2015-09-08 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8239166B2 (en) | 2007-05-14 | 2012-08-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US7751907B2 (en) | 2007-05-24 | 2010-07-06 | Smiths Medical Asd, Inc. | Expert system for insulin pump therapy |
US8221345B2 (en) | 2007-05-30 | 2012-07-17 | Smiths Medical Asd, Inc. | Insulin pump based expert system |
US20090164239A1 (en) | 2007-12-19 | 2009-06-25 | Abbott Diabetes Care, Inc. | Dynamic Display Of Glucose Information |
US20090177147A1 (en) | 2008-01-07 | 2009-07-09 | Michael Blomquist | Insulin pump with insulin therapy coaching |
US8133197B2 (en) | 2008-05-02 | 2012-03-13 | Smiths Medical Asd, Inc. | Display for pump |
US8924159B2 (en) | 2008-05-30 | 2014-12-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US8591410B2 (en) | 2008-05-30 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US8986208B2 (en) | 2008-09-30 | 2015-03-24 | Abbott Diabetes Care Inc. | Analyte sensor sensitivity attenuation mitigation |
US20100198034A1 (en) | 2009-02-03 | 2010-08-05 | Abbott Diabetes Care Inc. | Compact On-Body Physiological Monitoring Devices and Methods Thereof |
WO2010121084A1 (en) | 2009-04-15 | 2010-10-21 | Abbott Diabetes Care Inc. | Analyte monitoring system having an alert |
EP2425209A4 (en) | 2009-04-29 | 2013-01-09 | Abbott Diabetes Care Inc | Method and system for providing real time analyte sensor calibration with retrospective backfill |
US20100299155A1 (en) * | 2009-05-19 | 2010-11-25 | Myca Health, Inc. | System and method for providing a multi-dimensional contextual platform for managing a medical practice |
WO2010141922A1 (en) * | 2009-06-04 | 2010-12-09 | Abbott Diabetes Care Inc. | Method and system for updating a medical device |
EP4289355A3 (en) | 2009-07-23 | 2024-02-28 | Abbott Diabetes Care Inc. | Continuous analyte measurement system |
EP2932994B1 (en) | 2009-07-30 | 2017-11-08 | Tandem Diabetes Care, Inc. | New o-ring seal, and delivery mechanism and portable infusion pump system related thereto |
EP3001194B1 (en) | 2009-08-31 | 2019-04-17 | Abbott Diabetes Care, Inc. | Medical devices and methods |
DK3988470T3 (en) | 2009-08-31 | 2023-08-28 | Abbott Diabetes Care Inc | Display devices for a medical device |
US9320461B2 (en) | 2009-09-29 | 2016-04-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
US8185181B2 (en) | 2009-10-30 | 2012-05-22 | Abbott Diabetes Care Inc. | Method and apparatus for detecting false hypoglycemic conditions |
US8882701B2 (en) | 2009-12-04 | 2014-11-11 | Smiths Medical Asd, Inc. | Advanced step therapy delivery for an ambulatory infusion pump and system |
USD924406S1 (en) | 2010-02-01 | 2021-07-06 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
ES2881798T3 (en) | 2010-03-24 | 2021-11-30 | Abbott Diabetes Care Inc | Medical device inserters and medical device insertion and use procedures |
US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
US11064921B2 (en) | 2010-06-29 | 2021-07-20 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
US8762101B2 (en) | 2010-09-30 | 2014-06-24 | Fitbit, Inc. | Methods and systems for identification of event data having combined activity and location information of portable monitoring devices |
US11243093B2 (en) | 2010-09-30 | 2022-02-08 | Fitbit, Inc. | Methods, systems and devices for generating real-time activity data updates to display devices |
US8620617B2 (en) | 2010-09-30 | 2013-12-31 | Fitbit, Inc. | Methods and systems for interactive goal setting and recommender using events having combined activity and location information |
US8738323B2 (en) | 2010-09-30 | 2014-05-27 | Fitbit, Inc. | Methods and systems for metrics analysis and interactive rendering, including events having combined activity and location information |
US8738321B2 (en) | 2010-09-30 | 2014-05-27 | Fitbit, Inc. | Methods and systems for classification of geographic locations for tracked activity |
US9241635B2 (en) | 2010-09-30 | 2016-01-26 | Fitbit, Inc. | Portable monitoring devices for processing applications and processing analysis of physiological conditions of a user associated with the portable monitoring device |
US9390427B2 (en) | 2010-09-30 | 2016-07-12 | Fitbit, Inc. | Methods, systems and devices for automatic linking of activity tracking devices to user devices |
US9148483B1 (en) | 2010-09-30 | 2015-09-29 | Fitbit, Inc. | Tracking user physical activity with multiple devices |
US8954290B2 (en) | 2010-09-30 | 2015-02-10 | Fitbit, Inc. | Motion-activated display of messages on an activity monitoring device |
US8744803B2 (en) | 2010-09-30 | 2014-06-03 | Fitbit, Inc. | Methods, systems and devices for activity tracking device data synchronization with computing devices |
US10004406B2 (en) | 2010-09-30 | 2018-06-26 | Fitbit, Inc. | Portable monitoring devices for processing applications and processing analysis of physiological conditions of a user associated with the portable monitoring device |
US8694282B2 (en) | 2010-09-30 | 2014-04-08 | Fitbit, Inc. | Methods and systems for geo-location optimized tracking and updating for events having combined activity and location information |
US8805646B2 (en) | 2010-09-30 | 2014-08-12 | Fitbit, Inc. | Methods, systems and devices for linking user devices to activity tracking devices |
US8762102B2 (en) | 2010-09-30 | 2014-06-24 | Fitbit, Inc. | Methods and systems for generation and rendering interactive events having combined activity and location information |
US9253168B2 (en) | 2012-04-26 | 2016-02-02 | Fitbit, Inc. | Secure pairing of devices via pairing facilitator-intermediary device |
US8615377B1 (en) | 2010-09-30 | 2013-12-24 | Fitbit, Inc. | Methods and systems for processing social interactive data and sharing of tracked activity associated with locations |
US8712724B2 (en) | 2010-09-30 | 2014-04-29 | Fitbit, Inc. | Calendar integration methods and systems for presentation of events having combined activity and location information |
US10983945B2 (en) | 2010-09-30 | 2021-04-20 | Fitbit, Inc. | Method of data synthesis |
US9310909B2 (en) | 2010-09-30 | 2016-04-12 | Fitbit, Inc. | Methods, systems and devices for physical contact activated display and navigation |
US8954291B2 (en) | 2010-09-30 | 2015-02-10 | Fitbit, Inc. | Alarm setting and interfacing with gesture contact interfacing controls |
US9241631B2 (en) | 2010-10-27 | 2016-01-26 | Dexcom, Inc. | Continuous analyte monitor data recording device operable in a blinded mode |
BR112013012462A2 (en) * | 2010-11-19 | 2020-08-04 | Lifescan, Inc | analyte test method and system with notification of high and low analyte trends |
EP2458518A3 (en) * | 2010-11-26 | 2013-12-18 | Samsung Electronics Co., Ltd. | Remote healthcare system and healthcare method using the same |
US10098584B2 (en) * | 2011-02-08 | 2018-10-16 | Cardiac Pacemakers, Inc. | Patient health improvement monitor |
US9033877B2 (en) | 2011-02-23 | 2015-05-19 | Roche Diabetes Care, Inc. | Device and method for determining blood glucose characteristics |
EP3575796B1 (en) | 2011-04-15 | 2020-11-11 | DexCom, Inc. | Advanced analyte sensor calibration and error detection |
US8738925B1 (en) | 2013-01-07 | 2014-05-27 | Fitbit, Inc. | Wireless portable biometric device syncing |
US20130085349A1 (en) | 2011-06-21 | 2013-04-04 | Yofimeter, Llc | Analyte testing devices |
EP2756858B1 (en) * | 2011-09-12 | 2017-06-14 | Panasonic Healthcare Co., Ltd. | Drug injection device |
WO2013066849A1 (en) | 2011-10-31 | 2013-05-10 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
US8710993B2 (en) | 2011-11-23 | 2014-04-29 | Abbott Diabetes Care Inc. | Mitigating single point failure of devices in an analyte monitoring system and methods thereof |
WO2013078426A2 (en) | 2011-11-25 | 2013-05-30 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods of use |
FI3300658T3 (en) | 2011-12-11 | 2024-03-01 | Abbott Diabetes Care Inc | Analyte sensor methods |
EP2791782B1 (en) | 2011-12-15 | 2018-10-03 | Becton, Dickinson and Company | Near field telemetry link for passing a shared secret to establish a secure radio frequency communication link in a physiological condition monitoring system |
KR20140147849A (en) * | 2012-03-23 | 2014-12-30 | 시락 게엠베하 인터내셔날 | Positive reinforcement messages to users based on analytics of prior physiological measurements |
US9931065B2 (en) | 2012-04-04 | 2018-04-03 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
US9335910B2 (en) | 2012-04-23 | 2016-05-10 | Tandem Diabetes Care, Inc. | System and method for reduction of inadvertent activation of medical device during manipulation |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US20130321425A1 (en) | 2012-06-05 | 2013-12-05 | Dexcom, Inc. | Reporting modules |
US9715327B2 (en) | 2012-06-07 | 2017-07-25 | Tandem Diabetes Care, Inc. | Preventing inadvertent changes in ambulatory medical devices |
US9238100B2 (en) | 2012-06-07 | 2016-01-19 | Tandem Diabetes Care, Inc. | Device and method for training users of ambulatory medical devices |
US9641239B2 (en) | 2012-06-22 | 2017-05-02 | Fitbit, Inc. | Adaptive data transfer using bluetooth |
US10598627B2 (en) | 2012-06-29 | 2020-03-24 | Dexcom, Inc. | Devices, systems, and methods to compensate for effects of temperature on implantable sensors |
US10881339B2 (en) | 2012-06-29 | 2021-01-05 | Dexcom, Inc. | Use of sensor redundancy to detect sensor failures |
US20140012510A1 (en) | 2012-07-09 | 2014-01-09 | Dexcom, Inc | Systems and methods for leveraging smartphone features in continuous glucose monitoring |
EP2890297B1 (en) | 2012-08-30 | 2018-04-11 | Abbott Diabetes Care, Inc. | Dropout detection in continuous analyte monitoring data during data excursions |
EP2901153A4 (en) | 2012-09-26 | 2016-04-27 | Abbott Diabetes Care Inc | Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data |
US9788765B2 (en) | 2012-09-28 | 2017-10-17 | Dexcom, Inc. | Zwitterion surface modifications for continuous sensors |
US20140129151A1 (en) | 2012-11-07 | 2014-05-08 | Dexcom, Inc. | Systems and methods for managing glycemic variability |
US9872641B2 (en) | 2012-11-29 | 2018-01-23 | Abbott Diabetes Care Inc. | Methods, devices, and systems related to analyte monitoring |
US10383580B2 (en) | 2012-12-31 | 2019-08-20 | Abbott Diabetes Care Inc. | Analysis of glucose median, variability, and hypoglycemia risk for therapy guidance |
US9801541B2 (en) | 2012-12-31 | 2017-10-31 | Dexcom, Inc. | Remote monitoring of analyte measurements |
US9730620B2 (en) | 2012-12-31 | 2017-08-15 | Dexcom, Inc. | Remote monitoring of analyte measurements |
US9039614B2 (en) | 2013-01-15 | 2015-05-26 | Fitbit, Inc. | Methods, systems and devices for measuring fingertip heart rate |
US9728059B2 (en) | 2013-01-15 | 2017-08-08 | Fitbit, Inc. | Sedentary period detection utilizing a wearable electronic device |
US10357606B2 (en) | 2013-03-13 | 2019-07-23 | Tandem Diabetes Care, Inc. | System and method for integration of insulin pumps and continuous glucose monitoring |
EP2973082B1 (en) | 2013-03-14 | 2018-06-06 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US9445445B2 (en) | 2013-03-14 | 2016-09-13 | Dexcom, Inc. | Systems and methods for processing and transmitting sensor data |
US10335075B2 (en) | 2013-03-14 | 2019-07-02 | Dexcom, Inc. | Advanced calibration for analyte sensors |
US9525789B2 (en) * | 2013-03-15 | 2016-12-20 | Dropbox, Inc. | Shuffle algorithm and navigation |
US9737250B2 (en) | 2013-03-15 | 2017-08-22 | Dexcom, Inc. | Membrane for continuous analyte sensors |
US10076285B2 (en) | 2013-03-15 | 2018-09-18 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
EP2789295A1 (en) * | 2013-04-12 | 2014-10-15 | Modz Oy | Improved measurement device, system and method |
US9529503B2 (en) * | 2013-06-27 | 2016-12-27 | Lifescan Scotland Limited | Analyte-measurement system recording user menu choices |
FI20135852A (en) * | 2013-08-21 | 2015-03-06 | Modz Oy | Apparatus and systems for measuring and presenting the glucose level in the blood |
EP3041528A4 (en) | 2013-09-06 | 2017-04-26 | Tandem Diabetes Care, Inc. | System and method for mitigating risk in automated medicament dosing |
WO2015047870A1 (en) | 2013-09-26 | 2015-04-02 | Companion Medical, Inc. | System for administering a medicament |
EP3062686B1 (en) * | 2013-10-28 | 2019-05-08 | Dexcom, Inc. | Devices used in connection with continuous analyte monitoring that provide the user with one or more notifications, and related methods |
EP4250313A3 (en) | 2013-12-26 | 2023-11-22 | Tandem Diabetes Care, Inc. | Integration of infusion pump with remote electronic device |
US9814389B2 (en) | 2013-12-31 | 2017-11-14 | Senseonics, Incorporated | Continuous analyte monitoring system |
US9486580B2 (en) * | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
US9898585B2 (en) | 2014-01-31 | 2018-02-20 | Aseko, Inc. | Method and system for insulin management |
US9031812B2 (en) * | 2014-02-27 | 2015-05-12 | Fitbit, Inc. | Notifications on a user device based on activity detected by an activity monitoring device |
US11990019B2 (en) | 2014-02-27 | 2024-05-21 | Fitbit, Inc. | Notifications on a user device based on activity detected by an activity monitoring device |
FI3128902T3 (en) | 2014-04-10 | 2023-11-16 | Dexcom Inc | Sensor for continuous analyte monitoring |
US9344546B2 (en) | 2014-05-06 | 2016-05-17 | Fitbit, Inc. | Fitness activity related messaging |
US10279106B1 (en) | 2014-05-08 | 2019-05-07 | Tandem Diabetes Care, Inc. | Insulin patch pump |
US9672328B2 (en) | 2014-07-10 | 2017-06-06 | Companion Medical, Inc. | Medicine administering system including injection pen and companion device |
EP3174577A4 (en) | 2014-07-30 | 2018-04-18 | Tandem Diabetes Care, Inc. | Temporary suspension for closed-loop medicament therapy |
US11035818B2 (en) * | 2014-08-15 | 2021-06-15 | Roche Diabetes Care, Inc. | Blood glucose meter with low cost user interface having programmed graphic indicators |
US20160081597A1 (en) | 2014-09-22 | 2016-03-24 | Dexcom, Inc. | System and method for mode switching |
USD773529S1 (en) | 2014-11-14 | 2016-12-06 | Dexcom, Inc. | Display screen or portion thereof with icon for presentation of analyte data |
USD779505S1 (en) | 2014-11-14 | 2017-02-21 | Dexcom, Inc. | Display screen or portion thereof with graphical user interface for analyte data presentation |
USD779504S1 (en) | 2014-11-14 | 2017-02-21 | Dexcom, Inc. | Display screen or portion thereof with graphical user interface for presentation of analyte data |
WO2016099519A1 (en) * | 2014-12-18 | 2016-06-23 | Draeger Medical Systems, Inc. | Alarm sensitivity adjuster for medical device |
USD789391S1 (en) | 2014-12-31 | 2017-06-13 | Dexcom, Inc. | Display screen or portion thereof with graphical user interface and icons |
USD813268S1 (en) | 2014-12-31 | 2018-03-20 | Dexcom, Inc. | Display screen or portion therof with graphical user interface |
JP2016154648A (en) * | 2015-02-24 | 2016-09-01 | セイコーエプソン株式会社 | Information acquisition device |
JP6518105B2 (en) * | 2015-03-26 | 2019-05-22 | テルモ株式会社 | INFORMATION MANAGEMENT DEVICE, INFORMATION MANAGEMENT METHOD, AND INFORMATION MANAGEMENT PROGRAM |
US10213139B2 (en) | 2015-05-14 | 2019-02-26 | Abbott Diabetes Care Inc. | Systems, devices, and methods for assembling an applicator and sensor control device |
CA2991716A1 (en) * | 2015-07-10 | 2017-01-19 | Abbott Diabetes Care Inc. | System, device and method of dynamic glucose profile response to physiological parameters |
CN114767099A (en) | 2015-10-21 | 2022-07-22 | 德克斯康公司 | Transdermal analyte sensors, applicators therefor, and associated methods |
CA3200794A1 (en) | 2015-12-28 | 2017-07-06 | Dexcom, Inc. | Systems and methods for remote and host monitoring communications |
US10569016B2 (en) | 2015-12-29 | 2020-02-25 | Tandem Diabetes Care, Inc. | System and method for switching between closed loop and open loop control of an ambulatory infusion pump |
JP6983765B2 (en) | 2015-12-30 | 2021-12-17 | デックスコム・インコーポレーテッド | Enzyme-immobilized adhesive layer for analyte sensors |
WO2017132663A1 (en) * | 2016-01-29 | 2017-08-03 | Patek Stephen D | Method, system, and computer readable medium for virtualization of a continuous glucose monitoring trace |
US10864327B2 (en) | 2016-01-29 | 2020-12-15 | Companion Medical, Inc. | Automatic medication delivery tracking |
US10080530B2 (en) | 2016-02-19 | 2018-09-25 | Fitbit, Inc. | Periodic inactivity alerts and achievement messages |
EP3435866B1 (en) | 2016-03-31 | 2020-11-18 | Dexcom, Inc. | Analyte monitoring system |
US10328204B2 (en) | 2016-05-02 | 2019-06-25 | Dexcom, Inc. | System and method for providing alerts optimized for a user |
US10070808B2 (en) * | 2016-06-03 | 2018-09-11 | National Guard Health Affairs | Apparatus for in vivo detection and quantification of analytes in the peritoneal fluid |
US11515036B2 (en) | 2016-09-09 | 2022-11-29 | Dexcom, Inc. | Systems and methods for CGM-based bolus calculator for display and for provision to medicament delivery devices |
US10373519B1 (en) * | 2016-09-26 | 2019-08-06 | Glooko Inc. | System and method for determining and providing activity recommendations |
KR102486814B1 (en) | 2016-12-15 | 2023-01-10 | 삼성전자주식회사 | Server, user terminal apparatus, erectronic apparatus, and contrl method thereof |
WO2018175489A1 (en) | 2017-03-21 | 2018-09-27 | Abbott Diabetes Care Inc. | Methods, devices and system for providing diabetic condition diagnosis and therapy |
CA3056445A1 (en) * | 2017-04-20 | 2018-10-25 | Becton, Dickinson And Company | Diabetes therapy training device |
US11484657B2 (en) | 2017-06-09 | 2022-11-01 | Medtronic Minimed, Inc. | Intelligent medication delivery systems and methods |
EP3925522B1 (en) | 2017-06-23 | 2024-06-12 | Dexcom, Inc. | Transcutaneous analyte sensors, applicators therefor, and associated methods |
US11568975B2 (en) | 2017-10-12 | 2023-01-31 | Medtronic Minimed, Inc. | Intelligent medication delivery systems and methods for dose recommendation and management |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
DK3700416T3 (en) | 2017-10-24 | 2024-09-30 | Dexcom Inc | PRE-CONNECTED ANALYTE SENSORS |
WO2019094908A1 (en) * | 2017-11-13 | 2019-05-16 | Senseonics, Incorporated | Analyte monitoring system and method for determining system usage |
US11083852B2 (en) | 2017-12-12 | 2021-08-10 | Bigfoot Biomedical, Inc. | Insulin injection assistance systems, methods, and devices |
US11116899B2 (en) | 2017-12-12 | 2021-09-14 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems and devices |
EP3724891B1 (en) | 2017-12-12 | 2024-08-21 | Bigfoot Biomedical, Inc. | Medicine injection and disease management systems, devices, and methods |
US11077243B2 (en) | 2017-12-12 | 2021-08-03 | Bigfoot Biomedical, Inc. | Devices, systems, and methods for estimating active medication from injections |
US11464459B2 (en) | 2017-12-12 | 2022-10-11 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems including flash glucose monitor |
US10987464B2 (en) | 2017-12-12 | 2021-04-27 | Bigfoot Biomedical, Inc. | Pen cap for insulin injection pens and associated methods and systems |
US20190246914A1 (en) | 2018-02-09 | 2019-08-15 | Dexcom, Inc. | System and method for decision support |
US11561541B2 (en) * | 2018-04-09 | 2023-01-24 | SafeAI, Inc. | Dynamically controlling sensor behavior |
US11467590B2 (en) | 2018-04-09 | 2022-10-11 | SafeAI, Inc. | Techniques for considering uncertainty in use of artificial intelligence models |
US11169536B2 (en) | 2018-04-09 | 2021-11-09 | SafeAI, Inc. | Analysis of scenarios for controlling vehicle operations |
US11625036B2 (en) | 2018-04-09 | 2023-04-11 | SafeAl, Inc. | User interface for presenting decisions |
US20190328290A1 (en) * | 2018-04-27 | 2019-10-31 | Medtronic Minimed, Inc. | Glucose sensor-based tracking system |
US10898653B2 (en) | 2018-05-08 | 2021-01-26 | Companion Medical, Inc. | Intelligent medication delivery systems and methods for dose setting and dispensing monitoring |
US11664107B2 (en) | 2018-05-08 | 2023-05-30 | Medtronic Minimed, Inc. | Intelligent medication delivery systems and methods using a prescription-regulated software application |
USD893020S1 (en) | 2018-05-11 | 2020-08-11 | Companion Medical, Inc. | Injection pen |
USD892819S1 (en) | 2018-06-20 | 2020-08-11 | Companion Medical, Inc. | Display screen with graphical user interface |
US11587663B2 (en) | 2018-06-20 | 2023-02-21 | Medtronic Minimed, Inc. | Intelligent medication delivery systems and methods for medicine dose calculation and reporting |
USD926325S1 (en) | 2018-06-22 | 2021-07-27 | Dexcom, Inc. | Wearable medical monitoring device |
USD875766S1 (en) | 2018-08-10 | 2020-02-18 | Tandem Diabetes Care, Inc. | Display screen or portion thereof with graphical user interface |
USD875765S1 (en) | 2018-08-10 | 2020-02-18 | Tandem Diabetes Care, Inc. | Display screen or portion thereof with graphical user interface |
USD864219S1 (en) | 2018-08-20 | 2019-10-22 | Tandem Diabetes Care, Inc. | Display screen or portion thereof with graphical user interface |
USD864217S1 (en) | 2018-08-20 | 2019-10-22 | Tandem Diabetes Care, Inc. | Display screen or portion thereof with graphical user interface |
USD880496S1 (en) | 2018-08-20 | 2020-04-07 | Tandem Diabetes Care, Inc. | Display screen or portion thereof with graphical user interface |
USD882622S1 (en) | 2018-08-22 | 2020-04-28 | Tandem Diabetes Care, Inc. | Display screen or portion thereof with graphical user interface |
USD875767S1 (en) | 2018-08-23 | 2020-02-18 | Tandem Diabetes Care, Inc. | Display screen or portion thereof with graphical user interface |
US11464908B2 (en) | 2019-02-18 | 2022-10-11 | Tandem Diabetes Care, Inc. | Methods and apparatus for monitoring infusion sites for ambulatory infusion pumps |
US11948671B2 (en) | 2019-04-11 | 2024-04-02 | Medtronic Minimed, Inc. | Intelligent accessories for medicine dispensing device |
USD1002852S1 (en) | 2019-06-06 | 2023-10-24 | Abbott Diabetes Care Inc. | Analyte sensor device |
US11872033B2 (en) * | 2019-11-15 | 2024-01-16 | Lifescan Ip Holdings, Llc | Methods and devices for visualizing analyte measurements |
USD931306S1 (en) | 2020-01-20 | 2021-09-21 | Tandem Diabetes Care, Inc. | Display screen or portion thereof with graphical user interface |
IL273038B (en) | 2020-03-03 | 2022-02-01 | Ben Zion Karmon | Bone implant |
USD999913S1 (en) | 2020-12-21 | 2023-09-26 | Abbott Diabetes Care Inc | Analyte sensor inserter |
US11701473B2 (en) | 2021-06-23 | 2023-07-18 | Medtronic Minimed, Inc. | Reusable injection pens |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5730654A (en) * | 1995-12-18 | 1998-03-24 | Raya Systems, Inc. | Multi-player video game for health education |
US20030050537A1 (en) * | 2000-06-22 | 2003-03-13 | Guidance Interactive Technolgies | Interactive reward devices and methods |
US6537806B1 (en) * | 1998-06-02 | 2003-03-25 | University Of Washington | Compositions and methods for treating diabetes |
US20040054263A1 (en) * | 2001-08-20 | 2004-03-18 | Piet Moerman | Wireless diabetes management devices and methods for using the same |
US20050038680A1 (en) * | 2002-12-19 | 2005-02-17 | Mcmahon Kevin Lee | System and method for glucose monitoring |
US20050102159A1 (en) * | 2003-11-06 | 2005-05-12 | Mondshine Robert B. | Computer based risk level monitor and patient compliance method and system |
US20070179356A1 (en) * | 2005-12-29 | 2007-08-02 | Guidance Interactive Healthcare, Inc. | Programmable devices, systems and methods for encouraging the monitoring of medical parameters |
US20080086533A1 (en) * | 2006-07-12 | 2008-04-10 | Neuhauser Alan R | Methods and systems for compliance confirmation and incentives |
US20100106000A1 (en) * | 2008-10-27 | 2010-04-29 | Medtronic Minimed, Inc. | Methods and Systems for Evaluating Glycemic Control |
US20100312483A1 (en) * | 2007-02-06 | 2010-12-09 | Glumetrics, Inc. | Algorithms for calibrating an analyte sensor |
Family Cites Families (408)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US598724A (en) | 1898-02-08 | barker | ||
US623803A (en) | 1899-04-25 | Heel-rubber | ||
US3210578A (en) | 1962-01-12 | 1965-10-05 | Westinghouse Electric Corp | Multispeed motor connector |
NL289785A (en) | 1962-11-29 | |||
USRE31916E (en) * | 1970-11-10 | 1985-06-18 | Becton Dickinson & Company | Electrochemical detection cell |
GB1412983A (en) * | 1971-11-30 | 1975-11-05 | Debell & Richardson | Method of producing porous plastic materials |
US3943918A (en) * | 1971-12-02 | 1976-03-16 | Tel-Pac, Inc. | Disposable physiological telemetric device |
US3780727A (en) | 1972-02-25 | 1973-12-25 | Hoffmann La Roche | Cardiac pacer monitoring means with rate and pulse discrimination |
GB1442303A (en) | 1972-09-08 | 1976-07-14 | Radiometer As | Cell for electro-chemical analysis |
US3929971A (en) | 1973-03-30 | 1975-12-30 | Research Corp | Porous biomaterials and method of making same |
US3898984A (en) | 1974-02-04 | 1975-08-12 | Us Navy | Ambulatory patient monitoring system |
US3979274A (en) | 1975-09-24 | 1976-09-07 | The Yellow Springs Instrument Company, Inc. | Membrane for enzyme electrodes |
JPS5921500B2 (en) | 1978-01-28 | 1984-05-21 | 東洋紡績株式会社 | Enzyme membrane for oxygen electrode |
US4253469A (en) * | 1979-04-20 | 1981-03-03 | The Narda Microwave Corporation | Implantable temperature probe |
USRE32361E (en) * | 1979-05-14 | 1987-02-24 | Medtronic, Inc. | Implantable telemetry transmission system for analog and digital data |
US4403984A (en) | 1979-12-28 | 1983-09-13 | Biotek, Inc. | System for demand-based adminstration of insulin |
EP0047013B1 (en) | 1980-09-02 | 1986-01-22 | Medtronic, Inc. | Subcutaneously implantable lead with drug dispenser means |
US4436094A (en) * | 1981-03-09 | 1984-03-13 | Evreka, Inc. | Monitor for continuous in vivo measurement of glucose concentration |
US4431004A (en) * | 1981-10-27 | 1984-02-14 | Bessman Samuel P | Implantable glucose sensor |
US4415666A (en) | 1981-11-05 | 1983-11-15 | Miles Laboratories, Inc. | Enzyme electrode membrane |
NL193256C (en) | 1981-11-10 | 1999-04-02 | Cordis Europ | Sensor system. |
US4454295A (en) * | 1981-11-16 | 1984-06-12 | Uco Optics, Inc. | Cured cellulose ester, method of curing same, and use thereof |
US4494950A (en) * | 1982-01-19 | 1985-01-22 | The Johns Hopkins University | Plural module medication delivery system |
EP0098592A3 (en) | 1982-07-06 | 1985-08-21 | Fujisawa Pharmaceutical Co., Ltd. | Portable artificial pancreas |
US4506680A (en) * | 1983-03-17 | 1985-03-26 | Medtronic, Inc. | Drug dispensing body implantable lead |
CA1226036A (en) | 1983-05-05 | 1987-08-25 | Irving J. Higgins | Analytical equipment and sensor electrodes therefor |
US4655880A (en) * | 1983-08-01 | 1987-04-07 | Case Western Reserve University | Apparatus and method for sensing species, substances and substrates using oxidase |
US4554927A (en) | 1983-08-30 | 1985-11-26 | Thermometrics Inc. | Pressure and temperature sensor |
GB2149918A (en) | 1983-11-03 | 1985-06-19 | John Anderson | Sudden infant death syndrome monitor |
US4883057A (en) | 1984-05-09 | 1989-11-28 | Research Foundation, The City University Of New York | Cathodic electrochemical current arrangement with telemetric application |
US5030333A (en) | 1984-09-13 | 1991-07-09 | Children's Hospital Medical Center | Polarographic method for measuring both analyte and oxygen with the same detecting electrode of an electroenzymatic sensor |
US4577642A (en) * | 1985-02-27 | 1986-03-25 | Medtronic, Inc. | Drug dispensing body implantable lead employing molecular sieves and methods of fabrication |
US4781798A (en) | 1985-04-19 | 1988-11-01 | The Regents Of The University Of California | Transparent multi-oxygen sensor array and method of using same |
US4671288A (en) * | 1985-06-13 | 1987-06-09 | The Regents Of The University Of California | Electrochemical cell sensor for continuous short-term use in tissues and blood |
US4680268A (en) | 1985-09-18 | 1987-07-14 | Children's Hospital Medical Center | Implantable gas-containing biosensor and method for measuring an analyte such as glucose |
US4890620A (en) * | 1985-09-20 | 1990-01-02 | The Regents Of The University Of California | Two-dimensional diffusion glucose substrate sensing electrode |
US4994167A (en) * | 1986-04-15 | 1991-02-19 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
US4757022A (en) | 1986-04-15 | 1988-07-12 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
US4703756A (en) | 1986-05-06 | 1987-11-03 | The Regents Of The University Of California | Complete glucose monitoring system with an implantable, telemetered sensor module |
US4731726A (en) * | 1986-05-19 | 1988-03-15 | Healthware Corporation | Patient-operated glucose monitor and diabetes management system |
JPS636451A (en) * | 1986-06-27 | 1988-01-12 | Terumo Corp | Enzyme sensor |
US5002572A (en) * | 1986-09-11 | 1991-03-26 | Picha George J | Biological implant with textured surface |
DE3700119A1 (en) * | 1987-01-03 | 1988-07-14 | Inst Diabetestechnologie Gemei | IMPLANTABLE ELECTROCHEMICAL SENSOR |
AT391998B (en) * | 1987-02-02 | 1990-12-27 | Falko Dr Skrabal | Device for determining the concentration of at least one medicinal substance in living organisms |
US4759828A (en) | 1987-04-09 | 1988-07-26 | Nova Biomedical Corporation | Glucose electrode and method of determining glucose |
US5540828A (en) | 1987-06-08 | 1996-07-30 | Yacynych; Alexander | Method for making electrochemical sensors and biosensors having a polymer modified surface |
US4805625A (en) * | 1987-07-08 | 1989-02-21 | Ad-Tech Medical Instrument Corporation | Sphenoidal electrode and insertion method |
NL8702370A (en) | 1987-10-05 | 1989-05-01 | Groningen Science Park | METHOD AND SYSTEM FOR GLUCOSE DETERMINATION AND USEABLE MEASURING CELL ASSEMBLY. |
GB8725936D0 (en) | 1987-11-05 | 1987-12-09 | Genetics Int Inc | Sensing system |
US4852573A (en) | 1987-12-04 | 1989-08-01 | Kennedy Philip R | Implantable neural electrode |
US4890621A (en) * | 1988-01-19 | 1990-01-02 | Northstar Research Institute, Ltd. | Continuous glucose monitoring and a system utilized therefor |
US4849458A (en) | 1988-06-17 | 1989-07-18 | Matrix Medica, Inc. | Segmented polyether polyurethane |
CA1299653C (en) | 1988-07-07 | 1992-04-28 | Markwell Medical Institute, Inc. | Biological fluid measuring device |
US5208147A (en) * | 1988-07-21 | 1993-05-04 | Radiometer A/S | Means for measuring a characteristic in a sample fluid |
GB8817997D0 (en) | 1988-07-28 | 1988-09-01 | Cambridge Life Sciences | Enzyme electrodes & improvements in manufacture thereof |
EP0353328A1 (en) | 1988-08-03 | 1990-02-07 | Dräger Nederland B.V. | A polarographic-amperometric three-electrode sensor |
US5068536A (en) | 1989-01-19 | 1991-11-26 | Futrex, Inc. | Method for providing custom calibration for near infrared instruments for measurement of blood glucose |
US5077476A (en) | 1990-06-27 | 1991-12-31 | Futrex, Inc. | Instrument for non-invasive measurement of blood glucose |
DK115989D0 (en) | 1989-03-09 | 1989-03-09 | Nordisk Gentofte | METHOD AND METHOD FOR MEASURING A LIQUID COMPONENT |
US5269891A (en) | 1989-03-09 | 1993-12-14 | Novo Nordisk A/S | Method and apparatus for determination of a constituent in a fluid |
JPH02298855A (en) | 1989-03-20 | 1990-12-11 | Assoc Univ Inc | Electrochemical biosensor using immobilized enzyme and redox polymer |
US4986671A (en) * | 1989-04-12 | 1991-01-22 | Luxtron Corporation | Three-parameter optical fiber sensor and system |
US4953552A (en) | 1989-04-21 | 1990-09-04 | Demarzo Arthur P | Blood glucose monitoring system |
US4975636A (en) | 1989-05-01 | 1990-12-04 | Hewlett-Packard Company | Method and apparatus for selecting and displaying a high resolution window from a main display |
US4988341A (en) * | 1989-06-05 | 1991-01-29 | Eastman Kodak Company | Sterilizing dressing device and method for skin puncture |
CH677149A5 (en) | 1989-07-07 | 1991-04-15 | Disetronic Ag | |
US5431160A (en) | 1989-07-19 | 1995-07-11 | University Of New Mexico | Miniature implantable refillable glucose sensor and material therefor |
US5264104A (en) | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
US4944299A (en) | 1989-08-08 | 1990-07-31 | Siemens-Pacesetter, Inc. | High speed digital telemetry system for implantable device |
US5101814A (en) * | 1989-08-11 | 1992-04-07 | Palti Yoram Prof | System for monitoring and controlling blood glucose |
US5190041A (en) * | 1989-08-11 | 1993-03-02 | Palti Yoram Prof | System for monitoring and controlling blood glucose |
US5050612A (en) | 1989-09-12 | 1991-09-24 | Matsumura Kenneth N | Device for computer-assisted monitoring of the body |
FR2652736A1 (en) | 1989-10-06 | 1991-04-12 | Neftel Frederic | IMPLANTABLE DEVICE FOR EVALUATING THE RATE OF GLUCOSE. |
JPH03133440A (en) | 1989-10-18 | 1991-06-06 | Nishitomo:Kk | Clinical thermometer for ladies |
US5140985A (en) | 1989-12-11 | 1992-08-25 | Schroeder Jon M | Noninvasive blood glucose measuring device |
FR2656423A1 (en) | 1989-12-22 | 1991-06-28 | Rhone Poulenc Chimie | Electrochemical biosensor |
US5108819A (en) * | 1990-02-14 | 1992-04-28 | Eli Lilly And Company | Thin film electrical component |
US5316008A (en) * | 1990-04-06 | 1994-05-31 | Casio Computer Co., Ltd. | Measurement of electrocardiographic wave and sphygmus |
US5165407A (en) | 1990-04-19 | 1992-11-24 | The University Of Kansas | Implantable glucose sensor |
US5331555A (en) | 1990-05-11 | 1994-07-19 | Sharp Kabushiki Kaisha | Electronic apparatus |
JPH0820412B2 (en) | 1990-07-20 | 1996-03-04 | 松下電器産業株式会社 | Quantitative analysis method and device using disposable sensor |
WO1992003107A1 (en) * | 1990-08-28 | 1992-03-05 | Meadox Medicals, Inc. | Self-supporting woven vascular graft |
US5243983A (en) | 1990-12-14 | 1993-09-14 | Georgia Tech Research Corporation | Non-invasive blood glucose measurement system and method using stimulated raman spectroscopy |
WO1992013271A1 (en) | 1991-01-25 | 1992-08-06 | Markwell Medical Institute, Inc. | Implantable biological fluid measuring device |
US5593852A (en) | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
US5632272A (en) * | 1991-03-07 | 1997-05-27 | Masimo Corporation | Signal processing apparatus |
DE69221484T2 (en) | 1991-04-25 | 1998-02-19 | Univ Brown Res Found | IMPLANTABLE, BIOCOMPATIBLE IMMUNISOLATOR SUPPORT SUBSTANCE FOR DELIVERING SELECTED, THERAPEUTIC PRODUCTS |
US5198771A (en) * | 1991-09-03 | 1993-03-30 | Transducer Research, Inc. | Potentiostatic apparatus and methods |
JPH07508183A (en) | 1992-02-01 | 1995-09-14 | ザ ヴィクトリア ユニヴァーシティ オヴ マンチェスター | Improvements regarding monitoring system |
NL9200207A (en) | 1992-02-05 | 1993-09-01 | Nedap Nv | IMPLANTABLE BIOMEDICAL SENSOR DEVICE, IN PARTICULAR FOR MEASUREMENT OF THE GLUCOSE CONCENTRATION. |
EP0563795B1 (en) | 1992-03-31 | 1998-07-22 | Dai Nippon Printing Co., Ltd. | Enzyme-immobilized electrode, composition for preparation of the same and electrically conductive enzyme |
US5324322A (en) * | 1992-04-20 | 1994-06-28 | Case Western Reserve University | Thin film implantable electrode and method of manufacture |
US5287753A (en) * | 1992-05-02 | 1994-02-22 | Advanced Technology Laboratories, Inc. | Continuous display of peak and mean blood flow velocities |
GB9211402D0 (en) | 1992-05-29 | 1992-07-15 | Univ Manchester | Sensor devices |
US5434412A (en) | 1992-07-15 | 1995-07-18 | Myron J. Block | Non-spectrophotometric measurement of analyte concentrations and optical properties of objects |
US5330634A (en) | 1992-08-28 | 1994-07-19 | Via Medical Corporation | Calibration solutions useful for analyses of biological fluids and methods employing same |
US5376070A (en) | 1992-09-29 | 1994-12-27 | Minimed Inc. | Data transfer system for an infusion pump |
US5368224A (en) | 1992-10-23 | 1994-11-29 | Nellcor Incorporated | Method for reducing ambient noise effects in electronic monitoring instruments |
US5899855A (en) * | 1992-11-17 | 1999-05-04 | Health Hero Network, Inc. | Modular microprocessor-based health monitoring system |
US5956501A (en) * | 1997-01-10 | 1999-09-21 | Health Hero Network, Inc. | Disease simulation system and method |
US5678571A (en) * | 1994-05-23 | 1997-10-21 | Raya Systems, Inc. | Method for treating medical conditions using a microprocessor-based video game |
US5307263A (en) * | 1992-11-17 | 1994-04-26 | Raya Systems, Inc. | Modular microprocessor-based health monitoring system |
US7624028B1 (en) | 1992-11-17 | 2009-11-24 | Health Hero Network, Inc. | Remote health monitoring and maintenance system |
US20010011224A1 (en) | 1995-06-07 | 2001-08-02 | Stephen James Brown | Modular microprocessor-based health monitoring system |
US5933136A (en) | 1996-12-23 | 1999-08-03 | Health Hero Network, Inc. | Network media access control system for encouraging patient compliance with a treatment plan |
US6256522B1 (en) | 1992-11-23 | 2001-07-03 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Sensors for continuous monitoring of biochemicals and related method |
US5299571A (en) * | 1993-01-22 | 1994-04-05 | Eli Lilly And Company | Apparatus and method for implantation of sensors |
WO1994022367A1 (en) | 1993-03-30 | 1994-10-13 | Pfizer Inc. | Radiotelemetry impedance plethysmography device |
US5411866A (en) * | 1993-03-30 | 1995-05-02 | National Research Council Of Canada | Method and system for determining bioactive substances |
US5387329A (en) * | 1993-04-09 | 1995-02-07 | Ciba Corning Diagnostics Corp. | Extended use planar sensors |
DE4329898A1 (en) | 1993-09-04 | 1995-04-06 | Marcus Dr Besson | Wireless medical diagnostic and monitoring device |
FR2710413B1 (en) * | 1993-09-21 | 1995-11-03 | Asulab Sa | Measuring device for removable sensors. |
US5582184A (en) | 1993-10-13 | 1996-12-10 | Integ Incorporated | Interstitial fluid collection and constituent measurement |
US5781455A (en) | 1993-11-02 | 1998-07-14 | Kyoto Daiichi Kagaku Co., Ltd. | Article of manufacture comprising computer usable medium for a portable blood sugar value measuring apparatus |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
US5497772A (en) * | 1993-11-19 | 1996-03-12 | Alfred E. Mann Foundation For Scientific Research | Glucose monitoring system |
US5791344A (en) | 1993-11-19 | 1998-08-11 | Alfred E. Mann Foundation For Scientific Research | Patient monitoring system |
US5553616A (en) | 1993-11-30 | 1996-09-10 | Florida Institute Of Technology | Determination of concentrations of biological substances using raman spectroscopy and artificial neural network discriminator |
US5443080A (en) | 1993-12-22 | 1995-08-22 | Americate Transtech, Inc. | Integrated system for biological fluid constituent analysis |
US5391250A (en) * | 1994-03-15 | 1995-02-21 | Minimed Inc. | Method of fabricating thin film sensors |
US5390671A (en) * | 1994-03-15 | 1995-02-21 | Minimed Inc. | Transcutaneous sensor insertion set |
US5569186A (en) | 1994-04-25 | 1996-10-29 | Minimed Inc. | Closed loop infusion pump system with removable glucose sensor |
DE4415896A1 (en) * | 1994-05-05 | 1995-11-09 | Boehringer Mannheim Gmbh | Analysis system for monitoring the concentration of an analyte in the blood of a patient |
US5474552A (en) | 1994-06-27 | 1995-12-12 | Cb-Carmel Biotechnology Ltd. | Implantable drug delivery pump |
US5429735A (en) | 1994-06-27 | 1995-07-04 | Miles Inc. | Method of making and amperometric electrodes |
US5494562A (en) * | 1994-06-27 | 1996-02-27 | Ciba Corning Diagnostics Corp. | Electrochemical sensors |
US5513636A (en) * | 1994-08-12 | 1996-05-07 | Cb-Carmel Biotechnology Ltd. | Implantable sensor chip |
US5462051A (en) | 1994-08-31 | 1995-10-31 | Colin Corporation | Medical communication system |
CA2159052C (en) | 1994-10-28 | 2007-03-06 | Rainer Alex | Injection device |
IE72524B1 (en) | 1994-11-04 | 1997-04-23 | Elan Med Tech | Analyte-controlled liquid delivery device and analyte monitor |
US5697366A (en) | 1995-01-27 | 1997-12-16 | Optical Sensors Incorporated | In situ calibration system for sensors located in a physiologic line |
US5586553A (en) | 1995-02-16 | 1996-12-24 | Minimed Inc. | Transcutaneous sensor insertion set |
US5568806A (en) | 1995-02-16 | 1996-10-29 | Minimed Inc. | Transcutaneous sensor insertion set |
US5882494A (en) | 1995-03-27 | 1999-03-16 | Minimed, Inc. | Polyurethane/polyurea compositions containing silicone for biosensor membranes |
US5620579A (en) | 1995-05-05 | 1997-04-15 | Bayer Corporation | Apparatus for reduction of bias in amperometric sensors |
US5806517A (en) | 1995-05-26 | 1998-09-15 | The Regents Of The University Of Colorado | In vivo electrochemistry computer system and method |
US5743262A (en) * | 1995-06-07 | 1998-04-28 | Masimo Corporation | Blood glucose monitoring system |
US5584813A (en) | 1995-06-07 | 1996-12-17 | Minimed Inc. | Subcutaneous injection set |
AU6251196A (en) * | 1995-06-07 | 1996-12-30 | Gore Hybrid Technologies, Inc. | An implantable containment apparatus for a therapeutical dev ice and method for loading and reloading the device therein |
US5995860A (en) | 1995-07-06 | 1999-11-30 | Thomas Jefferson University | Implantable sensor and system for measurement and control of blood constituent levels |
US6212424B1 (en) * | 1998-10-29 | 2001-04-03 | Rio Grande Medical Technologies, Inc. | Apparatus and method for determination of the adequacy of dialysis by non-invasive near-infrared spectroscopy |
US5711861A (en) | 1995-11-22 | 1998-01-27 | Ward; W. Kenneth | Device for monitoring changes in analyte concentration |
CA2212826C (en) | 1995-12-28 | 2002-02-19 | Cygnus, Inc. | Methods for monitoring a physiological analyte |
FI118509B (en) | 1996-02-12 | 2007-12-14 | Nokia Oyj | A method and apparatus for predicting blood glucose levels in a patient |
IL127213A (en) * | 1996-07-08 | 2003-09-17 | Animas Corp | Implantable sensor and system for in vivo measurement and control of fluid constituent levels |
JP2943700B2 (en) | 1996-07-10 | 1999-08-30 | 日本電気株式会社 | Biosensor |
US6544193B2 (en) | 1996-09-04 | 2003-04-08 | Marcio Marc Abreu | Noninvasive measurement of chemical substances |
US5836887A (en) | 1996-09-19 | 1998-11-17 | Colin Corporation | Physical information monitor system having means for determining reference range for abnormality determination, based on moving average of previously obtained values |
US6168568B1 (en) * | 1996-10-04 | 2001-01-02 | Karmel Medical Acoustic Technologies Ltd. | Phonopneumograph system |
US6001068A (en) | 1996-10-22 | 1999-12-14 | Terumo Kabushiki Kaisha | Guide wire having tubular connector with helical slits |
WO1998024358A2 (en) | 1996-12-04 | 1998-06-11 | Enact Health Management Systems | System for downloading and reporting medical information |
US5964993A (en) | 1996-12-19 | 1999-10-12 | Implanted Biosystems Inc. | Glucose sensor |
US5836989A (en) | 1996-12-26 | 1998-11-17 | Medtronic, Inc. | Method and apparatus for controlling an implanted medical device in a time-dependent manner |
US5914026A (en) * | 1997-01-06 | 1999-06-22 | Implanted Biosystems Inc. | Implantable sensor employing an auxiliary electrode |
JP3121356B2 (en) | 1997-01-17 | 2000-12-25 | ビア メディカル コーポレイション | Calibration methods for sensors used in diagnostic tests |
US6093172A (en) | 1997-02-05 | 2000-07-25 | Minimed Inc. | Injector for a subcutaneous insertion set |
US6891317B2 (en) | 2001-05-22 | 2005-05-10 | Sri International | Rolled electroactive polymers |
US5749907A (en) * | 1997-02-18 | 1998-05-12 | Pacesetter, Inc. | System and method for identifying and displaying medical data which violate programmable alarm conditions |
US6309884B1 (en) | 1997-02-26 | 2001-10-30 | Diasense, Inc. | Individual calibration of blood glucose for supporting noninvasive self-monitoring blood glucose |
US6208894B1 (en) * | 1997-02-26 | 2001-03-27 | Alfred E. Mann Foundation For Scientific Research And Advanced Bionics | System of implantable devices for monitoring and/or affecting body parameters |
US20050033132A1 (en) | 1997-03-04 | 2005-02-10 | Shults Mark C. | Analyte measuring device |
US6862465B2 (en) | 1997-03-04 | 2005-03-01 | Dexcom, Inc. | Device and method for determining analyte levels |
US6558321B1 (en) | 1997-03-04 | 2003-05-06 | Dexcom, Inc. | Systems and methods for remote monitoring and modulation of medical devices |
US6001067A (en) | 1997-03-04 | 1999-12-14 | Shults; Mark C. | Device and method for determining analyte levels |
US6741877B1 (en) | 1997-03-04 | 2004-05-25 | Dexcom, Inc. | Device and method for determining analyte levels |
US7657297B2 (en) | 2004-05-03 | 2010-02-02 | Dexcom, Inc. | Implantable analyte sensor |
FR2760962B1 (en) | 1997-03-20 | 1999-05-14 | Sillonville Francis Klefstad | REMOTE MEDICAL ASSISTANCE AND SURVEILLANCE SYSTEM |
US6270455B1 (en) | 1997-03-28 | 2001-08-07 | Health Hero Network, Inc. | Networked system for interactive communications and remote monitoring of drug delivery |
US5961451A (en) | 1997-04-07 | 1999-10-05 | Motorola, Inc. | Noninvasive apparatus having a retaining member to retain a removable biosensor |
US6059946A (en) * | 1997-04-14 | 2000-05-09 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
US5944661A (en) | 1997-04-16 | 1999-08-31 | Giner, Inc. | Potential and diffusion controlled solid electrolyte sensor for continuous measurement of very low levels of transdermal alcohol |
TW357517B (en) | 1997-05-29 | 1999-05-01 | Koji Akai | Monitoring system |
US5954643A (en) | 1997-06-09 | 1999-09-21 | Minimid Inc. | Insertion set for a transcutaneous sensor |
US7267665B2 (en) | 1999-06-03 | 2007-09-11 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
US6558351B1 (en) | 1999-06-03 | 2003-05-06 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
CA2294610A1 (en) | 1997-06-16 | 1998-12-23 | George Moshe Katz | Methods of calibrating and testing a sensor for in vivo measurement of an analyte and devices for use in such methods |
US6093167A (en) | 1997-06-16 | 2000-07-25 | Medtronic, Inc. | System for pancreatic stimulation and glucose measurement |
US6013711A (en) | 1997-06-18 | 2000-01-11 | Ck Witco Corporation | Hydrophilic polysiloxane compositions |
SE9702739D0 (en) * | 1997-07-17 | 1997-07-17 | Siemens Elema Ab | Method for rinsing and calibrating sensors included in a body fluid analysis system |
US5861019A (en) * | 1997-07-25 | 1999-01-19 | Medtronic Inc. | Implantable medical device microstrip telemetry antenna |
US5871514A (en) | 1997-08-01 | 1999-02-16 | Medtronic, Inc. | Attachment apparatus for an implantable medical device employing ultrasonic energy |
US6259937B1 (en) | 1997-09-12 | 2001-07-10 | Alfred E. Mann Foundation | Implantable substrate sensor |
EP0910023A2 (en) | 1997-10-17 | 1999-04-21 | Siemens Aktiengesellschaft | Method and device for the neuronal modelling of a dynamic system with non-linear stochastic behavior |
US6088608A (en) | 1997-10-20 | 2000-07-11 | Alfred E. Mann Foundation | Electrochemical sensor and integrity tests therefor |
US6081736A (en) * | 1997-10-20 | 2000-06-27 | Alfred E. Mann Foundation | Implantable enzyme-based monitoring systems adapted for long term use |
US6119028A (en) | 1997-10-20 | 2000-09-12 | Alfred E. Mann Foundation | Implantable enzyme-based monitoring systems having improved longevity due to improved exterior surfaces |
US6117643A (en) | 1997-11-25 | 2000-09-12 | Ut Battelle, Llc | Bioluminescent bioreporter integrated circuit |
US6036924A (en) * | 1997-12-04 | 2000-03-14 | Hewlett-Packard Company | Cassette of lancet cartridges for sampling blood |
US6579690B1 (en) | 1997-12-05 | 2003-06-17 | Therasense, Inc. | Blood analyte monitoring through subcutaneous measurement |
US6120298A (en) * | 1998-01-23 | 2000-09-19 | Scientific Learning Corp. | Uniform motivation for multiple computer-assisted training systems |
US6134461A (en) | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
US6103033A (en) | 1998-03-04 | 2000-08-15 | Therasense, Inc. | Process for producing an electrochemical biosensor |
US6024699A (en) * | 1998-03-13 | 2000-02-15 | Healthware Corporation | Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients |
US5904708A (en) * | 1998-03-19 | 1999-05-18 | Medtronic, Inc. | System and method for deriving relative physiologic signals |
GB9805896D0 (en) | 1998-03-20 | 1998-05-13 | Eglise David | Remote analysis system |
US6091975A (en) | 1998-04-01 | 2000-07-18 | Alza Corporation | Minimally invasive detecting device |
JPH11296598A (en) | 1998-04-07 | 1999-10-29 | Seizaburo Arita | System and method for predicting blood-sugar level and record medium where same method is recorded |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
CA2330629C (en) * | 1998-05-13 | 2007-04-03 | Cygnus, Inc. | Method and device for predicting physiological values |
DE69910003T2 (en) | 1998-05-13 | 2004-04-22 | Cygnus, Inc., Redwood City | MONITORING PHYSIOLOGICAL ANALYSIS |
DK1077636T3 (en) * | 1998-05-13 | 2004-05-24 | Cygnus Therapeutic Systems | Signal processing for measurement of physiological analytes |
US5982285A (en) * | 1998-05-14 | 1999-11-09 | Bueche; Kenneth M. | Compliance monitoring system |
US6526298B1 (en) * | 1998-05-18 | 2003-02-25 | Abbott Laboratories | Method for the non-invasive determination of analytes in a selected volume of tissue |
US6302855B1 (en) | 1998-05-20 | 2001-10-16 | Novo Nordisk A/S | Medical apparatus for use by a patient for medical self treatment of diabetes |
US6702972B1 (en) | 1998-06-09 | 2004-03-09 | Diametrics Medical Limited | Method of making a kink-resistant catheter |
US6554798B1 (en) | 1998-08-18 | 2003-04-29 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
US6558320B1 (en) | 2000-01-20 | 2003-05-06 | Medtronic Minimed, Inc. | Handheld personal data assistant (PDA) with a medical device and method of using the same |
US6248067B1 (en) * | 1999-02-05 | 2001-06-19 | Minimed Inc. | Analyte sensor and holter-type monitor system and method of using the same |
US6107083A (en) | 1998-08-21 | 2000-08-22 | Bayer Corporation | Optical oxidative enzyme-based sensors |
CA2340005C (en) | 1998-08-26 | 2014-05-06 | Sensors For Medicine And Science, Inc. | Optical-based sensing devices |
US6233080B1 (en) * | 1998-08-26 | 2001-05-15 | Ciena Corporation | Crosstalk-free signal source for dense wavelength division multiplexed systems |
US6403349B1 (en) | 1998-09-02 | 2002-06-11 | Abbott Laboratories | Elongase gene and uses thereof |
DE69908602T2 (en) | 1998-09-30 | 2004-06-03 | Cygnus, Inc., Redwood City | METHOD AND DEVICE FOR PREDICTING PHYSIOLOGICAL MEASUREMENTS |
US6180416B1 (en) * | 1998-09-30 | 2001-01-30 | Cygnus, Inc. | Method and device for predicting physiological values |
US6201980B1 (en) * | 1998-10-05 | 2001-03-13 | The Regents Of The University Of California | Implantable medical sensor system |
EP2229879A1 (en) | 1998-10-08 | 2010-09-22 | Medtronic MiniMed, Inc. | Telemetered characteristic monitor system |
US6338790B1 (en) | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US6591125B1 (en) | 2000-06-27 | 2003-07-08 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
US6016448A (en) * | 1998-10-27 | 2000-01-18 | Medtronic, Inc. | Multilevel ERI for implantable medical devices |
EP1131114B1 (en) * | 1998-11-20 | 2004-06-16 | The University of Connecticut | Apparatus and method for control of tissue/implant interactions |
KR20010102951A (en) | 1998-12-02 | 2001-11-17 | 추후제출 | In vivo biosensor apparatus and method of use |
US6201993B1 (en) * | 1998-12-09 | 2001-03-13 | Medtronic, Inc. | Medical device telemetry receiver having improved noise discrimination |
US6329929B1 (en) | 1998-12-21 | 2001-12-11 | Medtronic Inc. | Telemetry system with phase-locking noise suppressing receiver |
WO2000047109A1 (en) | 1999-02-12 | 2000-08-17 | Cygnus, Inc. | Devices and methods for frequent measurement of an analyte present in a biological system |
US6360888B1 (en) | 1999-02-25 | 2002-03-26 | Minimed Inc. | Glucose sensor package system |
US6424847B1 (en) | 1999-02-25 | 2002-07-23 | Medtronic Minimed, Inc. | Glucose monitor calibration methods |
US6416651B1 (en) | 1999-02-26 | 2002-07-09 | Honeywell Measurex | Multi-electrode composition measuring device and method |
US6230059B1 (en) * | 1999-03-17 | 2001-05-08 | Medtronic, Inc. | Implantable monitor |
US7107253B1 (en) * | 1999-04-05 | 2006-09-12 | American Board Of Family Practice, Inc. | Computer architecture and process of patient generation, evolution and simulation for computer based testing system using bayesian networks as a scripting language |
AU4216900A (en) | 1999-04-07 | 2000-10-23 | Spectrx, Inc. | Assay device for measuring characteristics of a fluid on a continual basis |
US6223083B1 (en) * | 1999-04-16 | 2001-04-24 | Medtronic, Inc. | Receiver employing digital filtering for use with an implantable medical device |
US6475750B1 (en) | 1999-05-11 | 2002-11-05 | M-Biotech, Inc. | Glucose biosensor |
US6546268B1 (en) * | 1999-06-02 | 2003-04-08 | Ball Semiconductor, Inc. | Glucose sensor |
EP1191875A1 (en) | 1999-06-17 | 2002-04-03 | Medtronic MiniMed, Inc. | Characteristic monitor system for use with analyte sensor |
US7247138B2 (en) | 1999-07-01 | 2007-07-24 | Medtronic Minimed, Inc. | Reusable analyte sensor site and method of using the same |
US6471689B1 (en) | 1999-08-16 | 2002-10-29 | Thomas Jefferson University | Implantable drug delivery catheter system with capillary interface |
US6673022B1 (en) | 1999-08-20 | 2004-01-06 | Innerspace Medical, Inc. | Gas column pressure monitoring catheters |
US6343225B1 (en) | 1999-09-14 | 2002-01-29 | Implanted Biosystems, Inc. | Implantable glucose sensor |
EP1214596A1 (en) | 1999-09-15 | 2002-06-19 | The Regents Of The University Of California | Glucose sensing molecules having selected fluorescent properties |
US6527729B1 (en) * | 1999-11-10 | 2003-03-04 | Pacesetter, Inc. | Method for monitoring patient using acoustic sensor |
SE9904087D0 (en) | 1999-11-11 | 1999-11-11 | Pacesetter Ab | Recommended replacement time of an implantable medical device |
US6925393B1 (en) | 1999-11-18 | 2005-08-02 | Roche Diagnostics Gmbh | System for the extrapolation of glucose concentration |
US6635014B2 (en) | 2000-01-21 | 2003-10-21 | Timothy J. Starkweather | Ambulatory medical apparatus and method having telemetry modifiable control software |
US6582380B2 (en) * | 2000-01-24 | 2003-06-24 | Ambulatory Monitoring, Inc. | System and method of monitoring and modifying human activity-based behavior |
US6687521B2 (en) | 2000-02-03 | 2004-02-03 | Hamamatsu Photonics K.K. | Noninvasion biological optical measuring instrument, measured portion holding device, and method for manufacturing the same |
EP1130393A3 (en) * | 2000-02-03 | 2001-11-28 | Nihon Kohden Corporation | Gas sensor and gas sensor system |
CA2395868C (en) | 2000-02-10 | 2009-07-14 | Medtronic Minimed, Inc. | Improved analyte sensor and method of making the same |
US6895263B2 (en) | 2000-02-23 | 2005-05-17 | Medtronic Minimed, Inc. | Real time self-adjusting calibration algorithm |
US6551496B1 (en) | 2000-03-03 | 2003-04-22 | Ysi Incorporated | Microstructured bilateral sensor |
CA2406814A1 (en) | 2000-03-17 | 2001-09-20 | F. Hoffmann-La Roche Ag | Implantable analyte sensor |
US6405066B1 (en) | 2000-03-17 | 2002-06-11 | The Regents Of The University Of California | Implantable analyte sensor |
RU2283495C2 (en) | 2000-03-29 | 2006-09-10 | Юниверсити Оф Вирджиния Пэйтент Фаундейшн | Method, system and software product for evaluating diabetic glycemia control |
US6599281B1 (en) | 2000-05-03 | 2003-07-29 | Aspect Medical Systems, Inc. | System and method for adaptive drug delivery |
IT1314759B1 (en) | 2000-05-08 | 2003-01-03 | Menarini Farma Ind | INSTRUMENTATION FOR MEASUREMENT AND CONTROL OF THE CONTENT OF GLUCOSIOLACTATE OR OTHER METABOLITES IN BIOLOGICAL FLUIDS |
AU2001263022A1 (en) | 2000-05-12 | 2001-11-26 | Therasense, Inc. | Electrodes with multilayer membranes and methods of using and making the electrodes |
US6885883B2 (en) | 2000-05-16 | 2005-04-26 | Cygnus, Inc. | Methods for improving performance and reliability of biosensors |
JP3701608B2 (en) | 2000-05-23 | 2005-10-05 | ラジオメーター・メディカル・アー・ペー・エス | Sensor membrane, method for its preparation, sensor and layered membrane structure for such a sensor |
WO2002100266A1 (en) | 2000-06-13 | 2002-12-19 | Edward Henry Mathews | A dietary system: 'blood sugar predicting system' |
US7261690B2 (en) | 2000-06-16 | 2007-08-28 | Bodymedia, Inc. | Apparatus for monitoring health, wellness and fitness |
US6477392B1 (en) | 2000-07-14 | 2002-11-05 | Futrex Inc. | Calibration of near infrared quantitative measurement device using optical measurement cross-products |
US6589229B1 (en) | 2000-07-31 | 2003-07-08 | Becton, Dickinson And Company | Wearable, self-contained drug infusion device |
WO2002017210A2 (en) | 2000-08-18 | 2002-02-28 | Cygnus, Inc. | Formulation and manipulation of databases of analyte and associated values |
WO2002015778A1 (en) | 2000-08-18 | 2002-02-28 | Cygnus, Inc. | Analyte monitoring device alarm augmentation system |
WO2002018936A2 (en) | 2000-08-28 | 2002-03-07 | Cygnus, Inc. | Methods of monitoring glucose levels in a subject and uses thereof |
US6553241B2 (en) | 2000-08-31 | 2003-04-22 | Mallinckrodt Inc. | Oximeter sensor with digital memory encoding sensor expiration data |
GB2369778A (en) * | 2000-09-06 | 2002-06-12 | Discovery Health Ltd | Incentivising compliance in members of a disease management programme |
US6575905B2 (en) | 2000-09-22 | 2003-06-10 | Knobbe, Lim & Buckingham | Method and apparatus for real-time estimation of physiological parameters |
IL156245A0 (en) | 2000-12-22 | 2004-01-04 | Dca Design Int Ltd | Drive mechanism for an injection device |
US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
US6510329B2 (en) * | 2001-01-24 | 2003-01-21 | Datex-Ohmeda, Inc. | Detection of sensor off conditions in a pulse oximeter |
US6841389B2 (en) | 2001-02-05 | 2005-01-11 | Glucosens, Inc. | Method of determining concentration of glucose in blood |
WO2002064027A2 (en) | 2001-02-15 | 2002-08-22 | The Regents Of The University Of California | Membrane and electrode structure for implantable sensor |
US6574490B2 (en) | 2001-04-11 | 2003-06-03 | Rio Grande Medical Technologies, Inc. | System for non-invasive measurement of glucose in humans |
US7167734B2 (en) | 2001-04-13 | 2007-01-23 | Abbott Laboratories | Method for optical measurements of tissue to determine disease state or concentration of an analyte |
US7011630B2 (en) | 2001-06-22 | 2006-03-14 | Animas Technologies, Llc | Methods for computing rolling analyte measurement values, microprocessors comprising programming to control performance of the methods, and analyte monitoring devices employing the methods |
US7150737B2 (en) | 2001-07-13 | 2006-12-19 | Sci/Med Life Systems, Inc. | Methods and apparatuses for navigating the subarachnoid space |
US6702857B2 (en) | 2001-07-27 | 2004-03-09 | Dexcom, Inc. | Membrane for use with implantable devices |
US20030032874A1 (en) | 2001-07-27 | 2003-02-13 | Dexcom, Inc. | Sensor head for use with implantable devices |
US6544212B2 (en) * | 2001-07-31 | 2003-04-08 | Roche Diagnostics Corporation | Diabetes management system |
US7025760B2 (en) | 2001-09-07 | 2006-04-11 | Medtronic Minimed, Inc. | Method and system for non-vascular sensor implantation |
US6650915B2 (en) | 2001-09-13 | 2003-11-18 | Fovioptics, Inc. | Non-invasive measurement of blood analytes using photodynamics |
US6809507B2 (en) | 2001-10-23 | 2004-10-26 | Medtronic Minimed, Inc. | Implantable sensor electrodes and electronic circuitry |
US20050101841A9 (en) | 2001-12-04 | 2005-05-12 | Kimberly-Clark Worldwide, Inc. | Healthcare networks with biosensors |
US6952604B2 (en) | 2001-12-21 | 2005-10-04 | Becton, Dickinson And Company | Minimally-invasive system and method for monitoring analyte levels |
US20050027182A1 (en) | 2001-12-27 | 2005-02-03 | Uzair Siddiqui | System for monitoring physiological characteristics |
US7022072B2 (en) | 2001-12-27 | 2006-04-04 | Medtronic Minimed, Inc. | System for monitoring physiological characteristics |
US7018336B2 (en) | 2001-12-27 | 2006-03-28 | Medtronic Minimed, Inc. | Implantable sensor flush sleeve |
US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US7497827B2 (en) | 2004-07-13 | 2009-03-03 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US6998247B2 (en) | 2002-03-08 | 2006-02-14 | Sensys Medical, Inc. | Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers |
ATE482649T1 (en) | 2002-03-22 | 2010-10-15 | Animas Technologies Llc | PERFORMANCE IMPROVEMENT OF AN ANALYTE MONITORING DEVICE |
US7133712B2 (en) | 2002-04-05 | 2006-11-07 | Eyelab Group, Llc | Method and apparatus for non-invasive monitoring of blood substances using self-sampled tears |
US7060192B2 (en) | 2002-05-09 | 2006-06-13 | Lifescan, Inc. | Methods of fabricating physiological sample collection devices |
US7343188B2 (en) | 2002-05-09 | 2008-03-11 | Lifescan, Inc. | Devices and methods for accessing and analyzing physiological fluid |
AU2003279777A1 (en) | 2002-06-28 | 2004-01-19 | November Aktiengesellschaft Gesellschaft Fur Molekulare Medizin | Electrochemical detection method and device |
US7278983B2 (en) | 2002-07-24 | 2007-10-09 | Medtronic Minimed, Inc. | Physiological monitoring device for controlling a medication infusion device |
US6892093B2 (en) | 2002-08-01 | 2005-05-10 | Ge Medical Systems Information Technologies Inc. | Method and apparatus for real time display of filtered electrocardiogram data |
JP4599296B2 (en) | 2002-10-11 | 2010-12-15 | ベクトン・ディキンソン・アンド・カンパニー | System and method for initiating and maintaining continuous long-term control of the concentration of a substance in a patient's body using a feedback or model-based controller coupled to a single needle or multi-needle intradermal (ID) delivery device |
US7228160B2 (en) | 2002-11-13 | 2007-06-05 | Sorenson Medical, Inc. | System, apparatus and method for inferring glucose levels within the peritoneum with implantable sensors |
US7229288B2 (en) | 2002-12-20 | 2007-06-12 | Medtronic Minimed, Inc. | Method, system, and program for using a virtual environment to provide information on using a product |
US7811231B2 (en) | 2002-12-31 | 2010-10-12 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
US7885708B2 (en) * | 2003-01-15 | 2011-02-08 | Erchonia Corporation | Iontophoresis device |
CN1767872B (en) | 2003-04-02 | 2010-12-08 | 神经技术无限责任公司 | Implantable nerve signal sensing and stimulation device for treating foot drop and other neurological disorders |
US7134999B2 (en) | 2003-04-04 | 2006-11-14 | Dexcom, Inc. | Optimized sensor geometry for an implantable glucose sensor |
WO2004102329A2 (en) * | 2003-05-08 | 2004-11-25 | Good Health Network, Inc. | Secure healthcare database system and method |
WO2005010518A1 (en) | 2003-07-23 | 2005-02-03 | Dexcom, Inc. | Rolled electrode array and its method for manufacture |
US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
US7074307B2 (en) | 2003-07-25 | 2006-07-11 | Dexcom, Inc. | Electrode systems for electrochemical sensors |
US20050021372A1 (en) * | 2003-07-25 | 2005-01-27 | Dimagi, Inc. | Interactive motivation systems and methods for self-care compliance |
WO2005012871A2 (en) | 2003-07-25 | 2005-02-10 | Dexcom, Inc. | Increasing bias for oxygen production in an electrode system |
EP1648298A4 (en) | 2003-07-25 | 2010-01-13 | Dexcom Inc | Oxygen enhancing membrane systems for implantable devices |
WO2005019795A2 (en) | 2003-07-25 | 2005-03-03 | Dexcom, Inc. | Electrochemical sensors including electrode systems with increased oxygen generation |
US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
US7778680B2 (en) | 2003-08-01 | 2010-08-17 | Dexcom, Inc. | System and methods for processing analyte sensor data |
US20070208245A1 (en) | 2003-08-01 | 2007-09-06 | Brauker James H | Transcutaneous analyte sensor |
US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7519408B2 (en) | 2003-11-19 | 2009-04-14 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8369919B2 (en) | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
US8845536B2 (en) | 2003-08-01 | 2014-09-30 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US7261671B2 (en) | 2003-09-10 | 2007-08-28 | Ford Global Technologies, Llc | Hybrid vehicle powertrain with a multiple-ratio power transmission mechanism |
US7723099B2 (en) | 2003-09-10 | 2010-05-25 | Abbott Point Of Care Inc. | Immunoassay device with immuno-reference electrode |
US20050187749A1 (en) | 2003-10-24 | 2005-08-25 | Judy Singley | Method, system, and computer program for performing carbohydrate/insulin calculation based upon food weight |
US20050090607A1 (en) | 2003-10-28 | 2005-04-28 | Dexcom, Inc. | Silicone composition for biocompatible membrane |
US7299082B2 (en) | 2003-10-31 | 2007-11-20 | Abbott Diabetes Care, Inc. | Method of calibrating an analyte-measurement device, and associated methods, devices and systems |
CA2543961A1 (en) | 2003-10-31 | 2005-05-19 | Lifescan Scotland Limited | Electrochemical test strip for reducing the effect of direct and mediated interference current |
EP1711790B1 (en) | 2003-12-05 | 2010-09-08 | DexCom, Inc. | Calibration techniques for a continuous analyte sensor |
US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
US8774886B2 (en) | 2006-10-04 | 2014-07-08 | Dexcom, Inc. | Analyte sensor |
EP2316331B1 (en) | 2003-12-09 | 2016-06-29 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
US8147426B2 (en) | 2003-12-31 | 2012-04-03 | Nipro Diagnostics, Inc. | Integrated diagnostic test system |
WO2005070482A1 (en) | 2004-01-26 | 2005-08-04 | Novo Nordisk A/S | Impulse chamber for jet delivery device |
WO2005081119A2 (en) | 2004-02-19 | 2005-09-01 | Edward Henry Mathews | Interactive diabetes education system |
US8808228B2 (en) * | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US20050245799A1 (en) | 2004-05-03 | 2005-11-03 | Dexcom, Inc. | Implantable analyte sensor |
US8277713B2 (en) | 2004-05-03 | 2012-10-02 | Dexcom, Inc. | Implantable analyte sensor |
US20060015020A1 (en) | 2004-07-06 | 2006-01-19 | Dexcom, Inc. | Systems and methods for manufacture of an analyte-measuring device including a membrane system |
US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
US7905833B2 (en) | 2004-07-13 | 2011-03-15 | Dexcom, Inc. | Transcutaneous analyte sensor |
US8886272B2 (en) | 2004-07-13 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
US20060100588A1 (en) | 2004-07-23 | 2006-05-11 | Lennart Brunnberg | Needle handling device |
US7261691B1 (en) * | 2004-08-02 | 2007-08-28 | Kwabena Asomani | Personalized emergency medical monitoring and transmission system |
MX2007002043A (en) * | 2004-08-16 | 2007-10-11 | Quark Biotech Inc | Therapeutic uses of inhibitors of rtp801. |
US7291107B2 (en) * | 2004-08-26 | 2007-11-06 | Roche Diagnostics Operations, Inc. | Insulin bolus recommendation system |
US20080249384A1 (en) * | 2004-09-03 | 2008-10-09 | Novo Nordisk A/S | System and Method for Estimating the Glucose Concentration in Blood |
US20060089542A1 (en) * | 2004-10-25 | 2006-04-27 | Safe And Sound Solutions, Inc. | Mobile patient monitoring system with automatic data alerts |
US20070010950A1 (en) * | 2004-12-03 | 2007-01-11 | Abensour Daniel S | Method to determine the degree and stability of blood glucose control in patients with diabetes mellitus via the creation and continuous update of new statistical indicators in blood glucose monitors or free standing computers |
WO2006065784A2 (en) * | 2004-12-13 | 2006-06-22 | Cardiocore Lab, Inc. | Transfer of captured electrocardiogram |
US7985199B2 (en) * | 2005-03-17 | 2011-07-26 | Unomedical A/S | Gateway system |
GB0505763D0 (en) | 2005-03-22 | 2005-04-27 | Enigma Diagnostics Ltd | Polymorphism detection method |
WO2006105146A2 (en) | 2005-03-29 | 2006-10-05 | Arkal Medical, Inc. | Devices, systems, methods and tools for continuous glucose monitoring |
US20060272652A1 (en) | 2005-06-03 | 2006-12-07 | Medtronic Minimed, Inc. | Virtual patient software system for educating and treating individuals with diabetes |
EP1893079B1 (en) * | 2005-06-08 | 2012-06-27 | SHER, Philip Michael | Fluctuating blood glucose notification threshold profiles and methods of use |
US20070012324A1 (en) | 2005-07-18 | 2007-01-18 | Ratna Nirkondar | Handheld Dedicated Device for Diabetes Management |
US7359723B2 (en) | 2005-08-02 | 2008-04-15 | Qualcomm Incorporated | Systems, devices and methods for providing a reward based upon use of a mobile communications device |
WO2007066284A2 (en) * | 2005-12-05 | 2007-06-14 | Koninklijke Philips Electronics N.V. | Chronic illness goal management |
US7963917B2 (en) | 2005-12-05 | 2011-06-21 | Echo Therapeutics, Inc. | System and method for continuous non-invasive glucose monitoring |
US20080015422A1 (en) * | 2005-12-29 | 2008-01-17 | Guidance Interactive Healthcare, Inc. | Combined peripheral and health monitoring devices |
EP1991110B1 (en) | 2006-03-09 | 2018-11-07 | DexCom, Inc. | Systems and methods for processing analyte sensor data |
US20070288266A1 (en) * | 2006-06-02 | 2007-12-13 | Suzanne Sysko | System and methods for chronic disease management and health assessment |
ATE514755T1 (en) | 2006-07-25 | 2011-07-15 | Glumetrics Inc | FLUORESCENT DYES FOR USE IN GLUCOSE DETECTION |
US20080171967A1 (en) | 2006-10-17 | 2008-07-17 | Blomquist Michael L | Insulin pump having a food database |
US20130324823A1 (en) * | 2006-11-20 | 2013-12-05 | Modz Oy | Measurement device, system and method |
US8585593B2 (en) | 2006-11-27 | 2013-11-19 | University Of Virginia Patent Foundation | Method, system, and computer program product for the detection of physical activity by changes in heart rate, assessment of fast changing metabolic states, and applications of closed and open control loop in diabetes |
US8079955B2 (en) * | 2006-11-28 | 2011-12-20 | Isense Corporation | Method and apparatus for managing glucose control |
WO2008076868A2 (en) | 2006-12-18 | 2008-06-26 | Abbott Laboratories | Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1) |
WO2008098011A1 (en) | 2007-02-06 | 2008-08-14 | Glumetrics, Inc. | Method for polymerizing a monomer solution within a cavity to generate a smooth polymer surface |
US7829341B2 (en) | 2007-07-11 | 2010-11-09 | Glumetrics, Inc. | Polyviologen boronic acid quenchers for use in analyte sensors |
US7751863B2 (en) | 2007-02-06 | 2010-07-06 | Glumetrics, Inc. | Optical determination of ph and glucose |
EP2120680A2 (en) | 2007-02-06 | 2009-11-25 | Glumetrics, Inc. | Optical systems and methods for rationmetric measurement of blood glucose concentration |
US20090093687A1 (en) * | 2007-03-08 | 2009-04-09 | Telfort Valery G | Systems and methods for determining a physiological condition using an acoustic monitor |
ATE506368T1 (en) | 2007-05-01 | 2011-05-15 | Glumetrics Inc | PYRIDINE BORONIC ACID QUENCHER FOR USE IN ANALYTICAL SENSORS |
EP2150814A2 (en) | 2007-05-10 | 2010-02-10 | Glumetrics, Inc. | Device and methods for calibrating analyte sensors |
JP5517919B2 (en) | 2007-05-10 | 2014-06-11 | グルメトリクス、 インク. | Balanced non-consumable fluorescent sensor for immediate intravascular glucose measurement |
CA2688184A1 (en) | 2007-06-08 | 2008-12-18 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
CA2689459A1 (en) | 2007-06-11 | 2009-01-08 | Cesaroni Technology Incorporated | Body temperature controlling system |
US20080311968A1 (en) | 2007-06-13 | 2008-12-18 | Hunter Thomas C | Method for improving self-management of a disease |
EP2165320A2 (en) * | 2007-06-22 | 2010-03-24 | Medingo Ltd. | Communications for medicinal fluid delivery system |
US8160900B2 (en) * | 2007-06-29 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
EP2181160B1 (en) | 2007-08-06 | 2016-05-11 | Medtronic Minimed, Inc. | Hpts-mono cys-ma polymerizable fluorescent dyes for use in analyte sensors |
US7978062B2 (en) * | 2007-08-31 | 2011-07-12 | Cardiac Pacemakers, Inc. | Medical data transport over wireless life critical network |
US20090062645A1 (en) | 2007-09-03 | 2009-03-05 | Jens Fehre | Method for diagnosis and treatment of prostate cancer |
US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
WO2009067626A1 (en) | 2007-11-21 | 2009-05-28 | Glumetrics, Inc. | Use of an equilibrium intravascular sensor to achieve tight glycemic control |
US8892999B2 (en) | 2007-11-30 | 2014-11-18 | Nike, Inc. | Interactive avatar for social network services |
US8290559B2 (en) | 2007-12-17 | 2012-10-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
ES2680896T3 (en) * | 2007-12-26 | 2018-09-11 | F. Hoffmann-La Roche Ag | System for glycemic control |
US20090177147A1 (en) | 2008-01-07 | 2009-07-09 | Michael Blomquist | Insulin pump with insulin therapy coaching |
US9143569B2 (en) | 2008-02-21 | 2015-09-22 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
US20090242399A1 (en) | 2008-03-25 | 2009-10-01 | Dexcom, Inc. | Analyte sensor |
US8396528B2 (en) | 2008-03-25 | 2013-03-12 | Dexcom, Inc. | Analyte sensor |
WO2009129186A2 (en) | 2008-04-17 | 2009-10-22 | Glumetrics, Inc. | Sensor for percutaneous intravascular deployment without an indwelling cannula |
US8591410B2 (en) * | 2008-05-30 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
RU2531355C2 (en) * | 2008-08-28 | 2014-10-20 | Айсенс Корпорейшн | Method and system for wireless device communication |
US8974439B2 (en) | 2009-01-02 | 2015-03-10 | Asante Solutions, Inc. | Infusion pump system and methods |
US20100191075A1 (en) * | 2009-01-26 | 2010-07-29 | Kimon Angelides | Progressively Personalized Decision-Support Menu for Controlling Diabetes |
US20100240978A1 (en) * | 2009-02-16 | 2010-09-23 | Labastide Sebastiaan | Game display of a diagnostic device and method of playing |
EP2230018A1 (en) * | 2009-02-26 | 2010-09-22 | Roche Diagnostics GmbH | Consumption element cartridge for an analyte concentration measuring system |
WO2011082212A1 (en) * | 2009-12-29 | 2011-07-07 | Abbott Diabetes Care Inc. | System and method for analysis of medical data to encourage health care management |
US20140012510A1 (en) * | 2012-07-09 | 2014-01-09 | Dexcom, Inc | Systems and methods for leveraging smartphone features in continuous glucose monitoring |
WO2019094908A1 (en) * | 2017-11-13 | 2019-05-16 | Senseonics, Incorporated | Analyte monitoring system and method for determining system usage |
-
2010
- 2010-03-26 US US12/748,069 patent/US9446194B2/en active Active
- 2010-03-26 EP EP10756957.6A patent/EP2410910A4/en not_active Withdrawn
- 2010-03-26 WO PCT/US2010/028927 patent/WO2010111660A1/en active Application Filing
-
2013
- 2013-12-30 US US14/144,489 patent/US10610642B2/en active Active
-
2015
- 2015-12-04 US US14/960,127 patent/US10675405B2/en active Active
- 2015-12-16 US US14/971,886 patent/US10537678B2/en active Active
-
2019
- 2019-12-06 US US16/706,425 patent/US20200114078A1/en active Pending
-
2020
- 2020-04-29 US US16/862,429 patent/US20200254177A1/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5730654A (en) * | 1995-12-18 | 1998-03-24 | Raya Systems, Inc. | Multi-player video game for health education |
US6537806B1 (en) * | 1998-06-02 | 2003-03-25 | University Of Washington | Compositions and methods for treating diabetes |
US20030050537A1 (en) * | 2000-06-22 | 2003-03-13 | Guidance Interactive Technolgies | Interactive reward devices and methods |
US20040054263A1 (en) * | 2001-08-20 | 2004-03-18 | Piet Moerman | Wireless diabetes management devices and methods for using the same |
US20050038680A1 (en) * | 2002-12-19 | 2005-02-17 | Mcmahon Kevin Lee | System and method for glucose monitoring |
US20050102159A1 (en) * | 2003-11-06 | 2005-05-12 | Mondshine Robert B. | Computer based risk level monitor and patient compliance method and system |
US20070179356A1 (en) * | 2005-12-29 | 2007-08-02 | Guidance Interactive Healthcare, Inc. | Programmable devices, systems and methods for encouraging the monitoring of medical parameters |
US20080086533A1 (en) * | 2006-07-12 | 2008-04-10 | Neuhauser Alan R | Methods and systems for compliance confirmation and incentives |
US20100312483A1 (en) * | 2007-02-06 | 2010-12-09 | Glumetrics, Inc. | Algorithms for calibrating an analyte sensor |
US20100106000A1 (en) * | 2008-10-27 | 2010-04-29 | Medtronic Minimed, Inc. | Methods and Systems for Evaluating Glycemic Control |
Also Published As
Publication number | Publication date |
---|---|
US20100261987A1 (en) | 2010-10-14 |
EP2410910A4 (en) | 2014-10-15 |
EP2410910A1 (en) | 2012-02-01 |
US10610642B2 (en) | 2020-04-07 |
US20200114078A1 (en) | 2020-04-16 |
US20160101232A1 (en) | 2016-04-14 |
US9446194B2 (en) | 2016-09-20 |
US20140114161A1 (en) | 2014-04-24 |
US10537678B2 (en) | 2020-01-21 |
US20160081632A1 (en) | 2016-03-24 |
WO2010111660A1 (en) | 2010-09-30 |
US10675405B2 (en) | 2020-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200254177A1 (en) | Methods and systems for promoting glucose management | |
AU2021203385B2 (en) | System and method for mode switching | |
EP2329763B1 (en) | Signal processing for continuous analyte sensor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: DEXCOM, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KAMATH, APURV ULLAS;PRYOR, JACK;CARLTON, ALEXANDRA LYNN;AND OTHERS;SIGNING DATES FROM 20100602 TO 20100622;REEL/FRAME:055052/0498 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |